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Abstract 
Bladder cancer (BC) is the ninth most common cancer in the world. There are two main 
forms of the disease; non-muscle-invasive BC (NMIBC) and muscle-invasive BC 
(MIBC). NMIBC commonly recurs and multiple tumours may be resected from the 
same patient over many years. This provides a unique opportunity to study the 
molecular events that occur during disease evolution. Some patients receive 
intravesical courses of mitomycin-C (MMC) chemotherapy, which may provide a potent 
selective advantage during disease evolution.  
67 tumours from 23 patients with recurrent NMIBC were analysed for copy number 
alterations (CNAs) using shallow-pass whole genome sequencing. Recurrent tumours 
from each patient tended to share CNAs and common changes seen in BC, such as 
loss of chromosome 9, suggestive of a monoclonal origin. Some patients received a 
course of MMC. However no CNAs that specifically related to treatment were identified.  
To better understand chemotherapy related events in NMIBC, 18 tumours from 8 
patients who received a course of MMC were analysed using whole exome 
sequencing. A significant increase in non-synonymous mutations was identified post-
treatment. Unique mutations post-treatment displayed a significant increase in the 
number of transversions, specifically C:G>A:T substitutions, as well as an increase in 
the number of tandem substitutions, specifically at CC or GG dinucleotides. This is 
consistent with the types of mutations induced by MMC experimentally. Analysis of the 
sequence context shows that MMC produces a signature similar to that seen by 
aflatoxin. Analysis of the clonality of the MMC-induced mutations demonstrates that 
these unique mutations tend to be subclonal.  
Overall this work shows that MMC can cause DNA damage that can be identified in 
post-treatment tumours and this could influence the evolutionary trajectory of the 
cancer. Further work is required to confirm this mutational signature and fully discern 
the effect of MMC treatment on the clonal dynamics of NMIBC. 
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Chapter 1  
Introduction 
1.1 Bladder Cancer 
Bladder cancer is the most common cancer of the urinary tract and is the ninth most 
common cancer in the world with around 430,000 new cases and 165,000 deaths 
recorded in 20121. Bladder cancer affects three times more men than women2. There 
are multiple risk factors for the disease including occupational exposure to aromatic 
amines and polycyclic hydrocarbons as well as smoking. Smoking is the highest risk 
factor and accounts for approximately 50% of cases3. 
Bladder cancer is divided into two main disease forms; non-muscle-invasive bladder 
cancer (NMIBC) and muscle-invasive bladder cancer (MIBC) (Figure 1.1). MIBCs are 
those which have invaded the muscle and consist of tumours that are of a high-grade 
and are of stage T2 to T4. At diagnosis, MIBCs make up about 20% of all bladder 
cancer cases. These patients have a poor outcome with a five-year survival rate of 
<50% and around 50% of patients will progress to metastatic disease4.	NMIBC makes 
up 60-70% of cases and is limited to the urothelium and lamina propria5. NMIBC has a 
more favourable outcome with a five-year survival rate of around 90%4.	Carcinoma in 
situ (CIS) is a flat, high-grade lesion and, although limited to the mucosa, it is believed 
to be the precursor to invasive disease4,6. 
Histological examination of tumours is used to assess stage and grade. The staging of 
tumours describes the degree of invasion using the Tumour-Node-Metastasis (TNM) 
system7 whilst the grade defines the degree of differentiation of the tumour cells. 
Grading follows the World Health Organisation (WHO) 19738 or 20049 systems; low-
grade (LG) tumours (Grade 1 and 2) are well differentiated whilst high-grade (HG) 
tumours (Grade 2 and Grade 3) are poorly differentiated (Figure 1.1). 
Treatment of bladder cancer depends primarily on the stage and grade of the disease. 
Multifocality and tumour size are risk factors considered prior to treatment. Treatment 
of low-stage low-grade NMIBC patients involves transurethral resection of the bladder 
tumour (TURBT) followed by an intravesical instillation of mitomycin C (MMC) (or other 
chemotherapy) or, for higher-grade specimens, Bacillus Calmette–Guérin (BCG) 
therapy. Some patients will also undergo further instillations of chemotherapy10. 
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Patients are then monitored by cystoscopy at regular intervals6. High-risk NMIBC 
patients (stage T1 and/or grade 3 tumours) are particularly difficult to manage. They 
have a reduced recurrence-free survival compared to other NMIBC and an increased 
mortality rate11. Clinicians and patients have to choose between bladder conservative 
therapy (TURBT plus BCG therapy) or a cystectomy, where the whole bladder and 
nearby lymph nodes are removed. In some cases, cystectomy may be a potential over-
treatment and has its own risks associated with it6,11. Treatment of MIBC involves the 
removal of the bladder via cystectomy where possible as this can provide long-term 
disease free survival in over 70% of patients with organ-confined disease12. This is 
often combined with neoadjuvant systemic chemotherapy such as cisplatin-based 
combination therapies. For patients with non-organ confined disease, adjuvant 
chemotherapy or radiotherapy is often considered6. In the past few years, five immune 
check point inhibitors, known as immunotherapies, have been approved by the FDA for 
the second-line treatment of metastatic bladder cancer13. Additionally, two of the 
inhibitors have been approved for frontline use, expanding the treatment options for 
metastatic bladder cancers.  
 
 
 
Figure 1.1: Bladder cancer staging and grading. 
A) Staging of bladder cancer according to the TNM system7. Non-muscle-invasive bladder cancer 
consists of stages Tis, Ta and T1 whilst muscle-invasive bladder cancer encompasses stages T2 
to T4. B) Grading according to the 1973 World Health Organization (WHO) and 2004 
WHO/International Society of Urological Pathology (ISUP) criteria. PUNLMP = papillary urothelial 
neoplasm of low malignant potential. Figure adapted from Knowles and Hurst4. 
A 
B 
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Despite being associated with a good outcome, around 50-70% of NMIBCs will recur 
and 10-15% will progress to muscle-invasive disease. At present, predictive models for 
the recurrence and progression of NMIBC are unsatisfactory14 and there are currently 
no molecular biomarkers identified that can predict progression4. Consequently, 
patients require continued surveillance6, making bladder cancer one of the most 
expensive cancers to treat15. This highlights the need for a greater understanding of 
the spatial and temporal dynamics of bladder cancer evolution; from diagnosis and 
throughout the disease history including treatment, recurrence and progression. An 
understanding of this at a molecular level will enable the identification of biomarkers for 
the prediction of recurrence and progression. This may also identify new therapeutic 
targets or provide knowledge to guide therapeutic regimes for the maximal effect for 
each individual patient. The recurrent and often multifocal nature of NMIBC, combined 
with the relative ease of tumour sampling, makes it an ideal candidate for the type of 
longitudinal analysis required. 
1.2 Evolutionary theory, Cancer and Clonality 
1.2.1 Cancer evolutionary theory 
Charles Darwin’s theory of evolution by natural selection is probably one of the most 
well-known scientific theories of all time. The theory contains three main requirements:  
I. Individuals in a species show a wide range of variation 
II. These variations are heritable 
III. Variations lead to differential survival and reproduction in individuals16 
The variations that provide an advantage to an individual and enhance their survival 
will be positively selected whilst less well-adapted individuals will be negatively 
selected. Peter Nowell was one of the first to describe tumour progression as an 
evolutionary process in his clonal evolution theory17. In his theory, mutations are the 
variation that leads to differential survival of tumour cells. Some mutations are 
evolutionary dead ends and will be detrimental to the survival of the associated cells, 
whereas other mutations may confer a selective advantage to a tumour cell. This cell 
can then proliferate and its progeny cells can undergo further diversification and 
selection17. This means that all cells should contain the original mutation(s) but they 
may differ in the subsequent mutations creating heterogeneity within and between 
tumours. 
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Within evolutionary theory there is a debate on whether macro evolutionary trends and 
rules exist or whether complex life as we know it is the culmination of an unrepeatable 
series of possibilities18,19. These opposing arguments are termed convergence and 
contingency respectively. Convergence suggests that there is a limited set of 
potentially repeatable outcomes due to constraints to evolution20 and is presented as 
the development of a particular trait in independent lineages. The common evolutionary 
examples given to this argument are the evolution of wings (seen in bats, birds and 
insects) or the streamlined aquatic shape of some fish, dolphins and whales. 
Contingency on the other hand is best described by Gould’s famous assertion that a 
different evolutionary outcome would result if the tape of life were to be rewound and 
replayed21 i.e. evolution occurs by chance. These debates are also relevant to tumour 
evolution. If we can determine if there are spatial and temporal trends and patterns in 
tumour evolution, and we can decipher these, then this would be advantageous from a 
therapeutic perspective20.		
1.2.2 Historical methods for investigating clonality and 
heterogeneity 
The idea that cancers are clonally derived has been investigated thoroughly throughout 
the years. Early studies into clonality often focused on investigating the clonal 
relationships between multiple tumours from the same patient including multifocal 
tumours22 or primary and metastatic tumour-pairs23, whilst early studies into 
heterogeneity focussed on assessing different regions from the same tumour24,25. This 
section provides a brief overview of methods used to investigate clonality and 
heterogeneity before the genomics era. 
Loss of heterozygosity (LOH) analysis was a common method used to detect alleles 
that had been somatically lost in cancer cells. LOH is commonly assessed using 
polymerase chain reaction (PCR)-based analysis of polymorphic microsatellite markers 
in cancer cells and control germline samples from the same patient and has been used 
in the assessment of clonality of multifocal bladder tumours22,26. However, LOH 
analysis can be obscured by contaminating normal cells, homozygous deletions, 
karyotypic complexity and PCR artefacts27 meaning that data often requires 
confirmation by independent techniques28.  
Other focused methods for looking at clonal relationships include the sequencing of 
specific genes that are known to be mutated in a particular cancer28 such as TP53 
analysis22,29. A problem of these two approaches was that they were limited to analysis 
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of a particular locus or set of loci28. Shared markers may be missed whilst the presence 
of subclones and intratumour heterogeneity could lead to an incorrect assessment of 
non-clonality. Additionally, using highly mutable hotspots could indicate clonality when 
actually the events occurred independently. 
Other studies have used karyotypic complexity to assess clonality and heterogeneity 
within many cancers such as glioma24 and breast cancer25. Karyotype analysis uses 
ploidy and chromosomal banding patterns to identify differences in chromosome 
number and structure30. The main caveat to this technique is that it requires the 
culturing of the tumour cells which could alter clonal dynamics28. Fluorescence in situ 
hybridisation (FISH) has been used to study clonal heterogeneity in several 
cancers22,31. FISH uses fluorescently tagged probes complimentary to DNA regions to 
identify and label DNA with different types of probes used depending on the 
experiment. Probes can be targeted at centromeres for the specific detection of certain 
chromosomes or identification of aneuploidy31. Alternatively, probes can be designed to 
label specific genes to look for amplifications and deletions32. Additionally, probes have 
been designed to label entire chromosomes, known as whole chromosome painting 
and this can be used to identify chromosome translocations and large structural 
alterations33 but sensitivity is an issue as smaller structural alterations may be missed. 
One of the advantages of FISH is that it can be performed on cells in interphase, 
allowing for the detection of alterations in non-dividing cells34. However FISH is labor 
intensive and less suitable than other methods for high-throughput studies27. 
Copy number alterations (CNAs) have also been used to investigate clonality in some 
cancers23,35. Comparative genomic hybridisation (CGH) was one of the first techniques 
to generate a genome-wide estimate of CNAs. Relative copy numbers are estimated 
using differential labelling of normal and tumour DNA mixed in a 1:1 ratio36. These are 
hybridised to a normal metaphase spread and gains in the tumour DNA will result in 
more of that DNA binding, giving a higher readout of the tumour fluorescent label. 
Likewise, loss of a region in the tumour will lead to a higher read of the normal 
fluorescent label. This provides a global overview of gains and losses in the genome of 
a tumour36 and has the benefit of potentially many markers from which to identify 
relatedness. Despite not requiring culturing of the tumour cells this method still requires 
the generation of a metaphase spread of a normal cell37. The use of a metaphase 
spread limits sensitivity, as closely spaced events and events less than 20 Mb are 
difficult to detect38. CGH was later improved by hybridizing to an array of mapped 
sequences instead of a metaphase spread. This is known as array-CGH38. This has an 
improved resolution compared to regular CGH as each region is spatially separated on 
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a chip. This method has been widely used in the deciphering of clonality using 
CNAs23,39.		
Many of the technologies used in these studies have numerous limitations. The recent 
technological advances of next-generation sequencing (NGS) have allowed the 
analysis of structural rearrangements, CN alterations and somatic mutations of entire 
genomes to be studied at the single nucleotide level40. This unprecedented resolution 
has revolutionised the study of clonality and inter- and intra-tumour heterogeneity.  
1.3 The next-generation sequencing era 
Advances in sequencing technology over the past decade have revolutionised the field 
of cancer genetics. The introduction of massively parallel sequencing, known as next-
generation sequencing, has reduced the cost of genome sequencing substantially: the 
human genome project was published in full in 2003, cost around $2.7 billion US 
dollars and took 13 years to complete, whilst today a human genome costs in the 
region of $1,000 US dollars and sequencing takes as little as a day although analysis 
can take much longer41 (Figure 1.2). NGS has the ability to sequence heterogeneous 
mixtures of genomes simultaneously42 and has enabled the analysis of structural 
rearrangements, copy number alterations and somatic mutations of entire genomes to 
be studied at the single nucleotide level40. This unprecedented resolution has 
revolutionised the study of clonality and inter- and intra-tumour heterogeneity. 
 
 
Figure 1.2: Cost of sequencing the human genome over the years. 
The cost of sequencing the human genome has dramatically dropped since the introduction of 
NGS methodologies in 2008. Note the log-scale for the cost in US dollars. Data taken from41. 
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1.3.1 Large genome sequencing projects 
Since 2008 there have been thousands of cancer genomes and exomes sequenced, 
many as part of large projects under the International Cancer Genome Consortium 
(ICGC) or as part of The Cancer Genome Atlas (TCGA) project.  
The TCGA was launched by the National Cancer Institute and the National Human 
Genome Research institute in the US in 2006. It initially started as a pilot project to 
investigate the genomic and molecular features of ovarian cancer and glioblastoma 
multiforme but was extended to run for over 10 years and analysed over 11,000 
tumours from 33 of the most prevalent forms of cancer. This culminated in the 
production of the Pan-Cancer Atlas: a collection of 27 papers using cross-cancer 
analyses to explore overarching themes within cancer (https://www.cell.com/pb-
assets/consortium/pancanceratlas/pancani3/index.html). These papers highlight the 
important discoveries in three key areas: cell-of-origin patterns43, oncogenic 
processes44 and signalling pathways45. Key findings include the correlation of 
aneuploidy with the somatic mutation rate and expression of proliferation genes, the 
identification of pathogenic germline variants46 and the characterization of driver genes 
and mutations47. As well as publishing pan-cancer findings, TCGA have also produced 
detailed investigations into individual cancers through their working groups. 
Due to the shear scope of the cancer genomics field, the ICGC was created to 
coordinate large-scale cancer genome projects with the aim of defining the genomes of 
25,000 primary, untreated cancers. The key motives for the formation of the ICGC  
were to reduce the duplication of effort, generate more complete studies and provide a 
framework for the standardization of data to enable the merging and comparing of 
datasets48. This has resulted in over 20,000 tumour genomes available world-wide, 
providing a rich resource of data for cancer researchers. TCGA was a large provider of 
data to the ICGC and a recent initiative, the Pan Cancer Analysis of Whole Genomes 
(PCAWG), is a collaboration between the ICGC and TCGA49. This aims to analyse 
over 2,800 whole cancer genomes from the ICGC and explore somatic and germline 
variants in both coding and non-coding regions focusing on cis-regulatory sites, non-
coding RNAs, and large-scale structural alterations. 
These large projects have been instrumental in understanding the changes occurring in 
different cancers and for the identification of pan-cancer patterns. However, both 
projects have thus far focussed on the genomic characterisation of untreated cancers 
from the primary site. Whilst this is crucial information, it does not address the 
continuing development of cancer after the primary tumour. Only by the analysis of 
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multiple tumours over time and/or space within a patient can we really begin to 
understand the development and evolution of cancer throughout its lifespan. The ICGC 
have now developed an initiative named ICGC-ARGO; Accelerating Research in 
Genomic Oncology. This will use key clinical questions and patient clinical data to drive 
the interrogation of cancer genomes with the aims of answering questions related to 
cancer evolution as well as hoping to identify better ways of using treatments. 
1.3.2 Heterogeneity and tumour evolution 
Deep sequencing within and between tumours has provided an improved 
understanding of the evolutionary trajectory of cancer. Originally it was thought that 
cancer was a linear disease with successive rounds of acquisitions of advantageous 
mutations by a clone, followed by a selective sweep in which this advantageous clone 
would expand and replace the less fit clones in the tumour40,50. However current 
evidence suggests that this simple view occurs only rarely, such as in AML51, and the 
majority of cancers evolve in a branched or punctuated pattern resulting in tumours 
consisting of multiple different clones52,53. Cancers undergoing branched evolution will 
therefore be a dynamic population of clones resulting in spatial and temporal 
heterogeneity.  
Spatial and temporal heterogeneity has been described in many cancers including 
breast54, bladder55, lung56, renal57 and prostate58 to name a few. A recent pan-cancer 
analysis of whole genomes investigating intra-tumour heterogeneity identified evidence 
of recent subclonal expansions in over 95% of the tumours analysed59. As this work 
was carried out on single samples this can be considered a lower limit of intra-tumour 
heterogeneity as variants found to be clonal in one sample may be subclonal in 
another59. 
Researchers have investigated both recurrent51,60,61 and metastatic disease58,62-64 in a 
bid to understand clonal dynamics and factors influencing disease recurrence and 
progression. Analysis of spatially separated areas of the primary tumours and 
metastasis of renal cell carcinoma uncovered a branched evolutionary tract with one 
branch evolving into the clones at the metastatic sites and the other diversifying into 
primary regions53. Sequencing of spatially distinct areas of the primary tumour 
identified extensive intratumour heterogeneity with only 34% of all detected mutations 
being present in all regions sequenced. This spatial separation of clones has also been 
noticed in other cancers such as non-small cell lung cancer (NSCLC) where a study 
identified that if only one region of a tumour was sequenced, the probability of missing 
a potential driver gene was 83%56. These studies indicate that single biopsies from 
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solid tumours may not be representative of the entire tumour bulk, and this has 
important implications for therapy.  
1.3.3 Mechanisms driving heterogeneity and evolution 
1.3.3.1 Genetic drivers of heterogeneity 
As described above, studies investigating tumours over time or space have identified a 
significant amount of heterogeneity both within and between tumours. This 
heterogeneity is the fuel for tumour evolution as it provides an array of mutations which 
selective pressures can act upon65. Through the use of high throughput sequencing, a 
deeper understanding of the mechanisms driving heterogeneity has been gained 
(Figure 1.3). 
In order to generate the heterogeneity identified in cancers, many mutations need to 
accumulate. Using mathematical modelling, Loeb showed that the moderately large 
numbers of mutations seen in a colorectal cancer could not have arisen within the 
lifetime of a human if the mutation rate is the same as observed in normal tissues66. He 
suggested that cells need to adopt a mutator phenotype, which increases the rate of 
genetic mutation. The necessity for this mutator phenotype is contested67,68 and whilst 
pan-cancer studies clearly show an elevated mutation frequency for most cancers69,70, 
it still remains unclear if this is due to an increased mutation rate or simply due to more 
cell divisions at a low mutation rate52. 
The mutational diversity required for evolutionary processes can be generated in many 
ways. Genomic instability is a huge driver of genomic diversity and refers to an 
increase in the amount and tendency for alterations in the genome71. Genomic 
instability processes can create characteristic mutations leaving a pattern of base 
changes known as a “mutational signature”. The availability of large datasets has 
shown that whilst a cancer may have a few driver mutations, it can contain many more 
passenger mutations72. Although these passenger mutations may not contribute to 
disease, they are a vast resource that can be used to investigate these mutational 
signatures70,73,74. The spectrum of known mutational signatures was greatly expanded 
in the landmark paper by Alexandrov et al.70 who used data from over 7,000 tumours to 
identify 22 mutagenic signatures. Ongoing work by several groups has expanded the 
number of signatures identified and there are now 30 signatures in the Catalogue Of 
Somatic Mutations In Cancer (COSMIC) database 
(https://cancer.sanger.ac.uk/cosmic/signatures). Analysis of these signatures has 
identified the large contribution of exogenous mutagens, such as tobacco smoke and 
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UV, as well as endogenous processes, such as dysfunctional DNA damage response 
pathways and mutagenic activity of the apolipoprotein B mRNA editing enzyme, 
catalytic polypeptide-like (APOBEC) family of cytidine deaminases, towards genomic 
instability. 
There are several mutational signatures corresponding to DNA repair deficits70. An 
analysis of the mutational landscape of 12 major cancer types identified a significant 
correlation between high mutation frequency and DNA repair pathway genes69, 
suggesting that deregulation of DNA repair is common across at least a subset of 
cancers. Defects in mismatch repair can lead to increased instability at the nucleotide 
level because replication errors cannot be repaired effectively75. This results in 
increased rates of frameshift and/or point mutations76 and can generate microsatellite 
instability. Mutations in DNA damage response pathways have also been linked to 
genomic instability in hereditary cancer68,77 and alter the cells ability to deal with DNA 
damage. Alterations in the ability of cells to detect, analyse and repair DNA damage 
can cause the accumulation of genetic alterations leading to an increased mutation 
load and genetic instability. 
 
 
Figure 1.3: Factors driving heterogeneity, tumour evolution and resistance. 
Genomic instability is driven by many processes and results in the production of many different 
tumour subclones resulting in a heterogenous tumour. The microenvironment can select for the 
fittest clones in the local environment, fuelling tumour evolution, and can also increase genomic 
instability. Therapy provides a potent selection barrier that can result in the emergence of only a 
subset of resistant clones and can also contribute to genomic instability.  
 11 
Other prevalent endogenous mutagens include the activity of APOBEC cytidine 
deaminases. These enzymes have functions in innate immunity towards viruses and 
endogenous retroelements as well as in RNA editing78. However, they can also cause 
mutations in DNA through the deamination of cytosine residues in single stranded 
DNA79,80. This leaves a characteristic mutational signature of C > T or C > G mutations 
at TpC sequences70,80. APOBEC mutagenesis has been shown to be highly prevalent 
in several different cancer types, including bladder cancer81,82. In breast cancer, 
upregulation of APOBEC3B correlated with a doubling of C > T substitutions and 
overall mutation load79. In lung cancer, APOBEC mutations were shown to be present 
on the branches of the tumour tree rather than the trunk of the tree56. Interestingly, 
mutations in an APOBEC context were identified in driver genes, such as PIK3CA and 
EP300, on the branches suggestive of a possible impact of APOBEC mutagenesis on 
subclone diversity56. Indeed, PIK3CA is a common target of APOBEC mutagenesis 
with mutations in the helical domain displaying an APOBEC motif in human 
papillomavirus driven tumours83. 
Chromosomal instability is another common cause of genomic instability and can be 
characterised by structural and numerical karyotypic heterogeneity84. Aneuploid cells 
have an unbalanced number of chromosomes and aneuploidy is often attributed to 
chromosomal partitioning errors during mitosis85. In the cancer literature, aneuploidy 
has recently been further defined as somatic CNAs involving whole chromosomes or 
complete arms of chromosomes86. A recent pan-cancer analysis examining aneuploidy 
identified that 88% of cancers investigated had some aneuploidy. However the rate 
varied across cancer types; only 26% of thyroid carcinomas contained an aneuploid 
event, compared to 99% of all glioblastomas and testicular germ cell tumours86. A 
previous analysis of over 3,000 tumours from 12 tumour types identified an inverse 
relationship between the number of recurrent CNAs and the number of SNVs87. 
Contrastingly in this study, a positive correlation between aneuploidy score and 
mutation frequency was observed when hypermutated samples with high levels of 
microsatellite instability or POLE mutations were excluded86. Aneuploidy therefore may 
not only contribute to genomic instability through changes in large numbers of genes 
but may be linked to genomic instability at the SNV level. 
Not all mutations occur progressively. Investigations into whole cancer genomes have 
provided evidence that in some cases a huge number of mutations can occur in a short 
time frame. A process, termed chromothripsis, in which chromosomes shatter and are 
reassembled resulting in massive genome rearrangement shows how multiple genome 
rearrangements can occur in one catastrophic event88,89. Telomere attrition has also 
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been linked to massive genomic disruption90 and Kataegis, where multiple point 
mutations are acquired in one-off bursts, has been identified in breast cancer91 and 
multiple myeloma92. These catastrophic events suggest that cancer evolution is not 
always a gradual process and may provide a clone with a leap, rather than a step, 
towards malignancy93. 
1.3.3.2 Non-genetic drivers of heterogeneity and tumour evolution 
Evolution and heterogeneity do not have to be driven by genetic factors. Epigenetic 
changes, such as DNA methylation and histone deacetylation, are increasingly being 
recognised as being important during tumorigenesis94,95. Aberrant DNA methylation 
has been identified in many cancer types96. As epigenetic changes are inherited during 
the cell cycle and alter gene expression, they are also subject to evolutionary forces 
and can drive clonal evolution. Indeed, intratumour heterogeneity of DNA methylation 
has been shown to reflect clonal evolution in aggressive prostate cancer97. Deep 
sequencing studies have identified mutations in epigenetic modifiers in many 
cancers69,98-100 suggesting that deregulation of this process may be important to cancer 
progression. 
The tumour microenvironment also provides a strong role in the evolution of cancer. It 
is a complex system including surrounding vasculature, immune cells, fibroblasts and 
the extracellular matrix101. The interaction between cancer cells and their environment 
is implicated in cancer growth with invading immune cells inducing chronic 
inflammation and secreting factors that aid in tumour progression, allowing cancer cells 
to acquire hallmark functions102. Tumours may be made up of millions of cells each 
responding to the environment directly surrounding it. Different microenvironments may 
have varied degrees of selective pressures including acidity, oxygen and tumour 
growth factors103. Even early in carcinogenesis hypoxia can be present, providing a 
harsh landscape in which only the well-adapted cells can survive. Not only does 
hypoxia provide a form of selection but it can also lead to genomic instability through 
mechanisms such as reactive oxygen species (ROS). ROS are also produced during 
chronic inflammation and they can induce DNA damage and reduce activity of DNA 
damage response machinery77. Using these mechanisms, the microenvironment not 
only contributes to genomic instability, thus generating diversity and influencing 
heterogeneity, but can also act as a selection barrier and has been associated with 
chemotherapy resistance in serous ovarian cancer104.  
 13 
Therapy plays an important role in tumour evolution. It can contribute towards genomic 
instability, such as seen with temozolomide (TMZ) treatment in malignant melanomas 
and gliomas70. In chronic lymphocytic leukaemia (CLL), therapy correlated with an 
increase in subclonal mutations105, and in glioma TMZ treatment induced a 
hypermutator phenotype, likely through the mutation of the MSH6 mismatch repair 
gene, leading to genomic instability and resistance16. This increase in mutations can 
lead to an increase in tumour diversity for evolution to act upon. Therapy also acts as a 
potent selection barrier as only clones resistant to the therapy can survive and 
propagate.  
Genomic instability has been linked to drug resistance, poor prognosis and even 
progression in certain cancers106-109. These elevated levels of DNA variation combined 
with the selection forces of the local environment lead to inter- and intra-tumour 
heterogeneity. This heterogeneity within and between the tumour masses is the basis 
for selection of the fittest clones and thus is a major step in clonal evolution110. 
1.3.4 ITH and treatment 
Tumour heterogeneity, both within and between tumour lesions, may have huge 
implications for drug therapy in cancer. The most critical challenge for oncologists is 
drug resistance42. Targeted therapies aim to eradicate cancer by blocking key 
signalling proteins and cancers are often treated depending on the presence or 
absence of these targets. For example, in CML, patients are treated with imatinib, a 
competitive inhibitor of the BCR-ABL oncogene111. However, resistance can occur and 
examination of patients pre and post treatment (with imatinib) has identified very low 
frequency subclones carrying resistance mutations in the kinase domain of BCR-ABL 
prior to treatment in some patients. This emergence of resistant subclones has been 
identified in many cancers112-114 and multiple resistance mechanisms can occur in the 
same patient115. This highlights that single targeted therapeutics are likely to be futile 
and raises serious questions about the need for greater analysis of tumour 
heterogeneity before targeted treatment in order to determine the best combination 
therapy strategy. 
It is also possible that tumour heterogeneity can fuel de-novo drug resistance 
mechanisms through the contribution of genomic instability and/or mutagenic 
therapies. Chemotherapy-induced mutagenesis has been identified in AML and 
glioma60. In glioma, the mutagenic TMZ therapy combined with genomic instability led 
to hypermutation of the genome and malignant progression114. This also illustrates that 
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clonal evolution and heterogeneity can also be implicit in resistance to conventional 
chemotherapy. One problem with the categorising of resistance to de-novo 
mechanisms it that it is difficult to establish whether resistant subclones are generated 
during treatment or if they are present at very low levels prior to treatment116. Even 
ultra-deep sequencing may miss a subclone due to sampling bias or the subclone 
being particularly rare.  
Studies have begun to trace clonal evolution in cancer during treatment. 
Unsurprisingly, many of these studies have been in haematopoietic 
cancers60,112,113,117,118 as longitudinal sampling is much easier in these cancers116. A 
study in acute lymphoblastic leukaemia (ALL) identified that the relapsed clone was 
often ancestral to the diagnostic sample and backtracking analyses also identified the 
relapsed clone as a minor subpopulation at diagnosis112. Different clonal architecture at 
relapse compared to diagnosis is common117,118 and relapse can be driven by more 
than one subclone117. The dynamics of subclonal architecture was demonstrated in 
multiple myeloma in a case sampled at seven time points. This showed alternating 
clonal dominance between two subclones over the disease course113. These studies 
emphasise the dynamics in clonal evolution and demonstrate that therapy acts upon 
these dynamics, selecting for resistant clones. 
Fewer longitudinal studies have taken place in solid tumours, likely due to difficulties in 
sampling116. In BRAF-mutant melanoma, intratumour heterogeneity was seen as a 
major contributor to BRAF inhibitor resistance with temporally separated resistant 
clones and multiple resistance mechanisms115. Similar to the ALL study, ancestral 
clones were found in recurrent gliomas at recurrence compared to the dominant clone 
in the primary tumour114. Temporal evolution was identified in a study comparing 
mutations in a metastatic lobular breast cancer with the primary tumour from 9 years 
previously. Only 5 of the 32 mutations in the metastatic cancer were present in the 
primary tumour119. This shows that the tumour underwent substantial evolution during 
this time frame highlighting the implications that time has on heterogeneity. 
These studies show that clonal evolution and heterogeneity have an impact upon 
treatment, yet the understanding of this is still limited. To address this issue a large 
translational research study TRACERx (TRAcking Cancer Evolution through therapy 
[Rx]) has been set up with a focus on four cancer types: lung, melanoma, prostate and 
renal cancers. The aim of the study is to determine the relationship between 
heterogeneity and disease stage, clinical outcome and treatment response120. To date, 
interim findings have only been published for clear-cell renal cell carcinoma (ccRCC). 
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These have identified that the early events in ccRCC (chromosome 3p loss and 5q 
gain) happen extremely early, likely occurring during childhood or adolescence for the 
majority of the patients, 30-50 years before the kidney cancer was diagnosed121. Multi-
region sequencing identified a higher frequency of driver mutations compared to 
studies using single biopsies, emphasizing the importance of intra-tumour 
heterogeneity122. Convergence on the VHL pathway was detected in patients with 
multifocal or synchronous bilateral disease and parallel evolution of mutations in the 
same genes or pathways within distinct tumour subclones was identified in 13% of 
untreated primary tumours122, confirming observations from other studies57,64. These 
results suggest a deterministic nature to clonal evolution122. Analysis of metastases 
identified distinct patterns of metastatic dissemination and the presence of profound 
evolutionary bottlenecking123.  
Overall, a deterministic nature of the evolution of ccRCC has been described, the 
understanding of which could stratify patients for surgical intervention or therapeutic 
drug intervention123. Similar analyses are now needed in other cancers in order to 
define the evolutionary trajectory of each cancer type. If we can understand each 
cancer’s evolutionary process, especially with regards to treatment, then the outcomes 
of cancer growth and therapy response could be predicated. This would provide a 
basis on which to design therapeutic interventions that would be best for each 
individual patient and may identify evolutionary constraints that could be exploited76,124.	
1.4 The genomic landscape of bladder cancer 
1.4.1 The pre-genomics era 
Prior to the advancement of NGS, several molecular alterations were characterised in 
bladder cancer using techniques such as LOH analysis, copy number analysis and 
analysis of mutations in candidate gene studies. Many structural alterations have been 
identified in the genomes of bladder cancer tumours, including DNA copy number 
losses and gains, rearrangements, and regions of LOH. Typically, MIBCs exhibit many 
CNAs and can be highly aneuploid whilst NIMBC, especially stage Ta tumours, exhibit 
fewer CNAs125 and are often diploid or near diploid. Stage T1 tumours exhibit a mix of 
profiles126, with some stage T1 tumours having few CNAs, resembling stage Ta 
tumours, whilst others have more unstable genomes and more closely resemble MIBC 
profiles, suggesting the presence of multiple tumour subgroups125.  
An early karyotyping study in bladder cancer identified high levels of monosomy of 
chromosome 9127. Loss of chromosome 9, or parts thereof, has been confirmed in 
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subsequent studies125,126,128-130 and alterations of chromosome 9 by LOH or copy 
number loss have been identified as the most common structural alterations present in 
over 50% of all bladder tumours, irrespective of stage and grade125,131. Chromosome 9 
contains two key tumour suppressor genes in bladder cancer which are affected by 
chromosome loss. CDKN2A, which resides at cytoband location 9p21 and encodes 
cell-cycle regulators p16 and p14ARF, is commonly inactivated by homozygous 
deletion (HD) and has been linked to an increased risk of recurrence in NMIBC132. On 
9q, TSC1 is the best characterized tumour suppressor gene. This gene is present in 
many regions of LOH and is mutated in 12-16% of bladder cancer cases133,134. 
Along with loss of chromosome 9, additional alterations have been identified in stage 
Ta tumours. These include losses of chromosomal regions 10q(20%)135, 11p(10-
24%)125,135,136, 11q(21%)125, 17p(15-19%)125,135, 19p(19%)125 and 19q(19%)125, and 
gains of 20q(13-17%)135,136. MIBC have many copy number alterations125,135 with 
frequent alterations apparent in almost all chromosomes125,137. 
Key genes involved in bladder cancer, such as FGFR3, PIK3CA, TP53 and the RAS 
gene family, were initially identified in candidate gene studies. FGFR3 (fibroblast 
growth factor receptor 3) is one of four tyrosine kinase receptors that mediates the 
intracellular signalling of fibroblast growth factors (FGFs) 138. Activation of the receptor 
can lead to the activation of several signalling pathways including the mitogen-
activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) pathways139. 
Mutations of FGFR3 in bladder cancer were identified in the late 1990’s140 and have 
since been shown to be highly prevalent in the disease141-143. Activating point mutations 
are present in up to 80% of stage Ta tumours144 whilst mutation rates in MIBC and 
stage T1 tumours are lower141,145 with mutations found in 10-45% of stage T1 tumours 
and around 15% of MIBC144. Mutant FGFR3 has been shown to increase cell 
proliferation and promote anchorage-independent growth in vitro146 and is thought to 
contribute to urothelial hyperplasia in vivo144. 
The PI3K pathway is an important transducer of signals from tyrosine kinase receptors 
and is involved in signalling pathways regulating cell growth, differentiation and 
development147. PI3K signalling pathways are often disturbed in cancer and in bladder 
cancer, activating mutations of the p110α catalytic subunit (PIK3CA) have been 
identified148. Like FGFR3, PIK3CA mutations are more common in stage Ta tumours 
compared to stage T1 NMIBC and MIBC (~40-50% vs ~20%)134,148 and PIK3CA 
mutations have been shown to commonly occur with FGFR3 or RAS mutations143,148. 
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Mutations in the RAS gene family were the first genetic alterations implicated in cancer 
and activating mutations in these genes are common in many cancers149-151. In bladder 
cancer, mutations in HRAS and KRAS are more frequent than mutations in NRAS143. 
Unlike FGFR3 and PIK3CA, RAS mutations are not associated with stage or grade 
with 6-18% of all tumours containing mutations143,152. 
As both FGFR3 and the RAS family of genes activate the MAPK pathway, Jebar et 
al.142 investigated the possibility of mutual exclusivity in these genes through the 
analysis of a mixture of tumour samples and tumour-derived urothelial cell lines. They 
directly sequenced exons 7, 10 and 15 of the FGFR3 gene to detect mutations whilst 
exons 1 and 2 of the HRAS, KRAS and NRAS genes were investigated for mutations 
using fluorescent single-strand conformation polymorphism analysis. This was followed 
by sanger sequencing of samples with potential mutations. This identified a striking 
mutual exclusivity of these alterations which has since been confirmed in further 
studies143,153 including NGS studies82. 
The most common genetic alterations in bladder cancer are mutations of the 
telomerase reverse transcriptase (TERT) promoter which occur in all stages and 
grades at a very high frequency (60-80%)153-155. TERT encodes the catalytic sub-unit of 
the telomerase ribonucleoprotein and is transcriptionally repressed in human non-
progenitor or non-stem cells154. Hotspot mutations in the TERT promoter region create 
binding motifs for E-twenty-six (ETS) transcription factors which increase 
transcriptional activity155. Due to the high level of telomerase activity in human cancers, 
it is thought that the activation of telomerase is essential for the immortalization of 
human cells154. Indeed, the identification of TERT promoter mutations in both NMIBC 
and MIBC also suggests that this is a requirement for all pathways of bladder 
cancer156. 
The mutational spectrum of these well-characterised bladder cancer genes has been 
confirmed in NGS studies81,82,157. These NGS studies have also identified additional 
recurrent mutations and mutational processes shaping the genomic landscape of 
bladder cancer. These studies are described in section 1.4.3. 
 
1.4.2 The clonal origins of multifocal and recurrent bladder cancer 
Approximately 30% of bladder cancer patients develop multiple synchronous tumours 
(multifocality)158. Two theories have been put forward to explain multifocality; the 
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monoclonal and the field-cancerization hypotheses5. The monoclonal theory suggests 
that all tumours are descendants of a single malignant cell, which has proliferated, and 
its descendants have spread throughout the urothelial lining. This could be by 
intraepithelial spread, where malignant cells migrate throughout the epithelium, or by 
intraluminal seeding where tumour cells are released from the primary site into the 
urine where they implant at a secondary site. This spread of monoclonal cells 
throughout the urothelium is often referred to as a clonal “field change”4. The field 
cancerization theory suggests that carcinogens in the urine affect the urothelium at 
many sites, allowing several cells to obtain mutations capable of driving tumorigenesis, 
leading to multiple tumours that have arisen from genetically distinct cells159.  
Many studies have investigated the clonality of multifocal bladder cancer. Louhelainen 
et al.26 used LOH analysis to demonstrate monoclonality in non-muscle-invasive 
multifocal bladder cancer. Monoclonality of multifocal tumours was also identified by 
Sidransky et al.160. This study used X-chromosome inactivation to assess clonality, but 
X-chromosome inactivation is limited to analysis of samples from female patients only 
whilst the majority of bladder cancer patients are male. Additional limitations to this 
method include the problem of preferential inactivation of a particular allele or, for 
spatially close tumours, cells may have originated from the same stem cell, and will 
exhibit the same chromosome inactivation pattern as a consequence159. A few patients 
do show evidence for oligoclonal (i.e. independently forming) tumours. Hafner et al.161 
used LOH and TP53 mutation status to assess tumours and found a mix of monoclonal 
and oligoclonal tumours. 
Studies examining recurrent disease have identified clonal relationships between 
recurrent tumours35,162-165. Xu et al.162 demonstrated monoclonality between the 
majority of recurrent lesions assessed using TP53 mutation status. TP53 mutations, 
along with LOH in the 17p13 and 9p21 regions, were also used by Trkova et al.165 to 
determine a clonal relationship between recurrences. A limitation of using mutations in 
TP53 to investigate clonality in bladder cancer is their limited applicability to analysis of 
low-stage low-grade tumours that have very few alterations in this gene166. LOH has 
also been used to look at recurrences spanning periods of up to 17 years163. This study 
identified a clonal relationship in all the patients studied. Interestingly, they observed 
that the chronological order of tumour presentation did not parallel the genetic 
evolution of the tumour. Lindgren et al.167 examined both metachronous and 
synchronous tumours using CGH, LOH and mutation analysis. They noted that 
although most alterations were clonal, the recurrent tumours were unlikely to have 
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originated from the preceding tumour, further highlighting the complex genetic 
relationship between metachronous tumours.  
Some recurrent tumours may not arise from a monoclonal origin; CN analysis of 
recurrent tumours from four patients identified a monoclonal origin in three of the 
patients35. In the fourth patient a clonal relationship between two out of three tumours 
was identified, however the third tumour only shared a very small proportion of 
aberrations, making the authors question its clonality. Interestingly, this tumour was an 
invasive tumour (T3G3) whilst the other two were superficial TaG1 tumours35. Further 
analysis of mutations in tumours from this patient would aid in determining if these 
tumours were indeed clonally related. 
The complex relationships identified in these studies are suggestive of a widespread 
‘field change' in which a large amount of tissue contains molecular alterations4. Indeed, 
whole organ mapping identified a clonal relationship between geographically distant 
regions of altered mucosa168. These regions often appeared phenotypically normal 
supporting the idea of the clonal “field change” (Figure 1.4). 
With the advent of NGS techniques, studies have been able to take clonality analysis 
one step further by analysing tumours down to the single cell169. This has provided a 
huge insight into the clonal dynamics of bladder cancer and NGS studies of bladder 
cancer are discussed in the next section. 
 
Figure 1.4: Alterations in the tumour-bearing bladder. 
Circles represent the interior of the bladder cavity. A) A representation of what the surgeon sees 
at TURBT. At resection the primary tumour and an area of inflamed urothelium are resected. A 
recurrence is identified during surveillance and a second tumour and inflamed region are 
resected. B) The molecular picture. Large areas of the urothelium have been replaced with cells 
containing alteration “a” from which the primary and secondary tumours have developed. Within 
this field of change are regions of dysplasia which contain additional alterations to “a”. Both 
tumours contain the ancestral alteration “a” but they differ in their subsequent mutations. A region 
with normal histology with alteration “h” shows the possibility that independent initiating events 
could occur resulting in oligoclonal tumours. Figure adapted from Knowles and Hurst4. 
A B 
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1.4.3 The next generation sequencing era and bladder cancer 
Several studies have now employed NGS methodologies in the study of bladder 
cancer61,81,82,100,157,164,170-174. The largest study has been the comprehensive analysis of 
412 chemotherapy naïve MIBCs undertaken by the TCGA. In this study, tumours 
underwent WES, RNA-sequencing, DNA copy number analysis, methylation analysis 
and protein expression profiling81. This identified that MIBC is characterized by a high 
mutation rate with a mean of 8.2 non-synonymous mutations per megabase (Mb). A 
high frequency of alterations in genes involved in cell cycle regulation was identified 
and this has been shown to have an adverse prognostic significance175. TP53 was the 
most frequently mutated gene, altered in 48% of tumours81 consistent with other MIBC 
sequencing studies176. Chromatin modifiers and regulators also contained frequent 
alterations. Interestingly, 67% of all single nucleotide variants (SNVs) were identified 
within an APOBEC signature sequence context suggesting that APOBEC related 
mutagenesis is extremely prevalent in MIBC. Unsupervised clustering of samples by 
molecular signatures produced 4 clusters, one of which was characterized by a high 
APOBEC-associated mutational load as well as a high overall mutation burden. 
Patients within this cluster showed a high overall 5-year survival rate of 75% and this 
contrasted with patients in the cluster that had the lowest mutation rate where 5-year 
survival was just 22%. This high mutation rate correlated with a high predicted neo-
antigen load and it is hypothesized that the improved survival of these patients is likely 
due to a natural host immune reaction81. 
As MIBC has benefited from inclusion in TCGA studies, many research groups have 
focused their sequencing efforts on the analysis of NMIBC61,82,157,164,173. Hurst et al.82 
analyzed 140 primary stage Ta tumours, the majority of which were of a low grade, 
using a mix of WES, targeted gene panel sequencing, copy number analysis and 
microarray-based genome-wide mRNA expression analysis whilst Pietzak et al.157 used 
a targeted cancer gene panel to analyse 105 treatment-naïve NMIBC of mixed stages 
and grades. These studies have begun to build a detailed picture of the mutational 
landscape of NMIBC (Table 1.1). These studies have confirmed the high mutation 
rates seen in FGFR3 and PIK3CA82,157 and have clearly demonstrated the differential 
frequency of TP53 mutations across stages and grades; mutations were identified only 
very rarely in Ta low-grade tumours82,157 whilst an increased rate was observed in high-
grade and stage T1 tumours157,173. 
Overall, mutation rates are lower in NMIBC with a mean mutation rate of 2.41 
mutations per Mb identified in stage Ta low grade tumours82. Studies have also 
identified APOBEC as a large contributor to the overall mutation burden in 
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NMIBC61,82,164 with a contribution to 35% of overall mutations identified in Hurst et al.82. 
Interestingly, up to 60% of mutations were APOBEC-related in some individual 
tumours82. In high-risk NMIBC, a high mutational burden was linked to an increased 
response to BCG therapy and a lower progression rate173 though APOBEC signatures 
were not assessed. 
An interesting finding of these genome sequencing studies is the high frequency of 
chromatin modifier mutations identified. Frequently mutated chromatin modifier genes 
include KDM6A (a histone demethylase), the histone methyltransferases KMT2A, 
KMT2C, and KMT2D, the histone acetyltransferases CREBBP and EP300, and 
ARID1A (part of the SWI/SNF complex) amongst others (Table 1.1). These mutations 
were initially identified by Gui et al.100 who were the first group to report results from 
exome sequencing in bladder cancer. Since then, mutations in these genes have been 
identified in bladder tumours of all stages and grades81,82,157,164,173 and these mutations 
are often inactivating with nonsense mutations, small insertions and deletions and 
mutations in essential splice site regions identified61,81,82,157. 
KDM6A is the most frequently mutated chromatin modifier gene in NMIBC61,82,157,164 
with significantly more mutations than in MIBC81,164. KDM6A catalyses the 
demethylation of tri/di-methylated histone H3 lysine 27 (H3K27me2/3) creating a 
transcription-permissive chromatin state177. KDM6A forms a complex with KMT2C/D178 
and this acts to maintain gene expression. Inactivation of these genes would be 
predicted to result in reduced transcription. Intriguingly, more KDM6A mutations have 
been identified in non-muscle-invasive tumours from females than males, potentially 
indicating a gender difference in the epigenetic landscape82. However, the relatively 
small numbers of NMIBCs sequenced combined with a small proportion of those being 
from females is a major limitation and many more samples need to be analysed. 
Analysis of MIBC from TCGA did not show the same bias81. 
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Table 1.1: Frequently mutated genes in NMIBC and MIBC. 
Table from Knowles and Hurst179. aGenes presented were mutated at ³10% in the studies of Hurst 
et al.82 and TCGA 201781.  bData from Hurst et al.82 consisting of 79 TaG1/G2 and 3 TaG3 
tumours. WES sequencing of 24 tumours and targeted sequencing of 58 tumours was carried 
out. Mutation frequency is shown in brackets where only WES sequencing data is available. cData 
from Nordentoft et al.164 WES sequencing was carried out on 20 TaG1/G2 tumours. dData from 
Pietzak et al.157 Targeted sequencing of 55 Ta (23 grade1/2; 32 grade 3) and 38 T1 tumours was 
carried out. “NA” indicates that genes were not covered by the targeted panel used. eData from 
Guo et al.172 WES sequencing was carried out on 32 T1 tumours. fData from TCGA 201781. WES 
sequencing was carried out on 412 MIBC. 
Genea 
Hurst et 
al. 2017b 
Ta (%) 
Nordentoft 
et al. 2004c 
Ta (%) 
Pietzak et 
al. 2017d 
Ta (%) 
Pietzak et 
al. 2017d 
T1 (%) 
Guo et al. 
2013e 
T1 (%) 
TCGA 
2017f 
MIBC (%) 
FGFR3 79 40 66 30 25 14 
PIK3CA 54 25 36 22 6 22 
KDM6A 52 65 50 43 50 26 
STAG2 37 25 24 22 25 14 
KMT2D 30 15 31 26 0 28 
ARID1A 18 35 25 27 6 25 
EP300 18 25 20 8 16 15 
CREBBP 15 20 23 19 12 12 
KMT2C 15 20 16 5 3 18 
RHOB 13 0 NA NA 0 11 
HRAS 12 10 2 8 16 9 
KMT2A 11 0 9 11 9 11 
TSC1 11 5 5 22 12 8 
BRCA2 10 0 11 11 0 7 
COL11A1 10 0 NA NA 0 5 
RBM10 10 20 22 5 0 9 
TP53 4 5 11 35 25 48 
FAT1 (2) 10 13 17 0 12 
KRAS 2 0 11 8 6 4 
ATM (1) 5 13 19 3 14 
CDKN1A (1) 0 11 13 0 9 
ELF3 (1) 25 NA NA 12 12 
ERCC2 (1) 0 21 13 6 9 
ERBB2 (0) 0 11 19 3 12 
ERBB3 (0) 0 9 19 3 10 
RB1 (0) 5 0 5 9 17 
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A few studies have sequenced multiple bladder tumours or tumour regions from 
individual patients55,61,63,164,174,180. NGS has been employed to study the clonal 
relationships between multifocal tumours174,180. Analysis of physically separated, 
synchronous, multifocal tumours from 3 patients identified a clonal relationship in all 
three cases180. Interestingly APBOEC signature mutations tended to be shared across 
tumours suggesting that APOBEC mutagenesis was an early event in these tumours. A 
major limitation of this study was the use of “normal mucosa” as the matched normal. 
As previously discussed, phenotypically normal mucosa may contain some of the 
variants shared by the tumours. By using this as the matched normal some of the early 
events shared by all tumours may have been filtered out as germline variants when 
they were actually somatic, limiting the ability of the researchers to identify early shared 
events. Another study used NGS to investigate the relationship between six spatially 
distinct tumours from a single patient, one of which had an underlying invasive 
component174. This study identified that all tumours were related and the invasive 
component arose from a shared progenitor prior to tumour outgrowth. 
NGS has also been used to investigate metachronous tumours61,164. Analysis of paired 
samples from patients with NMIBC that had stage progression (two patients 
progressed from stage Ta to stage T1, two patients progressed from stage Ta to stage 
T2-4) identified that all paired tumours shared a set of mutations at a high cellular 
presence indicating a common ancestral clone164. The ancestral clones contained 
mutations in well-known cancer driver genes such as FGFR3, PIK3CA and TP53, 
suggestive of the ancestral clone being a major driver of the malignant process. 
Between 14% and 25% of SNVs were shared between paired tumours, and all tumours 
contained some private mutations. A general increase in the number of SNVs detected 
in the invasive tumours was identified. Subclone reconstruction identified between 3-4 
subclones per tumour. Some subclones present in the Ta tumours were lost in the 
progressed tumours and some subclonal populations that expanded in the progressed 
tumours were absent or a very minor subclone in the Ta tumours, demonstrating 
dynamic clonal evolution in these tumours164. 
Larger numbers of metachronous samples were analysed in the study of Lamy et al.61 
who sequenced two or more metachronous tumours from 29 patients. Comparisons 
between patients with progressive disease and patients with non-progressive disease 
identified no difference in mutation rates between the two groups but a higher intra-
patient variation of the mutation spectrum was observed in patients with progressive 
disease. To identify if this intra-patient mutational heterogeneity was reflective of intra-
tumour heterogeneity that may have been missed by sampling bias, the researchers 
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sequenced eight separate regions that had been laser microdissected from a single 
muscle invasive tumour61. All regions were evolutionary similar with few private 
mutations identified. Additionally, a similar intermix of the two main subclones was 
present in all regions, suggestive of low spatial heterogeneity. Two-thirds of patients 
with progressive disease had a high level of APOBEC mutagenesis compared to only 
one-third of non-progressive patients. Subclone analysis identified an ancestral clone 
present in all tumours from each patient, confirming a monoclonal origin of recurrent 
tumours. Few subclones were identified, with each tumour containing only 1 or 2 
private subclones61.  
Low spatial heterogeneity has been observed in primary tumours in an additional 
study63. Analysis of primary and metastatic lesions from three patients with metastatic 
bladder cancer showed that whilst heterogeneity in the primary tumours was low, a 
much higher level of intratumour heterogeneity was observed in the metastatic 
lesions63. Patients with multifocal disease have also been shown to have higher spatial 
heterogeneity than patients with unifocal disease using multi-region analysis55. 
Multifocal tumours were shown to be clonal in origin and analysis of the surrounding 
normal urothelium identified the presence of mutations shared by multifocal tumours 
suggestive of intraepithelial spread or seeding from tumours. Few mutations were 
identified in the surrounding normal tissue in the two patients with unifocal disease 
suggesting that the presence of “field disease” is likely linked with multifocality and 
recurrent tumours55. Sequencing of adjacent urothelium may provide targetable 
mutations in the field disease which could reduce recurrences55. Additionally, the 
mutational burden of the adjacent urothelium could provide a way to predict patients 
that are likely to recur. More studies are needed to assess this. 
Overall, NGS has driven progress in the molecular characterization of bladder cancers, 
yet the numbers of sequenced NMIBCs are still low. As this disease can be highly 
diverse in terms of recurrence and progression, many more studies are needed in 
order to elucidate relationships between genomic characteristics and outcome. The 
monitoring of recurrences from these patients throughout the disease course is 
required to identify potential markers of recurrence, whilst studies investigating pre- 
and post-treatment tumours can provide information on the differences between 
responders and non-responders and may identify markers of resistance that can help 
guide treatment options. 
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1.5 Therapy and bladder cancer 
Studies investigating the effect of chemotherapy on tumour evolution have been 
undertaken in MIBC62,176 and these have revealed important insights into the evolution 
of these cancers. Faltas et al.62 performed WES and clonality analysis on 16 matched 
sets of tumours collected before and after chemotherapy. They identified no significant 
difference in the number of SNVs between pre- and post-chemotherapy tumours but 
analysis of the number of shared and unique mutations showed a substantial level of 
mutational heterogeneity between the samples. On average, only 28.4% of mutations 
were shared across pre- and post-chemotherapy tumours and this heterogeneity was 
consistent across both primary-primary and primary-metastatic tumour pairs. Mutations 
in driver genes were not always shared and instances of convergent evolution were 
identified, exemplified by the presence of a TP53 mutation in a lung metastasis which 
was different to the TP53 mutation shared by other tumours from the patient. 
Phylogenetic reconstruction identified early branching evolution in all patients allowing 
for early metastatic spread. Interestingly, post-chemotherapy tumours demonstrated an 
increase in clonality which could be a reflection of the selective bottleneck caused by 
chemotherapy62,181. Analysis of CNAs between pre- and post-chemotherapy tumours 
showed very little intra-patient heterogeneity and tumours from the same patient 
tended to cluster together suggesting a relatively stable cancer at the CN level62. 
Another study investigating pre- and post-chemotherapy tumours in MIBC focused on 
characterizing the genetic alterations associated with cisplatin-based chemotherapy176. 
They identified a novel mutational signature in their post-chemotherapy tumours that 
was enriched in T > A and C > A substitutions. This signature shared features with an 
experimentally derived signature of cisplatin-induced mutagenesis176. Transcription 
strand bias, consistent with cisplatin crosslinking was also identified. As reported by 
Faltas et al.62, no significant change in mutation load was identified post-chemotherapy 
and the CNA landscape between matched pre- and post-chemotherapy tumours was 
very similar for the majority of tumours. Significant intratumour heterogeneity was 
identified and the level of heterogeneity, especially post-chemotherapy treatment, was 
found to predict overall survival in the cohort. 
As seen in other cancers60, these two studies show that chemotherapy plays an 
important role in the evolution of the genomic landscape of MIBC. Chemotherapy has 
been demonstrated to be a large driver of tumour evolution through its ability to 
generate new mutations176 as well as forming a selective pressure that only the fittest 
clones can pass. Chemotherapy is therefore likely to play a role in the evolution of 
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most cancers, including NMIBC. To date, there have been no studies investigating the 
effect of chemotherapy on tumour evolution in NMIBC.  
1.5.1 Treatment of NMIBC 
The treatment regime for NMIBC depends on the risk of recurrence and progression for 
that patient. Following the European Association of Urology (EAU) guidelines182, 
tumours considered low-risk are primary, solitary, stage Ta of low grade (G1) tumours 
less than 3cm in size and with no concurrent carcinoma in situ (CIS). High-risk tumours 
are tumours with any of the following: stage T1, high-grade/G3, CIS or stage Ta G1/2 
tumours that are multiple and recurrent and large (must be all 3). Intermediate risk 
tumours are any tumours that fall in between these two groups. Treatment of low-risk 
tumours consists of TURBT followed by an immediate single intravesical instillation of 
chemotherapy and follow up cystoscopy after 3 months182. Intermediate risk patients 
are also treated with a single instillation of chemotherapy, but this is considered 
incomplete treatment. For intermediate risk patients, an induction cycle of mitomycin C 
(MMC) is recommended in several guidelines10,182. Alternatively, intermediate risk 
patients can undergo BCG treatment for a year183. For high risk tumours BCG therapy 
should be carried out for 1-3 years whilst for the patients deemed at the highest risk 
(e.g. multiple and/or large HG/G3 stage T1 tumours, or, recurrent T1 HG/G3 tumours) 
radical cystectomy may be advised6. All patients with NMIBC should be followed up 
with frequent cystoscopy, the duration of which changes with the different risk 
groups182.  
1.5.2 Mitomycin C chemotherapy 
At our institution the chemotherapeutic agent MMC is used for the treatment of NMIBC 
patients (Figure 1.5A). As per the guidelines outlined above182, patients at low-risk will 
have an immediate instillation of MMC after TURBT whilst patients at an intermediate 
risk may go on to have an induction cycle, consisting of once-weekly instillations of 
MMC for 6 weeks. 
MMC is a type of anti-tumour antibiotic widely used as a cancer chemotherapy agent. 
MMC’s anti-tumour capacity is believed to come from its ability to crosslink DNA 
strands184, inhibiting both DNA replication and translation185. It is considered a bio-
reductive alkylating agent as it requires enzymatic reduction before it can react with 
DNA. The initially reduced molecule can alkylate DNA resulting in a monoadduct186 
(Figure 1.5B) or it can undergo a second alkylation step with DNA, resulting in 
intrastrand (Figure 1.5C) or interstrand (Figure 1.5D) crosslinks184,187,188.  
 27 
 
 
Figure 1.5: The structure and adducts of mitomycin C. 
MMC can form a range of DNA adducts. MMC (A) can undergo monofunctional activation and 
form monoadducts on guanine residues (B), or it can undergo bifunctional activation forming 
intrastrand (C) or interstrand (D) crosslinks. Figure adapted from Tomasz189 and Avenaño and 
Menéndez190. 
 
MMC has been shown to have sequence specificity189. Monoadduct formation can 
occur at NpG sequences where N is any base. However alkylation is enhanced at 5’-
CpG-3’ (CpG) sequences by 5-10 times191,192. Formation of interstrand crosslinks is 
absolutely specific for CpG sequences as MMC requires a second guanine base in the 
correct position for the second round of alkylation, and this can only occur at the 
guanine base opposite the cytosine of the CpG192. Intrastrand crosslinks occur at GpG 
dinucleotides and occur less frequently than interstrand crosslinks, likely due to the 
preferential binding of MMC to CpGs for monoadduct formation187. 
It is thought that the cytotoxicity, and subsequent anti-tumour activity, of MMC comes 
from its ability to crosslink DNA strands184, which can inhibit both DNA replication and 
translation. Monoadducts have been shown to inhibit DNA synthesis in a cell-free 
A B 
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system and this could potentially be a cytotoxic event. However, the lesion created by 
the monoadduct was bypassed at a low rate allowing replication to continue185, thus 
representing a potential source of mutation. Despite this, a study using a cell-line 
system provided evidence to suggest that the interstrand cross-link is the critical 
cytotoxic lesion193. They compared the cytotoxicity of MMC to that of 10-decarbamoyl 
mitomycin C (DMC), an artificial derivative of MMC that was thought to be 
monofunctional yet was reported to be more cytotoxic than MMC to certain cell lines. In 
their analysis they identified that DMC could, surprisingly, induce the formation of 
interstrand cross-links, albeit at a much-reduced rate to the formation of monoadducts, 
and this was at a similar rate of cross-link formation to that seen with MMC. Both drugs 
showed similar cytotoxicity and levels of interstrand crosslinking but varied on the 
number of monoadducts. Therefore, it was postulated that this correlation between 
cytotoxicity and cross-links was evidence for the cross-links being the critical cause of 
cell death193. This study focused only on the induction of cell death and did not assess 
any surviving cells for mutations. It is therefore possible that whilst monoadducts are 
unlikely to be cytotoxic, they could possibly be mutagenic. 
The genotoxicity and cytotoxicity of MMC has been investigated frequently over the 
years. Early studies in the 1960s used simple cell observations and growth curves to 
identify a dose-dependent inhibition of proliferation when cells were incubated with 
MMC. This inhibition persisted after removal of the drug194,195 and it was noted that the 
cells continued to grow but did not divide after treatment, resulting in the formation of 
giant cells. Moving on from simple cell growth observations, Cohen and Shaw196 used 
karyotyping to assess the effects of MMC over a range of concentrations. They 
identified that higher concentrations of MMC destroyed all cells whilst lower 
concentrations reduced the mitotic rate and induced numerous chromosome breaks 
and exchanges. Analysis of these breaks and exchanges was seen to be non-random 
with chromosomes 1, 9 and 16 most affected, a feature also identified by Morad et 
al.197. A drawback to the use of karyotyping in these studies was that at this time G-
banding was not available and it was impossible to identify many individual 
chromosomes so they were analysed as groups. Fortunately, chromosomes 1, 9 and 
16 were able to be individually identified at this time due to their regions of secondary 
constriction. 
The introduction of banding techniques paved the way for a more accurate assessment 
of MMC damage using karyotypic techniques198,199. Despite the advancement in 
technology these studies drew similar conclusions to those described previously; the 
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distribution of break points was seen to be non-random with chromosomes 1, 9 and 16 
most commonly affected, particularly in the heterochromatic, peri-centromeric regions. 
Induction of micronuclei in cells treated with MMC has been observed33,200. Analysis of 
leukocytes from a single donor using FISH identified an 18-fold higher induction of 
micronuclei by MMC compared to controls. Chromosome 9 was identified as the 
biggest contributor of material to the micronuclei with chromosome 1 being the next 
highest contributor33. Hovhannisyan et al.200 also used multi-coloured FISH, using both 
centromeric and whole-chromosome painting to identify the involvement of 
chromosomes 3, 4, 6, 7, 9, 16,17,18 and X in MMC-induced micronuclei formation. 
Material from chromosomes 9 and 16 were contained most often in micronuclei and 
this occurred more often than expected based on DNA content. However, chromosome 
9 was only involved in around one third of all micronuclei yet Fauth et al.33 found that 
around two thirds of micronuclei involved chromosome 9. This difference could be 
down to the difference in MMC concentration; Hovhannisyan et al. used 0.1µg/ml whilst 
Fauth et al. used 0.5µg/ml, a 5x larger dose. 
Whilst these cytogenetic studies gave valuable information on large events occurring in 
the DNA, they may have missed smaller changes in copy number where insertions or 
deletions are limited to a small part of the chromosome. They also do not provide any 
information on the molecular nature of MMC-induced events.  
There are a limited number of studies that have specifically investigated the mutational 
spectrum of MMC. Srikanth et al.201 were amongst the first to use sequencing to 
identify mutations caused by MMC. They used a shuttle vector system in which 
plasmid DNA was incubated in reduced MMC, replicated in cells and then used to 
transform bacteria to increase the material available for assay and sequencing.  
Mutational hotspots in the target region of the plasmid were identified in GC rich areas, 
correlating with the specificity of MMC for guanine bases. The most common types of 
mutations identified were substitutions, accounting for 76% of all mutations. 
Interestingly, 30% of the base substitutions were tandem substitutions, all of which 
were at GpG sites. Single base deletions were the second most common event 
identified. 
Maccubbin et al.202 also used a shuttle vector system to assess the mutagenic potential 
of MMC. This group focused on the mutations caused specifically by MMC-induced 
monoadduct formation by incubating the shuttle vector with MMC under conditions 
favouring monofunctional activation. Under these conditions, they frequently observed 
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single base substitutions corresponding to almost 60% of all mutations. Single base 
deletions accounted for 24.5% of all mutations and nearly 80% of mutations involving a 
single base occurred at G:C base pairs, confirming the specificity of the monoadduct. 
No tandem substitutions were identified, consistent with the monofunctional activation 
of MMC. 
Despite in vitro evidence suggesting that MMC can indeed induce substitutions, this 
was not reflected in an in vivo study. Takeiri et al.203 investigated the mutation 
spectrum of MMC in the bone marrow of mice. They identified many large deletions 
between 110bp and 8kb long, several of which contained 2-6bp short homologous 
sequences in their junctions that were eliminated when the DNA joined back together. 
Contrary to the findings in vitro, single base substitutions or deletions were not found at 
a higher level than in the control. They did, however, identify that tandem base 
substitutions were only found in the MMC-treated samples. When the group 
established a cell line from the mice and treated these with MMC they identified large 
deletions and tandem substitutions consistent with the in vivo data. Additionally, they 
identified single base substitutions, most commonly G:C > T:A transversions, which 
had not been identified in the in vivo data but correlated with the in vitro results seen 
previously204. 
The number of studies investigating MMC action on DNA declined in the early 2000s. 
Despite the vast improvements in technology in the interim, it was not until recently that 
next-generation sequencing was employed to look at the MMC-induced DNA mutation 
spectrum. Tam et al.205 used next-generation whole-genome sequencing to 
characterise the mutational spectrum of MMC in the model organism Caenorhabditis 
elegans. By using the genetic balancer hT2 they were able to capture and maintain 
mutations that would otherwise be lethal, such as mutations in essential genes. As in 
the study of Takeiri et al.203, they reported that MMC primarily induced deletions, with 
few SNVs or insertions identified. Analysis of the sequence context of the deletions 
showed a preference for 5’-CpG-3’ dinucleotides, consistent with previous 
data185,191,192. 
The contrast in findings between the in vitro and in vivo studies is interesting. It is 
possible that the large deletions caused by MMC may be missed in the in vitro systems 
of Srikanth and Maccubbin as such deletions could interfere with the packaging of the 
lambda phage. The large deletions were identified in vitro using a different method204. 
Maccubbin et al.202 restricted their analysis to monofunctional activation of MMC. This 
monofunctional activation could be rare in vivo where several enzymes have the 
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capacity to reduce MMC, thus reducing the observation of mutations caused by this 
adduct. Interestingly Tam et al.205 restricted their analysis of SNVs to only homozygous 
mutations which may have limited the discovery of MMC induced substitutions. 
Overall, the literature clearly shows that MMC can cause alterations to DNA that lead 
to mutations that are maintained. It may therefore be possible to identify CNVs, SNVs 
and tandem substitutions reflective of MMC-induced damage. The cytogenetic studies 
described above identified chromosomes 1, 9 and 16 as the most affected by MMC 
treatment, particularly in their areas of secondary constriction. These areas of 
secondary constriction are actually large areas of gene-poor peri-centromeric 
heterochromatin found on these 3 chromosomes. These regions have yet to be 
annotated with sequence and therefore will not have coverage following analysis of 
next generation sequencing data. This will mean that small changes in these regions, 
small deletions, SNVs etc., may not be identified. However, CN changes that span 
beyond these regions could occur, and these have the potential to be identified. 
Molecular data from the in vitro studies suggest that single base substitutions, 
particularly C > A transversions may be detected, though the in vivo data contradicts 
this. Reduction of the drug may occur differently within a tumour environment 
compared to within model organisms meaning that induction of SNVs cannot be ruled 
out. It will be interesting to see if any of these changes are detected in tumours after 
treatment. Additionally, the sequence specificity of MMC for CpG dinucleotides could 
have interesting consequences. The abundance of CpG dinucleotides in the human 
genome is less than expected considering the overall GC content. However, CpG 
dinucleotides are enriched in exons and promoter regions relative to the rest of the 
genome, likely due to coding restraints206. By specifically targeting these regions MMC 
has the potential to disrupt gene function or alter gene expression. 
1.5.3 Clinical studies of MMC 
MMC was first shown to be effective as a bladder cancer treatment in the 1970’s207. In 
the late 80’s to early 90’s, large scale randomised trials were published investigating 
the efficacy of intravesical chemotherapy for the treatment of bladder cancer208,209. 
Tolley et al.210 compared two chemotherapy regimens after complete transurethral 
resection: a single immediate instillation or an immediate instillation followed by four 
further instillations at check-ups within the first year. The control group underwent 
TURBT only. At their interim study with two years of follow up, all patients who received 
MMC (single or multiple instillations) experienced reduced rates of recurrence 
compared to TURBT alone, with those who received multiple installations having a 
considerably lower recurrence rate compared to a single instillation210. After seven 
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years of follow up a single instillation of MMC at TURBT was shown to have a long-
term advantage over TURBT alone, with a significantly decreased recurrence rate. 
There was a suggestion that 5 installations may offer an advantage over a single 
installation, but this was not significant209. This treatment effect may have been diluted 
as patients who recurred at 3 months were counted despite not having started the 
additional instillations211.  
Even with adjuvant treatment schedules, immediate instillation reduces the rate of 
recurrence compared to delayed instillation212. However results are conflicted as a 
meta-analysis suggested that this was only true if patients were treated for the shorter 
term of 6 months (9 instillations) rather than a year (11 instillations)211 whilst 
Bosschieter et al.212 identified a benefit even for patients receiving up to 15 instillations 
of MMC. Several meta-analyses have now confirmed the benefit of a single immediate 
instillation of chemotherapy post TURBT213-215. A large meta-analysis by Sylvester et al. 
looked at seven trials that compared TURBT alone with TURBT and an immediate 
instillation of chemotherapy214. Two of these studies used MMC chemotherapy. 
Overall, an immediate instillation of chemotherapy reduced the odds of recurrence by 
39%. Patients with one single tumour gained the most benefit from the instillation as 
patients with multiple tumours still had a high recurrence rate and further treatment was 
suggested. Despite the benefits of reduced recurrence rates, MMC treatment has not 
been shown to affect progression213. 
The use of multiple instillations of chemotherapy has been less investigated with fewer 
clinical studies available. The study by Tolley et al.209 suggested that maintenance 
treatment with an additional 4 instillations of MMC over the year may reduce the 
recurrence rate compared to a single instillation. Bouffioux et al.208 compared a total of 
four treatment schedules with patients receiving early (on the day of resection) or 
delayed instillation (7-15 days after resection) and then each of these groups having 
short-term treatment (instillations given every week for 4 weeks followed by every 
month for 5 months) or long term treatment (where the monthly treatment was 
extended by a further 6 months). This study identified that patients having delayed and 
short-term treatment did the worst. Unfortunately this study did not compare their 
extended schedule to TURBT or TURBT plus a single instillation of MMC. A study 
comparing one instillation of MMC a week for 6 weeks compared to 3 instillations a 
week for two weeks showed a higher response in the two week schedule216. However, 
this was neoadjuvant treatment with chemotherapy given prior to tumour resection after 
the detection of a recurrence. 
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BCG therapy has long been known to reduce recurrence in stage Ta and T1 NMIBC217 
and BCG treatment is the standard of care for patients with high risk disease218. Many 
trials investigating the use of a course of MMC treatment for intermediate or high risk 
tumours were done in comparison to BCG219-221. An early study comparing MMC and 
BCG identified a significant increase in the number of patients disease-free in the BCG 
arm compared to the MMC arm (49% vs. 34%) however BCG treatment gave more 
frequent side effects219. A limitation of this study was the short follow-up time; the 
median follow-up was only 39 months. A long-term study with 20 years of follow up 
identified a significantly reduced recurrence rate for patients treated with BCG 
compared to MMC221. The majority of these patients were of intermediate risk, however 
the study was limited by a small patient number (89 patients) and a low concentration 
of MMC (0.2 mg/ml). Another study comparing a 6-week cycle of either BCG or MMC 
treatment identified no significant difference in the recurrence rates between the two 
treatments. Three-year recurrence free rates were 65.5% for BCG therapy compared 
to 68.6% for MMC chemotherapy220. 
Due to the contradictory results from clinical studies, several meta-analyses have been 
performed. An early meta-analysis by the Cochrane group found that BCG was 
superior to MMC in reducing recurrences only in high risk patients222. No overall 
significant difference in progression rates was identified between BCG and MMC 
treated groups in a meta-analysis by Böhle and Bock223. However, additional treatment 
with BCG maintenance therapy was shown to be favorable with a significant reduction 
in progression compared to MMC treatment. Malmström et al.224 performed an 
individual patient data meta-analysis looking at the long-term outcome of studies 
comparing BCG and MMC. Overall, no difference in the risk of recurrence was 
identified between BCG and MMC. Separating the patients into patients who had BCG 
maintenance and patients who did not identified that BCG maintenance reduced the 
risk of recurrence by 32% compared to MMC treatment. However, a lack of BCG 
maintenance increased the risk of recurrence by 28% compared to MMC treatment. 
There were no significant differences identified regarding progression or overall 
survival. However, BCG therapy was associated with higher toxicity, leading to the 
suggestion from the authors that BCG with maintenance should be the standard of 
care for high-risk patients whilst MMC, being less toxic, could be considered for 
intermediate risk patients with failures switched to BCG. As there are still contradictory 
results about the beneficial effect of BCG over MMC regarding tumour recurrence and 
progression, an updated Cochrane systematic review comparing the use of BCG and 
MMC for the treatment of stage Ta and T1 bladder cancer is underway225. 
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Overall, BCG therapy with maintenance has become the standard of care for high-risk 
tumours whilst for intermediate-risk tumours the increased toxicity associated with BCG 
treatment219,226 alongside the evidence that MMC treatment can be as efficacious as 
BCG therapy has resulted in either BCG therapy or chemotherapy being advised for 
these tumours182. A lack of consistency with respect to the duration of treatment within 
trials has meant that there is debate concerning the optimal schedule for 
chemotherapeutic intervention211,220,227. At our institution patients at an intermediate risk 
are offered an induction cycle of MMC treatment consisting of 6 weekly instillations. 
This schedule has been widely used over the years, but there is an awareness that 
empirically defined habit has defined this schedule rather than biological rationale216. 
Additionally, treatment options for intermediate risk patients may have been affected by 
the recent worldwide shortage of BCG228. This has resulted in an increase in the use of 
chemotherapeutic regimes with BCG treatment being reserved for managing high risk 
tumours or for patients that have failed chemotherapy treatment229. 
Interestingly, a recent systematic review by Sylvester et al.213 identified that a single 
immediate instillation of chemotherapy after resection resulted in an increased risk of 
death in NMIBC patients. Separation of the cause of death by treatment group 
(according to the European Organisation  for Research and Treatment of Cancer 
(EORTC) recurrence risk score) suggested that for patients with a recurrence risk 
score of 5 or greater, more of those who received a single instillation died, and a higher 
percentage of these deaths were due to malignant disease (bladder cancer or other) 
compared to TURBT alone. This subgroup (EORTC recurrence risk score of 5 or 
greater) consisted of patients with multiple tumours, tumours 3cm or greater, and T1 
tumours. This data could suggest that chemotherapy is influencing tumour evolution, 
perhaps selecting for more aggressive disease, in this patient subgroup. 
NMIBC is an interesting disease as it is treated with harsh, DNA damaging 
chemotherapies despite having a favourable prognosis4. It is likely that treatment with 
genotoxic agents, such as MMC, may induce more mutations and this could alter the 
evolutionary trajectory in certain patient subgroups. Whilst this is accepted in treating 
later-stage disease when life-span is trying to be increased, should these agents be 
used in a cancer which has an otherwise good prognosis? To the best of our 
knowledge, there have been no studies investigating chemotherapy-related genetic 
changes in NMIBC to date. Therefore, the aim of this project was to identify any 
possible genetic alterations associated with MMC treatment. 
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1.6 Project Aims 
• To characterise the copy number landscape of tumours from patients with 
recurrent NMIBC. 
• To use copy number alterations and the mutation status of key bladder cancer 
genes to assess the clonal origins of tumours from the same patient. 
• To identify any features selected by mitomycin C chemotherapy and assess the 
effects of therapy on overall genomic complexity by comparing tumours from 
patients who did or did-not receive intravesical mitomycin C. 
• To investigate the subclonal composition of pre- and post-MMC treatment 
tumours and infer the temporal sequence of events during tumour evolution. 
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Chapter 2  
Methods 
2.1 Sample processing 
2.1.1 Ethics and sample collection 
Ethical approval for this study was granted by the Local Research Ethics Committee 
(Leeds East 99/156 and Leeds Multidisciplinary Research Tissue Bank (RTB) 
(10/H1306/7)). Informed consent was obtained from all patients. Could cup biopsies 
were collected, embedded in optimal cutting temperature (OCT) compound (VWR 
International) snap-frozen and stored in liquid nitrogen. The remainder of the sample 
was embedded in paraffin for diagnostic assessment. Sample grading and staging was 
carried out by a consultant urological pathologist (JR) using the 1973 WHO8 and TNM 
criteria, respectively. 
2.1.2 Sample selection and study participants 
Sixty-seven tumours from 23 patients with recurrent non-muscle-invasive bladder 
cancer (NMIBC) were included in the study. These were retrospectively selected from 
the Leeds RTB using the following criteria:  
-  Initial presentation of low stage (<T2) non-muscle-invasive disease  
-  Fresh frozen material available from at least two temporally separated tumours  
A search of the Leeds Multidisciplinary Research Tissue Bank (RTB) database for 
patients with recurrent bladder tumours was carried out in November 2014 and this 
identified 207 patients with more than one tumour in the tissue bank. Initially the focus 
of the study was on patients with multiple recurrent tumours of low stage and grade, 
therefore at this time patients were restricted to those with primarily stage Ta disease. 
Patients with synchronous events were not excluded from the study. This identified 57 
suitable patients with 2-5 tumour events (30 x 2 events, 17 x 3 events and 10 x 4-5 
events). The RTB database was checked periodically to identify new potential patients 
and check for new recurrences from patients already included in the study. Patients 
with the most recurrences were initially prioritised but due to difficulties extracting 
sufficient DNA from all tumours from such patients, numbers were bulked by the 
inclusion of patients with only two tumour events. Tumours from 20 patients were 
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sectioned for DNA extraction and sufficient DNA was obtained for 11 of these patients 
(P0198, P0536, P0712, P0717, P0933, P0990, P1175, P1326, P2065, P2104 and 
P2291) by May 2016. These samples were sufficient to fill a single lane for copy 
number analysis on the HiSeq3000.  
After sequencing of the first batch of patients for copy number analysis was completed 
the focus of the project changed to investigating genomic alterations associated with a 
course of MMC chemotherapy. A list of patients who had received a course of MMC 
chemotherapy treatment between June 2012 and December 2015 at St James’s 
University Hospital was provided by Urologist Mr Sanjay Jain. This was cross-
referenced with the list of patients who had provided informed consent for the RTB and 
54 patients were identified, of which 22 patients had recurrent tumours. Of those 22 
patients, 10 had tumour material available in the tissue bank from both pre- and post- 
MMC treatment and these were included in the cohort (P0468, P0533, P0926, P1485, 
P1777, P1870, P2161, P2218, P2329 and P2440). Patient P0960 had previously  been 
sectioned for copy number analysis however this sample was not ready for sequencing 
in the first batch. Analysis of clinical information for the samples sectioned for the first 
copy number analysis run identified that this patient had received a course of MMC 
treatment (before 2012). Patient P0418 was also identified as having received a course 
of MMC pre 2012 therefore both P0960 and P0418 were included in the second batch 
of samples. Patients P0536, P0717, P0990 and P1175 had also received a 6 week 
course of MMC treatment and had tumours from both pre- and post-treatment 
available. A summary of patient information is given in Table 2.1 and clinical timelines 
for each patient can be found in Appendix A.  
Overall there were 15 males (65%) and 8 females (35%) with a median age at 
diagnosis of 72 years (range 46-82). The number of tumours ranged from 2 to 5 
metachronous tumours per patient. A total of 67 tumours were included in the study: 8 
stage Ta grade 1 (G1), 42 stage Ta grade 2 (G2), 7 stage Ta grade 3 (G3), 4 stage T1 
G2, 2 stage T1 G3, 1 stage Ta(x) G3, 2 stage T1(x) G3 and 1 possible low-grade 
urothelial carcinoma in which small, heavily diathermied fragments of tissue made 
grading difficult. (x) refers to tumours where insufficient sampling of the muscle layer 
occurred and therefore invasion could not be ruled out. All (x) tumours were from a 
single patient and the disease history of that patient (P0418) suggests that these 
tumours were not invasive therefore the patient was included in the study.
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Table 2.1: Patient summary. 
Basic information about each patient and the histopathological stages and grades of all patients’ 
tumours used in the study are shown. The sample ID reflects the time point at which the sample 
was taken. Multifocal samples have an additional letter to identify tumours from the same time 
point. aMtr = months to recurrence. This is the number of months between the first tumour in the 
study and each subsequent tumour studied. bDenotes the cases where the first tumour available 
for the study was not the primary tumour for that patient. For more information on the timeline of 
events for each patient see the patient timelines in Appendix A. 
Patient ID Sex Age at Diagnosis Sample ID 
Stage and 
Grade Mtr
a 
P0198 M 70 P0198-S01b TaG2 0 
P0198-S02 T1G2 36 
P0198-S03 TaG2 43 
P0198-S04 TaG2 46 
P0418 F 73 P0418-S01 T1xG3 0 
P0418-S02 TaxG3 4 
P0418-S03 T1xG3 7 
P0468 M 53 P0468-S01 T1G2 0 
P0468-S03 TaG2 143 
P0468-S05 TaG2 153 
P0533 M 72 
 
P0533-S01b TaG2 0 
P0533-S02 TaG2 130 
P0533-S3A TaG2 137 
P0533-S3B TaG2 137 
P0533-S04 TaG3 146 
P0536 M 79 P0536-S01 TaG2 0 
P0536-S02 TaG2 4 
P0536-S03 TaG2 46 
P0712 M 80 P0712-S01 TaG2 0 
P0712-S02 TaG2 29 
P0712-S03 TaG3 46 
P0712-S04 TaG3 120 
P0712-S05 TaG2 129 
P0717 F 79 P0717-S01b TaG2 0 
P0717-S02 TaG2 2 
P0717-S03 T1G2 6 
P0717-S04 TaG2 15 
P0717-S05 T1G3 26 
P0926 F 62 P0926-S01b TaG1 0 
P0926-S03 TaG3 36 
P0933 F 74 P0933-S01 TaG2 0 
P0933-S02 TaG2 12 
P0960 F 73 P0960-S01 TaG2 0 
P0960-S03 TaG1 11 
P0960-S04 TaG2 28 
P0990 F 72 P0990-S01 TaG2 0 
P0990-S04 TaG2 75 
P0990-S05 T1G2 78 
P1175 M 69 P1175-S01 TaG2 0 
P1175-S02 TaG2 13 
  
 39 
Patient ID Sex Age at Diagnosis Sample ID 
Stage and 
Grade Mtr
a 
P1326 M 46 P1326-S01 TaG2 0 
P1326-S02 TaG2 101 
P1485 F 73 P1485-S01 TaG2 0 
P1485-S02 TaG1 91 
P1485-S03 TaG2 98 
P1777 M 82 P1777-S01 T1cG3 0 
P1777-S02 TaG3 56 
P1870 M 70 P1870-S01 TaG3 0 
P1870-S2A TaG2 43 
P1870-S03 TaG2 50 
P1870-S05 TaG1 75 
P2065 M 62 P2065-S01 TaG2 0 
P2065-S02 TaG2 36 
P2104 M 71 P2104-S01 TaG2 0 
P2104-S02 TaG2 28 
P2161 M 67 P2161-S01 TaG2 0 
P2161-S02 TaG2 26 
P2218 M 76 P2218-S1Ab TaG2 0 
P2218-S1Bb TaG2 0 
P2218-S02 TaG3 10 
P2291 M 64 P2291-S01 TaG2 0 
P2291-S02 TaG2 7 
P2329 M 74 P2329-S01b TaG2 0 
P2329-S02 TaG1 8 
P2329-S03 TaG2 21 
P2440 F 68 P2440-S01b TaG2 0 
P2440-S02 possible low grade UCC 5 
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2.1.3 Tissue sectioning 
Tissue sectioning of samples embedded in OCT compound was performed at -20°C in 
a Leica cryostat (Leica Microsystems Ltd). A 5 µm section was taken and stained in 
haematoxylin (Sigma-Aldrich) for 1 min to estimate tumour purity. If purity was 
estimated to be 70% or greater then tumours were sectioned into sets of 10 slices of 20 
µm thickness for nucleic acid extraction and stored at -80°C in micro-centrifuge tubes 
or at -180°C in cryo-tubes. A further 5 µm section on a glass slide was taken before 
and after each set of 10 slices for full haematoxylin and eosin (H&E) staining to monitor 
the purity of the sample throughout. If purity was estimated to be less than 70% then 
samples were sectioned for laser-capture microdissection (LCM). For LCM 10 µm 
sections were captured on polyethylene napthalate (PEN) coated slides (Applied 
Biosystems, part of Thermo Fisher Scientific). Depending on size, 4-16 sections were 
captured per slide and 4-8 slides filled per sample. A 5 µm section was taken before 
and after every 1-2 slides for H&E staining. 
2.1.4 H&E Staining 
2.1.4.1 Full H&E staining 
Slides were removed from -80°C storage and allowed to come to room temperature for 
5-10 min before being submerged in acetone for 1 min. Slides were then air-dried for 5-
10 min before submerging in haematoxylin for 3 min. Slides were then washed under 
running water for 1 min, submerged in Scotts tap water (Leica Biosystems, part of 
Leica Microsystems Ltd) for 1 min, washed in running water for a further 1 min, 
submerged in eosin (Leica Biosystems) for 1.5 min and washed for a further 30 
seconds in running water. Slides were then drained onto tissue before being 
submerged in a series of 100% ethanol washes (1 x 1 min, 3 x 3 min). Slides were 
drained onto tissue again before a series of 3 x 5 min xylene washes. Slides were left 
in xylene until they were mounted onto coverslips using DPX Mountant (Sigma-
Aldrich). Sections were examined under light microscopy. 
2.1.4.2 Staining of PEN slides for LCM 
Slides were stained as per the protocol described for full H&E staining (2.1.4.1) with a 
few modifications; submersion times for PEN slides in haematoxylin and eosin were 
reduced to 1.5 min and 45 seconds, respectively, and the xylene steps were removed. 
Instead, after the ethanol washes, slides were allowed to air dry before being stored at 
room temperature in a slide box containing desiccant. Tumour cells were then captured 
using LCM within 4 days. 
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2.1.5 Macrodissection and laser-capture microdissection 
Tumours that contained less than 70% tumour cells were sectioned onto slides for 
dissection. If areas of tumour cells were spatially distinct from the non-tumour cells 
then samples were macrodissected by cutting and capturing the area of the PEN 
membrane under the cells of interest using a dissecting microscope. If cells were more 
intermixed, LCM was performed using the ArcturusXTTM LCM system with CapSure 
Macro LCM (0211) caps (Applied Biosystems). This utilises a dual laser system to 
capture the tissue required; the area of interest is drawn around on the screen and this 
line is used as the UV cutting line. To ensure the tissue of interest is captured onto the 
caps a gentle infra-red laser is used to melt the film on the cap to the cells of interest. 
This was set at 30-100 mV. Tumour cells were isolated by one of two methods: 
drawing directly around the tumour cells and excising them onto the cap or by drawing 
around the stroma and contaminating normal cells and removing them from the slide. 
The film containing neoplastic cells was removed from the cap, or the PEN membrane 
containing the neoplastic cells if the stroma was removed from the slide, and placed in 
a 1.5 ml micro-centrifuge tube and stored at room temperature in a box containing 
desiccant for a maximum of three days before DNA extraction. 
2.2 DNA Extraction, Quantification and amplification 
2.2.1 Tumour DNA Extraction 
DNA was extracted using the Gentra PureGene Tissue kit (QIAGEN) according to the 
manufacturer’s instructions. Briefly tissue was lysed overnight by incubation at 55°C in 
lysis buffer containing proteinase K. Protein was then removed via a modified salt-
precipitation method and the DNA precipitated using isopropanol with glycogen added 
to help recovery. Precipitated DNA was pelleted via centrifugation and washed with 
70% ethanol before allowing the pellet to air dry. The pellet was re-suspended in 50 µl 
of DNA hydration solution. 
2.2.2 Blood DNA extraction 
DNA was extracted from venous blood using an Illustra Nucleon BACC DNA extraction 
kit (GE Healthcare Life Sciences) according to the manufacturer’s instructions. 
2.2.3 DNA quantification using PicoGreen assay 
DNA was quantified using the Quant-iT PicoGreen dsDNA assay kit (Invitrogen, part of 
Thermo Fisher Scientific) with the high-range standard curve protocol. The provided 
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lDNA standard was diluted in 1 x Tris-EDTA (TE) buffer (10mM Tris-HCl, 1mM EDTA, 
pH 7.5) to concentrations of 2 ng/ml, 20 ng/ml, 200 ng/ml and 2000 ng/ml whilst 
samples were prepared by adding 1 µl of sample to 499 µl of 1 x TE. PicoGreen 
reagent was diluted 200-fold in 1 x TE and 100 µl was added to 100 µl of 
sample/standard in a black 96 well optical plate (BMG Labtech Ltd) and incubated in 
the dark for 2-5 min. Fluorescence intensity was measured using a FLUOstar Galaxy 
fluorescence plate reader (BMG Labtech Ltd) at an excitation wavelength of 480 nm 
and emission of 520 nm. DNA concentration was determined using the standard curve. 
2.2.4 Whole Genome Amplification 
To preserve the maximum amount of genomic DNA (gDNA) available for NGS 
techniques, Whole Genome Amplification (WGA) was performed using the REPLI-g 
Mini Kit (QIAGEN) according to the manufacturer’s instructions. This kit uses the Phi29 
polymerase which is highly processive and has strong strand displacement activity230. 
This activity allows the polymerase to copy over the same material several times by 
extending new primers and displacing other amplified strands in an isothermal 
reaction231. This is known as multiple displacement amplification and generates 
micrograms of DNA from only 25 nanograms of input DNA. This WGA-DNA was used 
for the SNaPshot assays detailed below. A brief methodology for WGA follows. 
Briefly; samples were diluted to 10 ng/µl (where possible) and 2.5 µl of this was added 
to 2.5 µl of denaturation buffer and incubated at room temperature for 3 min. 
Denaturation was stopped by the addition of 5 µl of neutralisation buffer before addition 
of 40 µl of a master mix consisting of 1 µl REPLI-g Mini DNA polymerase, 29 µl of Mini 
Reaction Buffer and 10 µl of Nuclease Free Water (NFW). Samples were incubated at 
30°C for 16 h before heat inactivation at 65°C for 3 min. A WGA negative control 
consisting of 2.5 µl of NFW was included in each WGA run to check for contamination. 
After amplification, samples were aliquoted into 2 x 24 µl concentrated stocks, stored at 
-20°C and a dilute working aliquot, produced by diluting the WGA DNA 1 in 30 with 
NFW. The diluted working aliquot was stored at 4°C. The DNA produced was quality 
checked by PCR amplification using the PCR step of one of the SNaPshot assays (see 
section 2.4.1). 
2.3 Short Tandem Repeat profiling 
Short tandem repeat (STR) analysis uses the length of STRs from 16 locations in the 
genome to make comparisons between samples to see if they come from the same 
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individual. This was used to: 1) confirm that tumours and bloods were from the same 
person and 2) where monoclonality could not be determined, confirm that all tumours 
are from the same individual. 
The Promega PowerPlex 16 system (cat# DC6531) was used for STR analysis 
following the manufacturers protocol with some modifications. Briefly, genomic DNA 
was diluted to 0.5 ng/µl and 1 µl of this was combined with 1 µl of the PowerPlex 10x 
primer mix, 5 µl of QIAGEN multiplex PCR master mix (cat# 206143) and 3 µl of NFW 
to a total volume of 10 µl. Thermal cycling conditions were: an initial denaturation at 
95°C for 15 min then 96°C for 1 min, then 10 cycles of: denaturation at 94°C for 30 
seconds, annealing at 60°C for 2 min and extension at 70°C for 45 seconds, followed 
by 22 cycles of: denaturation at 90°C for 30 seconds, annealing at 60°C for 2 min and 
extension at 70°C for 45 seconds with a final extension at 60°C for 10 min before 
reactions were held at 4°C. After PCR amplification samples were prepared for 
sequencing: 0.6 µl of PCR products were combined with 0.5 µl internal lane standard 
(ILS) 600 and 10 µl HiDiTM formamide (Applied Biosystems). Immediately prior to 
running, samples were denatured at 95°C for 3 min then snap cooled on ice water. 
Samples were run on an ABI PRISM 3130xl Genetic Analyser with a 36cm length 
capillary and POP-7 polymerTM and analysed using the GeneMapper 3.7 software. 
Repeat lengths at each location for each allele were compared between samples.  
2.4 Single gene mutation analysis 
2.4.1 SNaPshot assay 
The SNaPshot assay combines a PCR amplification step and a primer-extension step 
for the rapid identification of known hotspot mutations. In bladder cancer hotspot 
mutations occur in FGFR3, PIK3CA and the RAS family of genes and also in the TERT 
promoter. SNaPshot assays have been designed to identify 11 hotspot mutations in 
FGFR3232, 4 hotspot mutations in PIK3CA233, 3 mutations in the TERT promoter156, 7 
hotspot mutations in HRAS and KRAS and 8 in NRAS143. These four SNaPshot assays 
were run on WGA-DNA from each of the tumours. The assay workflow and a brief 
description of the methodology is shown in Figure 2.1.  
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Figure 2.1: Workflow for the SNaPshot assay. 
A) Basic outline of the SNaPshot assay workflow. *SAPEX treatment refers to treatment with 
Shrimp Alkaline Phosphatase and Exonuclease I. ** SAP treatment is treatment with Shrimp 
Alkaline Phosphatase . B) The SNaPshot single base extension reaction. The SNaPshot probe 
anneals next to the hotspot mutation and is extended by the incorporation of a single fluorescently 
labelled dideoxynucleotide triphosphate(ddNTP). Each probe has a tail of T bases at the 5’ end 
that differs in size. This allows for separation of the fragments during sequencing. 
  
A 
B 
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2.4.1.1 PCR amplification, agarose gel electrophoresis and SAP/ExoI 
treatment 
For each gene the regions of interest were amplified in a multiplex PCR reaction, 
except for the TERT promoter in which two separate singleplex PCR reactions were 
run (for a list of regions targeted in each assay and the primers used see Table 2.2). 20 
ng of gDNA or 2 µl of diluted WGA product was used for amplification in a 15 µl 
reaction containing 1 x PCR buffer, 1.5 mM MgCl2, 0.17 mM dNTPs, 5% glycerol and 1 
unit of GoTaq DNA polymerase (Promega) with primer concentrations as detailed in 
Table 2.2. 2 µl water was used as a PCR negative control. Thermal cycling conditions 
were: an initial denaturation at 95°C for 5 min, followed by 35 cycles of: denaturation at 
95°C for 45 seconds, annealing for 45 seconds (60°C for FGFR3 and PIK3CA, 65°C 
for TERT and 55°C for RAS), and extension at 72°C for 45 seconds, followed by a final 
extension at 72°C for 10 min. The number of cycles was increased to 40 for WGA 
material. 
PCR products were checked for yield and quality using agarose gel electrophoresis. 3 
µl of PCR product was combined with 6 µl of water and 1 µl of 10 x DNA loading dye 
(40% w/v sucrose, 0.25% w/v bromophenol blue) and loaded onto a 2% agarose gel 
cast in 1 x Tris-Borate-EDTA (TBE) buffer (0.089M Tris, 0.089M Boric Acid, 0.002M 
EDTA, pH 8.3) (Severn Biotech Ltd) and containing 0.7 µg/ml ethidium bromide, 
alongside a 100 bp DNA ladder (New England Biolabs (NEB)). Samples were 
electrophoresed in 1 x TBE for 1 h at 90V. Gels were visualised using a ChemiDoc 
XRS system (Bio-Rad Laboratories Ltd) and imaged using Image Lab software (Bio-
Rad Laboratories Ltd., Version 5.2.1). PCR product sizes were estimated by 
comparison to the 100 bp DNA ladder. 
The remaining 12 µl of PCR product was incubated at 37°C for 60 min with 3 units of 
shrimp alkaline phosphatase (SAP) (GE Healthcare Life Sciences) and 2 units of 
exonuclease I (ExoI) (Applied Biosystems) to remove excess dNTP’s and primers, 
respectively. SAP and ExoI were subsequently heat inactivated by incubation at 72°C 
for 15 min. 
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Table 2.2: Regions of interest and primer sequences for SNaPshot assays. 
 
 
  
Gene 
Regions 
of 
interest 
Strand 
Sequence 
(5’->3’) 
Concentration PCR 
product 
sizes 
(bp) 
In 
primer 
mix 
(µM) 
In PCR 
reaction 
(µM) 
FGFR3 Exon 7 Forward AGTGGCGGTGGTGGTGAGGGAG 18 1.2 
115 
Reverse GCACCGCCGTCTGGTTGG 18 1.2 
Exon 10 Forward CAACGCCCATGTCTTTGCAG 7.5 0.5 
135 
Reverse AGGCGGCAGAGCGTCACAG 7.5 0.5 
Exon 15 Forward GACCGAGGACAACGTGATG 10 0.67 
161 
Reverse GTGTGGGAAGGCGGTGTT G 10 0.67 
PIK3CA Exon 9 Forward AGTAACAGACTAGCTAGAGA 10 0.67 
138 
Reverse ATTTTAGCACTTACCTGTGAC 10 0.67 
Exon 20 Forward GACCCTAGCCTTAGATAAAAC 10 0.67 
109 
Reverse GTGGAAGATCCAATCCATTT 10 0.67 
RAS HRAS 
exon 1 
Forward CAGGAGACCCTGTAGGAGG 9 0.6 
139 
Reverse TCGTCCACAAAATGGTTCTG 9 0.6 
HRAS 
exon 2 
Forward GGAGACGTGCCTGTTGGA 5 0.33 
140 
Reverse GGTGGATGTCCTCAAAAGAC 5 0.33 
KRAS 
exon 1 
Forward GGCCTGCTGAAAATGACTG 5 0.33 
163 
Reverse GGTCCTGCACCAGTAATATG 5 0.33 
KRAS 
exon 2 
Forward CCAGACTGTGTTTCTCCCTT 5 0.33 
155 
Reverse CACAAAGAAAGCCCTCCCCA 5 0.33 
NRAS 
exon 1 
Forward GGTGTGAAATGACTGAGTAC 5 0.33 
128 
Reverse GGGCCTCACCTCTATGGTG 5 0.33 
NRAS 
exon 2 
Forward GGTGAAACCTGTTTGTTGGA 5 0.33 
103 
Reverse ATACACAGAGGAAGCCTTCG 5 0.33 
TERT 
promoter 
 
Position  
-57bp 
Forward AGCACCTCGCGGTAGTGG 10 0.67 
175 
Reverse AGCCCCTCCCCTTCCTTT 10 0.67 
Position  
-124/-
146bp 
Forward CAGCGCTGCCTGAAACTC 10 0.67 
163 Reverse GTCCTGCCCCTTCACCTT 10 0.67 
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2.4.1.2 SNaPshot single base extension reactions 
SNaPshot single base extension reactions were performed using a SNaPshot Multiplex 
Kit (Applied Biosystems) and probes designed as described previously156,232,233. 
Reactions were performed in a total volume of 9 µl and contained 2.5 µl of SNaPshot 
Ready Mix (Applied Biosystems), 2 µl of 5x BigDye sequencing buffer v1.1 (Applied 
Biosystems), 1 µl of SNaPshot probe mix (Table 2.3), 2.5 µl NFW and 1 µl of SAP/ExoI 
treated PCR product. Thermal cycling conditions for extension reactions were 35 
cycles of denaturation at 96°C for 10 seconds and annealing/extension at 58.5°C for 40 
s. Extension products were treated with 1 unit SAP and incubated at 37°C for 60 min 
then 72°C for 15 min. Products were diluted 1/10 with NFW. 1 µl of diluted product was 
added to 10 µl formamide mix (9.8 µl HiDiTM formamide, 0.2 µl of 1/10 diluted 
GeneScan-120LIZ size standard (Applied Biosystems)) and denatured at 100°C for 5 
min before snap-cooling on ice. Products were run on an ABI PRISM 3130xl Genetic 
Analyser with a 36 cm length capillary and POP-7 polymerTM and analysed using 
GeneMapper 3.7 software (Applied Biosystems). Genotypes were scored manually 
based on peak colour and position. 
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Table 2.3: SNaPshot probes for the detection of FGFR3, PIK3CA, RAS gene and 
TERT promoter mutations.  
For the RAS probe sets position refers to the position of the nucleotide in the cDNA with 
numbering starting from the first base of the ATG start codon. For the TERT promoter, the number 
refers to the distance from the ATG translation start site in bp. 
Gene Probe Sequence (5’->3’) Size 
(bp) 
Mutation Concentration 
in mix (µM) 
FGFR3 R248C T46 CGTCATCTGCCCCCACAGAG 66 C>T 2 
S249C T36 TCTGCCCCCACAGAGCGCT 55 C>G 1.2 
G372C T29 GGTGGAGGCTGACGAGGCG 48 G>T 0.4 
Y375C T43 ACGAGGCGGGCAGTGTGT 61 A>G 1.2 
A393E T34 CCTGTTCATCCTGGTGGTGG 54 C>A 2.4 
K652M/T T20 CACAACCTCGACTACTACAAGA 42 A>T/C 0.8 
K652Q/E T50 GCACAACCTCGACTACTACAAG 72 A>G/C 0.6 
S373C T19 GAGGATGCCTGCATACACAC 39 T>A 0.5 
G382R T56 GAACAGGAAGAAGCCCACCC 76 C>T 1.2 
PIK3CA E542K T19 TACACGAGATCCTCTCTCT  38 G>A 0.8 
E545G T29 TCCTCTCTCTGAAATCACTG 49 A>G 2.3 
E545K T34 ATCCTCTCTCTGAAATCACT 54 G>A 1.5 
H1047R/L T46 TGAAACAAATGAATGATGCAC 67 A>G/T 1.5 
RAS set 1 HRAS pos.34 T17 CTGGTGGTGGTGGGCGCC 35 G>C/T/A 5 
HRAS pos.182 T18 GCATGGCGCTGTACTCCTCC 38 T>G/C/A 1.5 
KRAS pos.34 T25 GGCACTCTTGCCTACGCCAC 45 C>G/A/T 5 
HRAS pos.35 T31 CGCACTCTTGCCCACACCG 50 C>G/A/T 7 
NRAS pos.182 T33 GACATACTGGATACAGCTGGAC 55 A>G/C/T 5 
KRAS pos.181 T41 CTCATTGCACTGTACTCCTCTT 63 G>T/C 2 
HRAS pos.181 T46 CATCCTGGATACCGCCGGC 65 C>A/G 7 
KRAS pos.35 T49 AACTTGTGGTAGTTGGAGCTG 70 G>C/T/A 2 
HRAS pos 37 T55 CAGCGCACTCTTGCCCACAC 75 C>G/A/T 7 
NRAS pos.34 T62 CTGGTGGTGGTTGGAGCA 80 G>C/T/A 2 
RAS set 2 KRAS pos.37 T15 CAAGGCACTCTTGCCTACGC 35 C>G/A/T 7 
NRAS pos.181 T18 CTCATGGCACTGTACTCTTCTT 40 G>T/C 2 
NRAS pos.37 T26 GGTGGTGGTTGGAGCAGGT 45 G>C/T/A 2 
KRAS pos.183 T29 CCTCATTGCACTGTACTCCTC 50 T>A/G 7 
KRAS pos.38 T33 CTTGTGGTAGTTGGAGCTGGTG 55 G>C/T/A 2 
NRAS pos.183 T38 CTCTCATGGCACTGTACTCTTC 60 T>G/C/A 5 
NRAS pos.38 T44 GTCAGTGCGCTTTTCCCAACA 65 C>G/A/T 5 
NRAS pos.180 T49 GGACATACTGGATACAGCTGG 70 A>T 3 
KRAS pos.182 T56 ATTCTCGACACAGCAGGTC 75 A>T/C/G 5 
HRAS pos.183 T62 CCTGGATACCGCCGGCCA 80 G>C/T/A 3 
HRAS pos.38 T64 GTCAGCGCACTCTTGCCCACA 85 C>A/T 5 
NRAS pos.35 T71 CTGGTGGTGGTTGGAGCAG 90 G>C/A/T 5 
TERT 
Promoter 
-57 probe T29 TCCTCGCGGCGCGAGTTTC 48 A>C 2 
-124 probe T19 GGGGCTGGGAGGGCCCGGA 38 G>A/T 1.5 
-146 probe T34 GGCTGGGCCGGGGACCCGG 53 G>A 3 
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2.4.2 PCR/Sanger sequencing analysis of RAS gene mutations  
The RAS SNaPshot is heavily multiplexed and can produce less clear SNaPshot 
profiles than observed with the other genes. Therefore, RAS gene mutations identified 
by SNaPshot analysis were confirmed by Sanger sequencing. Briefly the exon of the 
RAS gene with a suspected mutation was PCR amplified using 10-20 ng of gDNA in a 
25 µl reaction containing 1 x PCR Gold buffer (Applied Biosystems), 2.5 mM MgCl2, 0.2 
mM dNTPs, 0.2 µM of each forward and reverse primer for the relevant exon, and 1 
unit of AmpliTaq Gold DNA polymerase (for primer details see Table 2.4). Thermal 
cycling conditions were: 95°C for 5 min, followed by 35 or 40 cycles of 95°C for 30 
seconds annealing for 30 seconds (at 55°C for HRAS exon 2, NRAS, KRAS or 60°C 
for HRAS exon 1), and 72°C for 30 seconds followed by a final extension at 72°C for 
10 min. 5 µl of PCR product was analysed on a 2% agarose-TBE gel to check PCR 
product sizes and yield. 2.5 µl of PCR product was then treated with 1 µl of ExoProStar 
(GE Healthcare Life Sciences) and incubated at 37°C for 15 min to remove excess 
dNTPs and primers. Reactions were heat inactivated at 80°C for 15 min. 
Sanger sequencing of PCR products was performed using the same primers used for 
PCR. Reactions contained 0.16 µM primer (forward or reverse), 1 µl of ExoProStar 
treated template, 1 x BigDye sequencing buffer and 0.25 µl BigDye terminator ready 
reaction mix v1.1 (Life Technologies, part of Thermo Fisher Scientific) in a final volume 
made up to 10 µl with NFW. The sequencing thermal cycler profile consisted of: 96°C 
for 1 min followed by 25 cycles of: 96°C for 10 seconds, 50°C for 5 seconds and 60°C 
for 4 min. Sequencing reactions were then precipitated by addition of 1 µl of 3 M 
sodium acetate and 25 µl of ice cold 95% ethanol followed by incubation at room 
temperature for 30 min. 96 well plates containing precipitated DNAs were then 
centrifuged at 2250 x g for 30 min to pellet the DNA. The supernatant was removed by 
inverting the plate onto absorbent paper and centrifuging at 180 x g for 1 min. The 
pellet was washed by addition of 70 µl of 70% ethanol and the plate was centrifuged at 
1650 x g at 8°C for 15 min. The supernatant was removed by inverting the plate onto 
absorbent paper and centrifuging at 180 x g for 1 min. The pellet was then dried by 
heating the plate to 95°C for 1 min in a PCR machine and resuspended in 15 µl of 
HiDiTM formamide. Immediately before running, samples were heated to 95°C for 1 min 
then snap-cooled on ice. Samples were run on an ABI PRISM 3130xl Genetic Analyser 
with a 36cm length capillary and POP-7 polymerTM. Sequence traces were evaluated 
manually for mutations.  
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Table 2.4: Primers used for PCR amplification and sequencing of RAS genes. 
Target 
Exon Primer Sequence 5’-> 3’ 
PCR product size 
(bp) 
HRAS 
exon 1 
H1_F 
H1_R 
CAGGAGACCCTGTAGGAGGA 
TCGTCCACAAAATGGTTCTG 
139bp 
HRAS 
exon 2 
H2_F 
H2_R 
TCCTGCAGGATTCCTACCGG 
GGTTCACCTGTACTGGTGGA 
194bp 
KRAS 
exon 1 
K1 _Brose F 
K1_R 
GTGTGACATGTTCTAATATAGTCA 
GTCCTGCACCAGTAA 
214bp 
KRAS 
exon 2 
K2_2F 
K2 _2R 
GTGCACTGTAATAATCCAGAC 
CCTATAATGGTGAATATCTTC 
220bp 
NRAS 
exon 1 
N1_2F 
N1_2R 
TAAAGTACTGTAGATGTGGC 
AAGATGATCCGACAAGTGAG 
240bp 
NRAS 
exon 2 
N2_F 
N2_2R 
GGTGAAACCTGTTTGTTGGA 
TTCAGAACACAAAGATCATC 
197bp 
 
2.5 Copy number analysis 
2.5.1 Library preparation 
The NEBNext® DNA Library Prep Master Mix Set for Illumina® (NEB) was used for 
library preparation procedures. 
2.5.1.1 Shearing 
500 ng of gDNA was volume-adjusted to 250 µl with 1 x TE buffer, pH8 low EDTA (0.1 
mM) and transferred into a Covaris tube compatible with the Covaris S2 system 
(Covaris Ltd). Samples were sheared by sonication using the Covaris S2 system by 
running 38 cycles with batch settings as detailed in Table 2.5. 
Table 2.5: Covaris settings 
The 500 cycles per burst (cpb) and 1000 cpb settings were combined in a batch which was run 
for 38 cycles to shear the DNA. 
Cycles per burst Duty Cycle Intensity 
1000 19.9% 9.9 
500 15% 8 
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After shearing the DNA was cleaned up with a MinElute kit (QIAGEN) and eluted in 11 
µl of Buffer EB. 2 µl was analysed using the Agilent TapeStation High Sensitivity 
D1000 kit (Agilent) with an Agilent 2200 TapeStation System (Agilent) to check that the 
DNA had sheared appropriately, with the peak size being between 175 and 205 bp. 
2.5.1.2 End-repair of fragmented DNA 
After shearing, the ends of the fragmented DNA were repaired. In a 96 well optical 
plate the remaining 9 µl of sheared DNA was end-repaired in a 50 µl reaction 
containing 1 x NEBNext end repair reaction buffer and 2.5 µl of NEBNext end repair 
enzyme mix. The reaction was incubated at 20°C for 30 min in a PCR machine without 
the use of a heated lid. The end-repaired sample was purified using a QIAquick PCR 
Purification kit (QIAGEN) and eluted in 21 µl of Buffer EB. 
2.5.1.3 dA-tailing of end-repaired DNA 
End-repaired DNA was dA-tailed to enable ligation of the adaptor. For each sample, 
the end-repaired DNA (21 µl) was added to a well of a 96 well plate containing 2.5 µl of 
NEBNext dA-tailing reaction buffer (10x) and 1.5 µl of Klenow (3’>5’ exo-) and 
incubated at 37°C for 30 min in a PCR machine without the use of a heated lid. dA-
tailed DNA was purified using a MinElute kit and eluted in 12.5 µl of Buffer EB. 
2.5.1.4 Adaptor ligation of dA-tailed DNA 
The NEBNext Adaptor was ligated to dA-tailed DNA in a 25 µl reaction containing the 
dA-tailed DNA (12.5 µl), 1x Quick ligation reaction buffer, 2.5 µl of the NEBNext 
Adaptor and 2.5 µl of Quick T4 ligase. This was incubated at 20°C for 15 min in a PCR 
machine without the use of a heated lid then 3 µl of USER enzyme was added and the 
reaction mix further incubated in a PCR machine at 37°C for 15 min without the use of 
a heated lid. After incubation, 25 µl of Buffer EB was added to give a total volume of 50 
µl and size selection was performed immediately. 
2.5.1.5 Size selection of adaptor ligated DNA 
Adaptor ligated DNA was size selected to remove any free adaptors and select 
fragments of the correct size for the PCR enrichment step. 40 µl of suspended AMPure 
XP beads (Beckman Coulter) was added to 50 µl of DNA solution from the adapter 
ligation step and mixing performed by pipetting. Samples were incubated at room 
temperature (r.t.) for 5 min then placed in a magnetic stand for 5 min to concentrate the 
magnetic beads at the back of the tube. The supernatant was transferred to a new tube 
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and the beads, containing the larger fragments, were discarded. 10 µl of beads were 
added to the supernatant, mixed by pipetting, and incubated for 10 min at r.t.. Samples 
were placed in the magnetic stand for 5 min to concentrate the beads and the 
supernatant discarded. Beads were then washed with 2 x 200 µl of 80% ethanol (whilst 
in the magnetic stand) and the supernatant discarded before allowing the beads to air-
dry for 10 min. Tubes were removed from the rack, the beads were resuspended in 22 
µl of Buffer EB and incubated at r.t. for 3 min to elute the DNA. Beads were 
concentrated for 3 min using the magnetic stand and the supernatant transferred to a 
new tube and stored for PCR enrichment.  
2.5.1.6 PCR enrichment of size-selected adaptor ligated DNA 
Size-selected DNA was tagged with an index primer and enriched using PCR in 25 µl 
reactions containing either 10 µl or 8.15 µl of size-selected adaptor ligated DNA 
(depending on the kit version), 1x NEB High Fidelity PCR master mix, 1.25 µl or 3.1 µl 
of Universal PCR primer (at 25 µM or 10 µM respectively, depending on the kit version) 
and 1.25 µl of indexing primer (25 µM) and carried out in 96 well optical plates. 
Indexing primers used for each sample were recorded. The library was amplified using 
the following thermal cycler conditions: 1 cycle at 98°C for 30 s, then 12 cycles of 10 s 
at 98°C, 30 s at 65°C and 30 s at 72°C, followed by a final extension for 5 min at 72°C. 
2.5.1.7 Purification of PCR products 
PCR products were purified using AMPure XP beads. PCR products (25 µl) were 
transferred into a 1.5 ml microcentrifuge tube containing 25 µl of NFW. 62.5 µl of 
suspended AMPure XP beads were added, mixed by pipetting and incubated at r.t. for 
5 min with intermittent mixing. Beads were separated from the supernatant using a 
magnetic stand for 5 min. Once clear, the supernatant was discarded and the beads 
were washed with 2 x 200 µl of 70% ethanol (whilst in the magnetic stand) before 
allowing the beads to air-dry for 10 min. Once dry, the tubes were removed from the 
rack and the beads were resuspended in 42 µl of Buffer EB and incubated at r.t. for 3 
min. Beads were then concentrated using a magnetic stand for 3 min and the 
supernatant transferred to a new tube for storage and QC analysis. 
The indexed library was checked for quality using the Agilent TapeStation High 
Sensitivity D1000 kit. 2 µl of library was analysed to ensure that the fragment size was 
within the range of 220 and 260 bp and that there were no significant primer dimer 
peaks (significant peaks were designated as those that were >10% of the total 
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integrated area). Libraries passing these quality criteria were stored at -20°C ready for 
pooling. For sequencing, 30 ng of each library were pooled in batches of 50 samples.  
2.5.2 Data processing 
Pooled libraries were run on the Illumina HiSeq3000 at the University of Leeds with 
150 bp paired end sequencing. Samples were sequenced to an average raw coverage 
depth of 0.7x. Quality control (QC) checks were performed on the raw FASTQ files 
using FastQC 0.10.0234. Reads were quality trimmed with a threshold of 20 to remove 
low quality read tails, adaptor sequences were removed and reads shorter than 20 bp 
were discarded with cutadapt 1.14. These trimmed reads were then quality checked 
again by FastQC before alignment with BWA 0.7.15235 to hg38 to create the sequence 
alignment map (SAM) file. Samtools 1.5236 was used to convert the SAM to a binary 
alignment map (BAM.) Aligned reads were sorted and PCR duplicates were marked 
using Picard 2.10.2 prior to indexing with samtools. Indels were identified and local 
realignment performed using the GATK v3.7 RealignerTargetCreator and 
IndelRealigner. Post-processing was performed with samtools to remove low-quality 
reads such as those with a mapping quality <20, those marked as PCR duplicates or 
reads that were unmapped.  
A pseudo-CGH algorithm, ngCGH (https://github.com/seandavi/ngCGH), was used to 
compare read counts in the tumour and matched normal with a window size of 1000 
reads. This algorithm requires two BAM files, one from the tumour and one from the 
matched normal. The normal sample is segmented into blocks of 1000 reads - this is 
known as the genomic window. The number of reads within each of these genomic 
windows in the matched tumour is then quantified. A ratio is made between the number 
of reads in the normal and tumour for each genomic window and this is log2 
transformed. The resulting dataset is then median centred to get the final values and 
the data is converted to a format that can be read by the Nexus Copy Number software 
(BioDiscovery). 
The Nexus Copy Number software package was used for GC correction and 
segmentation using the FASST2 Segmentation algorithm, which is a hidden Markov 
model (HMM) based approach. The segmentation significance threshold was set at 
1.0E-5, with a requirement for a minimum of 2 probes per segment and a maximum 
probe spacing of 1000 Kbp between adjacent probes. Single copy gain and single copy 
loss log2 ratio thresholds were set at 0.25 and -0.25 respectively. Log2 ratio thresholds 
for two or more copy gains and homozygous losses were set at 1.2 and -1.2 
respectively. For some samples, the log2 ratio thresholds for single copy gains and 
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losses were modified to 0.3 and -0.3 respectively in order to compensate for a higher 
level of “noise” in the data from these samples and to reduce the risk of erroneous 
segmentation. The patients for whom the boundaries were modified were: P1175, 
P1485, P1777, P2161, P2218, P2329 and P2440. Initially no filtering or blacklisting 
was applied to the data and data was manually curated to remove centromeric events 
or to insert any shared missed breakpoints. A list of all the regions removed from the 
tumours due to them being centromeric or telomeric and unreliable was compiled into a 
blacklist (Error! Reference source not found.) that was later applied to all samples 
for image acquisition. 
2.5.3 Data analysis 
2.5.3.1 Genome-wide frequency plots and statistical comparisons 
The Nexus Copy Number software package was used for generating genome-wide 
frequency plots and statistical comparisons. The comparisons function was used to 
identify significant differences in the CN data for specified sample subgroups. This 
takes the two groups and subtracts the profile of one from the other then uses a 
Fishers exact test with a p-value cut-off of 0.05 and a differential threshold of 25% to 
identify regions with significant differences. Comparisons were made with respect to 
stage, grade, tumour resection timepoint and mitomycin C course treatment. 
2.5.3.2 Construction of phylogenetic trees from CN data 
Analysis of shared and unique copy number alterations (CNAs) in tumours from the 
same patients can be used to reconstruct the relationship between individual tumours, 
infer clonality and also order specific events. To analyse the relationship between 
tumours from the same patient in this study the TuMult algorithim was applied35. 
TuMult uses the simple reasoning that two tumours descended from the same 
cancerous cell will have a number of genetic events in common. Clones that separated 
early on will have fewer shared genetic events than clones that separated later. By 
analysing common and unique chromosome breakpoints, TuMult can reconstruct the 
sequence of chromosomal events that gave rise to each tumour. 
The TuMult algorithm is run through the R programming language and was designed 
for use on arrayGCH and SNP array data. These methods use a series of probes to 
assess the CN status of a sample and this probe level data is required as an input to 
the TuMult algorithm. The NGS data had to undergo a series of manipulations to create 
the probe-style input required by the TuMult algorithm. This was done within R using 
basic R manipulations and the package “bedr” which provides a R-wraparound for the 
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command line tool, bedtools. Briefly, the output of the ngCGH script was used to create 
the probe backbone required for analysis (see Appendix C for an example of this file 
format). As described above, ngCGH works using a windowing methodology set to 
1000 reads. Each window can be used as the equivalent of a probe making it 
compatible for use with TuMult. Each window (probe) was given a unique identifier and 
labelled with the cytoband region of the probe. Any probes that corresponded to 
blacklisted regions were removed to create the final probe table with column headers 
of: Name (unique identifier), Chromosome, StartPosition, EndPosition, StartCytoband, 
EndCytoband (see Appendix C for an example of this file format). The segmented CN 
profiles for each tumour from a patient were then joined to the probe table and probes 
with no CN changes were set to a value of 0. Segmented data was used as the raw 
output from the ngCGH contains noise and GC bias that is filtered and corrected for 
during segmentation. A discretized CN value was then given to every probe encoded 
as follows: 0 = no CN alteration (log2 ratio between -0.25 and +0.25), +1 = gain (log2 
value >0.25, <1.2), +2 = high level gain (log2 value ≥1.2), -1 = loss (log2 value >-1.2, <-
0.25) and -2 = high level loss (log2 value ≤ -1.2). A “profiles file” was then created by 
sub-setting the table to include only the exact log ratio (Sample1.value) and the 
discretized CN status (Sample1.status) for each tumour from the patient (see Appendix 
C for an example of this file format). The lines in the profiles file and probe table are 
kept in the same order. A reference data set was created which contains all the probes 
with a discretized reference value. For the NGS data this value was set to 0 because 
germ-line CNVs are effectively normalized using the ngCGH script (see Appendix C for 
an example of this file format).  
2.5.3.3 Clustering 
Clustering was performed using discretized CN data for the samples in this study along 
with data for 141 low-stage low-grade NMIBC tumours from Hurst et al.82. One-way 
unsupervised hierarchical cluster analysis was performed using Partek Genomics Suite 
6.6 (Partek Inc.). This requires the CNAs to be aligned to bacterial artificial 
chromosome (BAC) clone IDs and locations. The BAC clone locations were converted 
from hg19 to hg38 using the Lift-Over tool within the Galaxy web environment on the 
public server at usegalaxy.org237. The segmented CN profiles for each tumour were 
joined to the BAC clones using the bedr package within the R software environment. A 
discretized CN value was given to each probe as per section 2.5.3.2. All discretized 
data was joined together and the resulting file was used for clustering. Samples were 
clustered using one-way unsupervised hierarchical cluster analysis with Euclidean 
distance and the Ward method of linkage. RJA generated the input files and clustering 
was performed by Dr Carolyn Hurst. 
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2.6 Whole-exome and targeted sequencing 
Whole exome sequencing (WES) was performed on matched pre- and post-MMC 
tumours from 8 patients with peripheral blood used as a germline control. Patients 
were selected for WES from the copy number cohort using the following criteria: 
- No BCG treatment between pre- and post-MMC tumours 
- No more than 1.5 years between pre- and post-MMC tumours 
- More than 200ng of gDNA available for sequencing 
Patients who had previously undergone BCG therapy prior to the pre-MMC tumour or 
proceeded to BCG therapy after the post chemotherapy tumour were not excluded. 
Targeted sequencing of a panel of 140 genes that have previously been identified to be 
altered in bladder cancer82,100,164,170-172 was performed on any additional tumours from 
the 8 patients in the WES cohort (for genes in targeted sequencing panel see Appendix 
D). Tumours from patients for whom a monoclonal origin could not be identified using 
CNAs and hotspot mutation analysis also underwent targeted sequencing. 
2.6.1 Library preparation 
Libraries were generated using 200 ng of DNA and enriched for exonic regions using 
either the SureSelectXT Human All Exon V6 (WES) or the SureSelectXT targeted 
sequencing panel described above, according to the manufacturer’s instructions (see 
Figure 2.2 for an outline of the library preparation process). Six sample libraries were 
pooled per lane, with tumours and matched bloods run in the same library pool. 
2.6.2 Next generation sequencing and variant calling 
FASTQ processing and variant calling on WES samples was performed by our in-
house bioinformatician Dr Guo Cheng. An outline of the process can be seen in Figure 
2.3. Pooled libraries were run on the Illumina HiSeq3000 at the University of Leeds 
with 150 bp paired end sequencing. Quality control checks were performed on the raw 
FASTQ files using FastQC. Reads were quality trimmed with a threshold of 20 to 
remove low quality read tails, adaptor sequences were removed and reads shorter 
than 20 bp were discarded using cutadapt 1.14. These trimmed reads were then 
quality checked again by FastQC before alignment with BWA 0.7.15 to hg38 to create 
the SAM file. Samtools 1.5 was used to convert the SAM to a BAM. Aligned reads were 
sorted and PCR duplicates were marked using Picard 2.10.2 prior to indexing with 
samtools. Indels were identified and local realignment performed using the GATK v3.7 
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RealignerTargetCreator and IndelRealigner. Post-processing was performed with 
samtools to remove low-quality reads such as those with a mapping quality <20 or 
reads that were unmapped. 
SureSelect targets are provided in hg19. These were converted to hg38 coordinates 
using UCSC liftOver and used as the target files for variant calling. Variant calling was 
performed using Mutect2 from GATK, Strelka2238 and EBCall239 with additional calling 
performed by VarScan2240 and Muse241 for exome samples from P418 and P2161 
initially to identify the best combination of callers. Variant calling was performed using 
the default parameters for all callers. 
 
 
 
 
Figure 2.2: Workflow for WES and targeted sequencing. 
Practical steps in the generation of NGS libraries are presented. Blue boxes represent steps prior 
to hybridization, steps post hybridization are in green and the final sequencing step is in yellow. 
*Hybridization step is performed using either the whole-exome target capture baits or the bladder 
cancer gene panel targeted capture baits. 
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Figure 2.3: FASTQ processing for variant calling. 
An overview of the steps undertaken to convert the raw read data (FASTQ) into a format ready 
for variant calling. 
 
2.6.3 Downstream variant analysis 
2.6.3.1 Identification of shared variants and consensus variant calling 
Development of a two-pronged variant calling pipeline is detailed in Chapter 4 and was 
performed by RJA. Briefly: to reduce the number of false positive calls, the outputs 
from the five variant callers were used to identify the best combination of three variant 
callers for consensus calling. Consensus calls were generated for all 10 possible 
combinations of callers using the vcftools function “vcf-isec” with “-n +2” specified so 
that only variants present in two or more input VCFs were kept and the best 
combination of callers was identified. Variants were taken forward if they were 
identified by at least two of these three variant callers. Additionally, variants were 
included if they were identified in both tumours from a patient by any one caller of the 
final three. This is based on the methodology proposed by Droop et al.242 who reason 
that variants are internally validated if they are identified in paired tumours, regardless 
of the strength of evidence in any one tumour. Once all shared and consensus called 
variants had been identified, a variant call format (VCF) file was generated for each 
tumour. An additional VCF file was generated containing the post-MMC unique variants 
for each patient for further analysis. The bcftools (https://github.com/samtools/bcftools) 
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package was used to generate stats for each VCF such as the number of transitions, 
transversions and variants for each base change.  
2.6.3.2 MAF generation and variant annotation 
All VCF files were converted into a single mutation annotation file (MAF) using 
“vcf2maf” from MSKCC (https://github.com/mskcc/vcf2maf/blob/master/README.md). 
This annotates the variants using the Variant Effect Predictor (VEP) from Ensembl243. 
MAF manipulations and visualizations were performed using maftools244 within the R 
software environment. This included the generation of oncoplots. 
2.6.3.3 Identification of tandem substitutions 
Each patient’s VCF files were analysed in R to find any consecutive variants. These 
variants were subset out from the large MAF file to create a tandem substitution MAF 
file. Any tandem substitutions with a classification of “frameshift” were removed as 
these were obviously erroneous. Two tandem substitutions were filtered at this point. 
Each tandem substitution was then investigated in the interactive genome viewer (IGV) 
version 2.4.6 to check for miss-labelling due to a near-by indel, to ensure that both 
variants were present on the same read and, where a tandem substitution is unique, 
ensure there were no reads in the other tumour(s). Two tandem substitutions were 
filtered at this point. 
2.6.3.4 Calculation of mutations/Mb 
Coverage files for the SureSelect Human All Exon Version 6 whole exome capture kit 
were downloaded from Agilent. The total number of bases covered were calculated for 
each interval using (end position – start position) +1. This was divided by 1000000 to 
get the number of megabases (Mb). The number of variants was then divided by the 
number of Mb to obtain the total number of variants per Mb. 
2.6.4 FACETS CN estimation 
Allele-specific copy number (ASCN) estimations were generated from the WES data 
using the FACETS package as per the authors’ instructions245. Briefly; sequence 
readcount information is parsed from tumour-normal BAM files and readcounts for 
SNPs in both the tumour and the normal are generated using “snp-pileup”. Positions 
with a total readcount below 35 or above 1000 in the matched normal are removed. To 
reduce hyper-segmentation in SNP-dense regions SNPs are subsampled in 150—250 
bp regions. The readcount in the tumour vs normal is used to calculate log ratio (logR) 
which provides information on the total CN ratio. A log-odds-ratio (logOR) for each 
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position is also calculated and is defined by the log-odds ratio of the variant allele count 
in the tumour vs the normal. Data is normalised for the library size and GC corrected 
using a loess regression model along 1 kb windows. Segmentation is performed using 
an extension to the circular binary segmentation (CBS) algorithm to include both logR 
and logOR. Allele-specific CN is then estimated and further refined using the “fit$cncf” 
command and estimates of tumour purity and ploidy are generated. 
2.6.5 Kernel density plots 
Kernel density plots were generated to give a preliminary indication of the presence or 
absence of intratumour heterogeneity. Analysis was restricted to potentially functional 
variants (missense, nonsense, frameshift or mutations of the invariant dinucleotides at 
splice junctions) in regions that did not exhibit altered CN. These were obtained by 
sub-setting for variants within regions where the FACETS prediction of the total CN 
was 2 and the minor CN was 1 thereby excluding any variants with gains, losses or CN 
neutral LOH. Density plots were then generated using the “ggplot2” package within the 
R software environment. 
2.6.6 PyClone 
PyClone version 0.13.0 was used to infer the prevalence of point mutations within the 
tumours according to the authors’ instructions246. To gain a better understanding of 
events that may influence protein structure or function, analysis was restricted to 
potentially functional variants. Briefly; input files were generated per sample by 
combining the CN analysis data from FACETS with the read count data for each 
variant. The PyClone “run_analysis_pipeline” command was then run using tumour 
purity estimates generated by visual analysis of the H&E stained tissue samples (Table 
2.6) unless otherwise stated and “parental_copy_number” as formerly specified. This 
command runs the entire pipeline. Plots were restricted to a minimum cluster size of 2 
mutations unless otherwise stated. 
2.6.7 ClonEvol 
ClonEvol was used for clonal ordering and clonal evolution visualisation as per the 
authors instructions247. ClonEvol infers consensus clonal evolution trees using the 
clustering of variants identified using other tools, such as PyClone, as an input. It 
estimates the cancer cell fraction of the clones (CCF) via a bootstrap resampling 
approach. Driver gene status was extracted from Bailey et al.47 using the list of 299 
genes that have been identified as drivers in some form of cancer. Fishplot models 
containing both tumours were created using the fishplot package in R248. 
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Table 2.6: Tumour purity estimates from H&E stained tissue samples. 
Tumour purity was estimated using the H&E stained tissue samples taken throughout the cutting 
process. *indicates sample underwent laser-capture microdissection prior to DNA extraction. In 
these cases the purity was estimated to be 95% to arbitrarily account for impurities in the sample 
that may have been missed. $ this sample underwent LCM however kernel density analysis 
suggested a lower purity for this sample due to a shift away from a VAF of 0.5 for heterozygous 
mutations. Therefore, the purity estimation from FACETS was used. 
Tumour ID H&E purity 
estimate  
Tumour ID H&E purity 
estimate 
P0418-S02-BX 0.90 P1870-S2A-BX 0.8 
P0418-S03-PX 0.98 P1870-S03-PX 0.87 
P0533-S3B-BX 0.85 P2161-S01-BX 0.8 
P0533-S04-PX 0.95* P2161-S02-PX 0.8 
P0960-S01-BX 0.8 P2218-S1A-BX 0.85 
P0960-S03-PX 0.95* P2218-S1B-BX 0.7 
P0960-S04-PX 0.92 P2218-S02-PX 0.7 
P1175-S01-BX 0.8 P2329-S02-BX 0.66$ 
P1175-S02-PX 0.95* P2329-S03-PX 0.8 
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Chapter 3  
 Analysis of copy number alterations and hotspot mutations 
in tumours from patients with recurrent NMIBC 
3.1 Introduction 
An objective of this study was to characterise the genomic landscape of somatic copy 
number alterations (CNAs) in tumours from patients with recurrent non-muscle-invasive 
bladder cancer (NMIBC). A number of studies have profiled CNAs in bladder tumours. 
This has identified the most common alteration to be loss of chromosome 9 which is 
present in over 50% of all bladder tumours irrespective of stage and grade125,131. On 
chromosome 9, loss of 9p21.3, the region containing the tumour suppressor gene 
CDKN2A, is the most common event occurring in 50-60% of all tumours4 and 
homozygous deletion (HD) of this region is associated with high stage and grade125,249 
and has been linked to recurrence in NMIBC132 
MIBC and NMIBC genomes are very different; MIBC are chromosomally unstable with 
frequent alterations identified in almost all chromosomes whilst NMIBC are more stable 
with fewer CNAs identified125. Profiling of stage Ta tumours has identified recurrent 
CNAs including losses of 11p125,135,136 and 17p125,135, and gain of 20q135,136. A recent 
study investigating CNAs in patients with multiple tumours identified that homozygous 
deletions occur more frequently in patients with multiple tumours250. Homozygous 
deletion on chromosomes 10q, 11q, 18q and 21q were identified exclusively in 
recurrent or multifocal tumours and these regions were demonstrated to contain cell 
adhesion genes. Deletion of these genes was postulated to contribute to the spread of 
tumour cells in the bladder and could contribute the multiplicity of bladder tumours 
within patients250.  
The majority of these studies used array comparative genomic hybridization (aCGH) for 
the generation of copy number (CN) profiles125,135,250. The advent of next generation 
sequencing (NGS) has enabled the study of cancer genomes in much greater detail 
than ever before. CN analysis using NGS-based approaches has an improved 
resolution and faster turnaround time compared to array-based methods251,252. There 
are several different methods that can be used to extract CNAs from NGS data. Read-
depth methods use the depth of coverage to determine CN. This method assumes that 
the number of reads mapping to a particular region is proportional to the CN of the 
region. Therefore, regions of gain or amplification will have a higher sequencing 
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coverage whilst deletions will have lower coverage253. The advantage of this method is 
that very low depth of coverage, as low as 0.1x, can be used to generate CN 
profiles254,255 making it a very cost-effective method for the screening of multiple 
samples. Mate-pair sequencing uses the knowledge of the insert size between paired 
ends to identify read-pairs that map discordantly. Read pairs that map too far apart are 
indicative of deletions whilst pairs mapping too closely together indicate insertions256. 
Sequencing depth can be as low as 1-5x although greater sensitivity is found at 5x252. 
However, analysis is more challenging than read-depth methods and insertions larger 
than the insert size cannot be identified without additionally using read depth 
analysis251,257. Split-read methods use unmapped or partially mapped reads for the 
identification of breakpoints, however this can only be applied to unique regions of the 
genome251. 
Due to its low cost and ease of analysis, we employed shallow-pass whole genome 
sequencing and the read depth approach for the detection of CNAs in our cohort of 67 
tumours from 23 patients. This  method has been used extensively in our lab82 and 
previous work carried out by the group has shown that the results generated are 
compatible with results generated by aCGH (see Appendix E for a comparison of CNAs 
in tumour P0468-S01 identified by aCGH and NGS). CNAs were used to identify 
recurrent regions of alteration and investigate differences in tumours according to stage 
and grade. We also investigated potential changes in CNAs between pre- and post-
treatment tumours from a subset of patients who underwent a course of MMC 
chemotherapy.  
Copy number profiles have also been used to define genomic subgroups of tumours. 
Hurst et al.82 recently described two distinct genomic subgroups of stage Ta bladder 
tumours termed Genomic Subtype 1 (GS1) and Genomic subtype 2 (GS2). GS1 was 
characterized by no or few CNAs whilst GS2 was more genomically unstable with 
characteristic loss of 9q and a higher mutation rate. Genomic subgroups have also 
been identified for stage T1 grade 3 bladder tumours with hierarchical clustering 
identifying 3 separate clusters that differed with respect to CN profile125. We carried out 
hierarchical clustering using the CN data for tumours profiled in the study of Hurst et 
al.82 alongside our CN data with the aim of identifying which subgroup the recurrent 
tumours cluster into. Hierarchical clustering was also performed on tumours from our 
cohort alone to examine if tumours from the same patient tend to cluster together. 
Patients with bladder cancer often have multiple tumours and these can be 
synchronous tumours resected at the same time (multifocal disease) or metachronous, 
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where recurrent tumours are resected over a period of time. Historically there has been 
much debate on the clonal origins of such tumours159. Evidence from previous studies 
suggests that the majority of bladder tumours are monoclonal in 
origin26,29,160,163,165,167,174 but there is also some evidence for oligoclonality35,161. We used 
our CN data to identify if tumors from our cohort were monoclonal or oligoclonal in 
origin. Additionally, CNAs were used to order the predicted genomic evolution of each 
tumour and create a phylogenetic tree for each patient. 
As detailed in the introduction, key genes that are altered in bladder cancer include 
FGFR3, PIK3CA, HRAS, KRAS and NRAS, and the promoter region of the TERT 
gene. These genes are frequently mutated in bladder cancer and contain hotspot 
mutations that can be targeted using simple SNaPshot assays143,156,232,233. To improve 
the assessment of clonality, tumours from our cohort were analysed for hotspot 
mutations in these genes and associations between mutation status and CNAs were 
investigated.  
 
3.2 Results 
3.2.1 Copy number alterations 
To assess copy number alterations (CNAs), shallow-pass whole genome sequencing 
was performed on 67 tumours from 23 patients. Samples were sequenced to an 
average raw coverage depth of 0.7x and analysed for CN changes using a pseudo-
CGH algorithm followed by GC correction, segmentation and visualisation with the 
Nexus Copy Number software. Single copy gains were defined as regions with a log2 
ratio greater than or equal to 0.25, and regions were classed as amplifications if the 
log2 ratio was greater than or equal to 1.2. Single copy losses were defined as regions 
with a log2 ratio less than or equal to -0.25, and regions were classified as homozygous 
deletions if the log2 ratio was less than or equal to -1.2. Overall, there was 
heterogeneity in the frequency of CNAs; some tumours from patients had no or few 
CNAs whilst others exhibited multiple regions of loss or gain.  
To give an overview of CNAs within the cohort, a genome-wide frequency plot (GWFP) 
of CNAs identified in all 67 tumours was generated using Nexus (Figure 3.1A). 
Including all of the tumours in the analysis may artificially inflate the frequency of CNAs 
in certain regions if they are present in multiple tumours from the same person. To 
investigate this, GWFPs were generated for the first and last tumour from each patient 
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only (Figure 3.1B). These plots are very similar to the GWFP for all tumours, however, 
on visual inspection some CNAs appear to differ between the two groups; regions of 
CN gain on chromosomes 1, 3 and 12 appear to be a feature of the later tumours whilst 
the early tumours appear to have a higher frequency of chromosome 7 gain. 
To investigate whether these apparent differences between early and late tumours 
were statistically significant, the genome wide frequencies of copy number alterations 
in the first and last tumours were compared using the Nexus software. The analysis 
subtracts the genome wide frequencies of CNAs in one group from the other then uses 
a Fisher’s exact test to check for a significant difference in the frequency of CNAs 
between the two groups (p < 0.05, differential threshold of 25%). No significant 
differences in the frequencies of copy number events were identified. 
The fraction of genome altered (FGA) is a measure of how much of the genome is 
affected by CNAs and provides a measure of chromosomal instability. Overall, the 
median FGA of the cohort of 67 tumours was 6.08% (range 0-25%). To investigate if 
there was a difference in chromosomal stability of the first and last tumours, the FGA 
was compared. No statistical difference between these two groups was identified and 
both groups showed very similar median FGA values (first = 5.165%, last = 5.549%, 
p=0.1231, two-tailed Wilcoxon matched-pairs signed rank test). 
3.2.2 Copy number alterations and stage and grade 
Tumour stage and grade are key components in the assessment of risk of recurrence 
and progression. Previous studies have identified an increased frequency of alterations 
in tumours of a higher stage or grade125. To assess if this is also the case in our cohort, 
GWFPs for stage Ta and T1 tumours were created (Figure 3.2A). Stage Ta tumours 
(n=57) demonstrate a stable genome overall, with deletion of chromosome 9 the only 
recurrent event. In contrast, the stage T1 tumours (n=8) exhibited a higher frequency of 
CNAs.  
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We were interested to identify if there were any statistically significant regions of CNA 
associated with stage. Using the Nexus comparisons function 70 regions distributed 
across the genome were identified to be differentially altered (25% threshold; p < 0.05) 
between stage Ta and T1 tumours (Figure 3.2B). All 70 events were regions of gain or 
loss that were significantly more frequent in the stage T1 tumours. Most notably, an 
increase in chromosome arm level gains of 7p, 7q and 8q as well as gain of 
chromosome region 17q22-q25.3 were identified in the stage T1 tumours. 
Separation of tumours by grade (as defined by the 1973 WHO guidelines8) revealed a 
GWFP profile similar to that generated for tumours separated according to stage 
(Figure 3.2C). Of the 12 grade 3 (G3) tumours, 4 were stage T1 and 8 stage Ta. 
Chromosome 9 deletion remained the most common event in both groups whilst the 
chromosome 7 gains seen in stage T1 tumours were equally divided between G1/2 and 
G3 tumours. The comparisons function within Nexus was used to identify if any regions 
were significantly different according to grade. This identified 56 regions that differed 
significantly in frequency between G1/2 and G3 tumours (Figure 3.2D). All 56 regions 
were statistically more frequent in grade 3 tumours and included gain of chromosome 
region 6p25.3 – p21.1 (p = 0.005), loss of 11p15.5 - p14.3 (p = 0.007), loss of 18q12.2 
- q12.3 and loss of 18q21.1 - q21.2 (p = 0.012 for both) (25% differential threshold, 
Fishers exact test). 
Quantification of the level of chromosomal instability using FGA identified a significantly 
higher median FGA in the stage T1 tumours compared to the stage Ta tumours (Figure 
3.2E, Mann-Whitney U test, p=0.0012, Ta median=5.55, T1 median = 17.08), and in 
grade 3 tumours compared to grade 1&2 tumours (Figure 3.2F, Mann-Whitney U test, 
p=0.0114, G1&G2 median=5.55, G3 median = 14.11), confirming the higher level of 
chromosomal instability in higher stage and/or grade tumours.  
3.2.3 Alterations involving chromosome 9 
The most common deletion identified in bladder cancer is deletion of all or part of 
chromosome 9125,131. Analysis of GWFPs identified deletion of chromosome 9 to be the 
most common event in this cohort, and this remained true when analysing only the first 
or last tumours from each patient (Figure 3.1). Ten patients demonstrated a loss of the 
whole of chromosome 9. Loss of chromosome 9 was identified in all tumours from a 
given patient, suggesting that it is an early event in these patients. 
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Figure 3.2: Genome-wide frequency plots and fraction of genome altered for 
tumours according to stage and grade. 
A) Genome-wide frequency plots of CNAs in tumours according to stage. B) Frequency difference 
plot for Ta versus T1 tumours. The difference is obtained by subtracting the CNA frequencies of 
the stage Ta tumours from the stage T1 tumours. Gains are plotted in blue, losses in red. If the 
magnitude of gain or loss is greater in the stage T1 tumours then the gain is plotted in blue above 
the 0 baseline and the loss is plotted in red below the 0 baseline. If the magnitude of gain or loss 
is greater in the stage Ta tumours then the gain is plotted in blue below the 0 baseline and the 
loss is plotted in red above the 0 baseline. Regions with a significant difference (p < 0.05, 25% 
differential threshold, Fisher’s exact test) are indicated at the bottom of the plot by coloured 
blocks. C) Genome-wide frequency plots in tumours according to grade. D) Frequency difference 
plot for grade 1&2 versus grade 3 tumours. The difference is obtained by subtracting the CNA 
frequencies of the grade 1&2 tumours from the grade 3 tumours. Gains are plotted in blue, losses 
in red. If the magnitude of gain or loss is greater in the grade 3 tumours then the gain is plotted in 
blue above the 0 baseline and the loss is plotted in red below the 0 baseline. If the magnitude of 
gain or loss is greater in the grade 1&2 tumours then the gain is plotted in blue below the 0 
baseline and the loss is plotted in red above the 0 baseline.  E&F) FGA was compared according 
to stage and grade and represented as boxplots. A significant difference in FGA was detected 
between; E) stage Ta and T1 tumours (p=0.0012; Ta median=5.55, T1 median=17.08) and F) 
grade 1&2 (G1&G2) and grade 3 (G3) tumours (p=0.0114; G1&G2 median=5.55, G3 
median=14.11). Boxes show the interquartile range and median with the whiskers showing the 
range of the data. Significance was tested with the Mann-Whitney U test. 
A 
B 
C 
D 
E F 
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Figure 3.3: Copy number analysis reveals differences in CDKN2A loss between 
tumours from the same patient. 
Analysis of chromosome 9 identified some patients where the tumours differed with respect to 
CDKN2A loss. The images show individual chromosome plots of CN data for chromosome 9. The 
CDKN2A locus is highlighted by the black arrows. Regions of CN loss are shaded in red below 
the zero line whilst regions of CN gain are shaded in blue above the zero line. Chromosome 9 
with cytobands is depicted above each plot. Regions of CNA are highlighted by blue (gains) or 
red (loss) lines above and below the chromosome respectively. A single red line represents loss 
of the region (log2 ≤-0.25 >-1.2), whilst a double red line represents homozygous deletion (log2 ≤-
1.2). A) P0923-S03 shows loss of the CDKN2A locus whereas P0926-S01 does not. B) P0468-
S03 has HD of the CDKN2A locus whereas P4068-S01 has only loss of this region due to loss of 
the whole of chromosome 9. C) Loss of CDKN2A was identified in P2440-S01 whilst HD of this 
region was identified in P2440-S02. D) The HD of CDKN2A seen in P1485-S01 is not present in 
P1485-S02. The x-axis is the chromosome position (Mb) whilst the y-axis is the log2 value. 
A B 
C D 
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The most common event involving chromosome 9 was loss of copy number at 9p21.3. 
A total of 47 tumours from 15 patients had loss in this region. In one patient, P0926, 
loss of this region was identified only in the recurrent tumour (Figure 3.3A). Of the 47 
tumours with loss of 9p21.3, 31 tumours from 10 patients had HD at this locus. Three 
patients had tumours that exhibited different levels of loss and HD at 9p21.3. In patient 
P0468, the initial tumour (P0468-S01) had loss of the whole of chromosome 9 only, 
whilst in the recurrent tumour (P0468-S03), an additional focal loss of 9p21.3 resulted 
in HD of this region (Figure 3.3B). In patient P2440, tumour P2440-S01 contained a 
focal loss of 9p21.3 whilst in tumour P2440-S02 this was a HD (Figure 3.3C). In patient 
P1485, tumour P1485-S01 demonstrated HD of 9p21.3 whilst tumour P1485-S02 did 
not (Figure 3.3D), suggesting that tumour P1485-S02 may be genomically ancestral to 
tumour P1485-S01, despite being resected at a later date. 
The size of the region of homozygous deletion at 9p21.3 varied between patients. 
Patient P0533 had the largest region of deletion, containing 33 genes including the 
IFNa cluster, MLLT3 and the CDKN2A/B genes. This extended deletion was also seen 
in tumour P2218-S1B. The region deleted in tumours from patient P1777 and tumour 
P1485-S01 also included the IFN1a cluster but did not include MLLT3. The minimum 
deletion region in all tumours included 5 genes (MTAP, C9orf53, CDKN2A, CDKN2B 
and CDKN2B-AS1). To give a more accurate representation of the frequency of 
deletion in these regions, the CDKN2A minimum region was listed separately (Table 
3.1). 
Five other homozygous deletions were identified on chromosome 9; all five tumours 
from patient P0533 contained a HD of 9p23 (PTPRD), all five tumours from patient 
P0712 contained a HD of 9p22.3-p22.2 (CCDC171, BNC2, C9orf92, CNTLN, 
SH3GL2), all four tumours from patient P0198 contained a HD of 9p21.2 (CAAP1, 
PLAA, IFT74, TEK, MOB3B), tumour P0717-S02 contained a HD of 9q21.13 (RORB, 
TRPM6, OSF1, CARNMT1) and tumour P0960-S01 contained a HD of 9q22.31-q22.32 
(PHF2, BARX1) (Table 3.1). 
3.2.4 Focal regions of copy number change 
It is difficult to identify the target gene(s) in large regions of copy number alteration 
where many genes may be affected by the alteration. In contrast, potential candidate 
genes are more easily identifiable in focal regions of CNA. Focal CNAs tend to be less 
than 3 Mb in size258 and these are often regions of amplification or HD. Amplifications 
are genetic alterations that produce high copy numbers of a small section of the 
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genome whilst HD are deletions of both copies of a genomic region. These regions 
often contain oncogenes or tumour suppressor genes, respectively, making their 
identification important in the analysis of cancer development and progression. 
3.2.4.1 Amplifications 
Overall there were 7 regions of amplification detected in 5 tumours (Table 3.1). Two 
amplification events were each unique to an individual tumour; 11q13.3 (P1485-S01) 
and 13q33.3-q34 (P0468-S01). The remaining five amplification events (3p25.2, 7q34, 
7p21.1, 17q21.33 and 18p11.32-p11.21) were present in the three tumours from 
patient P0418. 
Figure 3.4 illustrates the high-level amplifications at 11q13.3 and 13q13.3-q34, 
detected in patients P1485 and P0468, respectively. The amplification detected at 
11q13.3 contained 16 candidate genes including CCND1 and FGF3, FGF4 and 
FGF19. This high-level amplification (log2 = 4.03) was present in tumour P1485-S01 
but not in any additional tumours from this patient (Figure 3.4A). The high-level 
amplification at 13q33.3-q34 was identified in tumour P0468-S01. This region contains 
12 genes including IRS2, RAB20, COL4A1 and COL4A2. In P0468-S01 this 2Mb 
region of high-level amplification was surrounded by focal losses (Figure 3.4B). A 
smaller part of this region, containing IRS2 and COL4A1 and a long intergenic non-
protein coding RNA (LINC00676), was gained in P0468-S03 but not in tumour P0468-
S05 (Figure 3.4B).  
Patient P0418 proved to be an interesting case. The three tumours from this patient, 
shared over 49 regions of focal gain/amplification across the genome (Figure 3.5A). 
Only the sex chromosomes and autosomes 15 and 21 did not contain any focal gains. 
Despite the large number of gains, there were only five regions of amplification: 3 
regions shared by all three tumours and 2 regions shared by two tumours only. A 1.2 
Mb amplification on chromosome 3p25.2 was shared by all 3 tumours (Figure 3.5B). 
This region contains 13 genes including RAF1 and PPARG.  All 3 tumours also shared 
a region of amplification on chromosome 17q21.33. In this case, the size of this region 
differed for tumour P0418-S02 which had a larger region of amplification compared to 
the other two tumours. As the other two tumours had a smaller amplification it is likely 
that this is the minimal region and this contains 17 genes including SPAG9 (Table 3.1).  
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Figure 3.4: Examples of regions of focal amplification identified in two patients. 
Amplifications identified on chromosome 11 and chromosome 13 in tumours P1485-S01 and 
P0468-S01 respectively, are depicted on whole chromosome CN plots. Regions of CN loss are 
shaded in red below the zero line whilst regions of CN gain are shaded in blue above the zero 
line. The chromosome with cytobands is depicted above the plot. Regions of CNA are highlighted 
by blue (gains) or red (loss) lines above and below the chromosome respectively. A single line 
represents gain/loss whilst a double line represents amplification or HD (log2 ≥1.2 or ≤-1.2 
respectively). The x-axis is the chromosome position (Mb) whilst the y-axis is the log2 value. A) 
Individual chromosome 11 CN plots for tumours from patient P1485. P1485-S01 has an 
amplification at 11q13.3 highlighted in blue. This amplification is not present in the other tumours 
from this patient (blue arrows depict where the amplification would be). B) Individual chromosome 
13 CN plots for tumours from patient P0468. P0468-S01 has an amplification of 13q33.3-q34 
highlighted in blue. In P0468-S03 gain of this region is detected but there is no amplification and 
in P0468-S05 there are no CNAs in this region. Blue arrows depict where the gain would be seen 
in the other tumours.  
  
A B 
  
75 
 
 
Figure 3.5: Focal gains and amplifications identified in patient P0418 
The genome of patient P0418 is punctuated with several regions of focal CN gain and  
amplification. A) A summary of all events detected within the three tumours from patient P0418. 
Each chromosome is depicted with losses in red to the left and gains in blue to the right. These 
are stacked so that the thickness is related to the number of tumours with that alteration. B-C) 
Individual chromosome CN plots of chromosomes 3 and 7 for each tumour. Regions of CN gain 
are shaded in blue above the zero line. The chromosome with cytobands is depicted above each 
plot. Regions of gain/amplification are highlighted by blue above the chromosome. A single line 
represents a gain whilst a double line represents an amplification (log2 ≥1.2). The x-axis is the 
chromosome position (Mb) whilst the y-axis is the log2 value. B) A region of amplification at 3p25.2 
is present in all 3 tumours. This region contains the genes RAF1 and PPARG. C) All three tumours 
have 3 focal regions of gain on chromosome 7. Tumours P0418-S01 and P0418-S02 also contain 
a whole chromosome gain. This likely occurred after the focal gains.  
A 
B C 
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All 3 tumours from patient P0418 also contained a high-level amplification of a region of 
18p11.32 - p11.21 (log2 = 1.76-1.90) which contains 98 genes including YES1 and 
TYMS (Table 3.1). On chromosome 7, all three tumours from patient P0418 shared 3 
focal alterations;  7p21.1, 7q11.23 and 7q34. In tumours P0418-S01 and P0418-S02, 
the alterations at 7p21.1 and 7q34 were amplifications whilst in tumour P0418-S03 
these were focal gains (Figure 3.5C). Tumours P0418-S01 and P0418-S02 also 
contained a gain of the whole of chromosome 7. This could suggest that the focal gains 
occurred first followed by gain of the whole of chromosome 7. The region at 7q34 
contains the proto-oncogene BRAF whilst the region at 7p21.1 contains no genes 
currently implicated in cancer. 
3.2.4.2 Homozygous deletions 
Deletions of chromosome Y were common, with 22 tumours from 5 patients showing 
complete loss of all or part of chromosome Y. Two tumours from P0712 had loss of 
Xq25, a region containing 4 genes (XIAP, STAG2, SH2D1A and TENM) (Table 3.1). 
This was a HD event in tumour P0712-S03 with a log2 value of -1.52 whilst in tumour 
P0712-S02 this was a focal loss with a log2 value of -0.99. 
3.2.4.3 The effect of MMC chemotherapy course on CNAs 
A subset of 16 patients underwent at least one 6-week course of MMC chemotherapy 
during their disease span. In vitro and in vivo studies have identified structural 
alterations and deletions associated with MMC treatment. Therefore we hypothesized 
that post-MMC treatment tumours may contain more CNAs. Although some patients 
had multiple tumours available, only a single tumour pre-MMC and post-MMC 
treatment was analysed per patient. These were the tumours resected closest to the 
treatment time. GWFP were generated for pre-MMC and post-MMC treatment tumours 
(Figure 3.6A). Visualisation of these profiles suggested that they were very similar, 
although the post-MMC samples appeared to have slightly more gains than the pre-
MMC group. Statistical analysis using the Nexus comparisons function identified no 
significantly different regions of CNA (Fishers exact test, differential threshold of 25%). 
The relationship between FGA and treatment status was also compared and no 
significant difference was identified between the pre- and post-chemotherapy samples 
(Figure 3.6B, paired t-test p=0.4715). 
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3.2.5 Whole genome plots of individual tumours 
Recurrent and multifocal bladder tumours from an individual patient have been shown 
to be clonally related with only a few instances of oligoclonality identified within the 
literature. We investigated whether the recurrent tumours were clonally related. Whole 
genome plots (WGP) were created for each tumour to enable visualisation of genome-
wide changes on a global scale. Comparison of these plots allows easy identification of 
shared and unique CNAs amongst tumours from the same patient as well as 
assessment of overall chromosome stability. Some patients had chromosomally stable 
tumours with few CNAs, whilst other tumours contained many CNAs. An example of 
WGP from two patients (P1175; P2161) with stable genomes can be seen in Figure 3.7 
whilst an example of tumours from a patient (P0712) with more CNAs is shown in 
Figure 3.8. WGPs for all other patients are presented in Appendix F. 
Overall, shared CNAs suggestive of a clear monoclonal origin were found for 15 
patients (P0198, P0418, P0533, P0712, P0717, P0926, P0960, P1175, P1326, P1485, 
P1777, P1870, P2104, P2329 and P2440). For 3 patients, P0933, P2065 and P2291, 
monoclonality could not be established as tumours did not share any CNAs. For a 
further 4 patients (P468, P536, P2161 and P2218) there was a suggestion of 
monoclonality due to shared loss of chromosome 9 (P468 and P2218) or alterations of 
chromosome Y (P0536 and P2161). However, these are common alterations in bladder 
cancer and could have occurred independently. For the final patient, P0990, a 
monoclonal origin between tumours P0990-S04 and P0990-S05 could be established 
as these shared all their CNAs, but tumour P0990-S01 did not contain any CNAs, 
therefore a monoclonal origin for this tumour could not be inferred. 
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Figure 3.7: Examples of whole genome copy number plots for two patients. 
A) WGPs of tumours from patient P2161 which exhibit very stable genomes with the exception of 
a gain of chromosome Y seen in both tumours. B) WGPs of tumours from P1175. These two 
tumours share two regions of CNA (a gain of chromosome 7 and a loss of chromosome 9) 
highlighted in the blue boxes. The x-axis represents the chromosome number and the y-axis the 
log2 values. 
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Figure 3.8: Whole genome copy number plots for five tumours from patient 
P0712. 
The genomes of tumours from patient P0712 exhibit several regions of CNA. Some of these are 
shared between all tumours (highlighted by blue boxes) allowing a monoclonal origin to be 
inferred. These tumours also exhibit diversity in copy number alterations, with some events being 
shared by more than one tumour but not all tumours (green box). Some tumours also have unique 
events (red box).  
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3.2.6 Hotspot mutation analysis of key genes 
Bladder cancer has mutational hotspots in the coding regions of five key genes: 
FGFR3, PIK3CA, HRAS, KRAS and NRAS. Additionally, recurrent mutations in the 
promoter region of the TERT gene have been identified. These genes play an 
important role in cellular processes and have been heavily implicated in carcinogenesis 
where they can act as oncogenes. Analysis of mutations in these genes may provide 
insight into factors driving tumour growth. Additionally, shared and unique mutations 
can provide more information for the assessment of clonality. This may be useful in the 
eight cases where clonality could not be established from CNAs alone. 
The mutation status of hotspot mutations was interrogated using SNaPshot assays 
(Table 3.2). Mutations in the TERT promoter were most frequent, with mutations 
detected in at least one tumour for 21 patients (61/67 tumours). A total of 18 patients 
demonstrated FGFR3 mutations in at least one of their tumours with a total of 48/67 
tumours containing FGFR3 mutations (43/59 stage Ta (72.9%), 4/8 stage T1 (50%) 
and 1 possible low grade UCC where a highly fragmented sample did not allow for 
accurate staging and grading). The most common FGFR3 mutation was S249C seen in 
32 tumours from 12 patients, followed by Y375C which was detected in 11 tumours 
from 4 patients. G372C and R248C mutations were identified in one patient each. Only 
2 patients had RAS mutations (P0198 and P0533) and these were mutually exclusive 
with FGFR3 mutations. 
Analysis of FGFR3 mutations in P1175 identified that tumour P1175-S01 was 
homozygous for the G372C mutation whilst tumour P1175-S02 was heterozygous 
(Figure 3.9A). To see if this was due to changes in CN, the genomic position at which 
the FGFR3 gene is located on chromosome 4 was examined. No changes in CN were 
identified (Figure 3.9B), suggesting that tumour P1175-S01 has CN neutral loss of 
heterozygosity (LOH) in this region. We considered the possibility that LOH may not 
have been detected in tumour P1175-S02 due to the presence of contaminating normal 
cells. Examination of H&E sections for the two tumours showed that tumour P1175-S01 
was large with a purity of >90% tumour cells whilst S02 was small and mostly impure. 
However, P1175-S02 had good spatial separation of the tumour and non-tumour cells, 
enabling the tumour cells to be isolated using macrodissection prior to DNA extraction. 
This would have resulted in a tumour purity of close to 100%, therefore it is unlikely that 
contamination of normal DNA obscured detection of LOH in this tumour. This suggests 
that the evolutionary path of the tumours diverged prior to the LOH event. 
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PIK3CA was mutated in 26.9% of tumours (18/67) with the majority of these tumours 
containing concurrent FGFR3 mutations (13/18). Patient P0533 represented an 
interesting case as only 2 of the 5 tumours contained a PIK3CA mutation and these 
were both different (Figure 3.10). Tumour P0533-S02 contained an E542K mutation 
and tumour P0533-S04 contained an E545K mutation, neither of which were detectable 
in the other tumours from this patient. As this analysis was completed using whole-
genome amplified DNA we decided to assess the mutation status in unamplified 
genomic DNA. This confirmed that both mutations were present and different. 
Mutations in the RAS family of genes were identified in two patients only (P0198 and 
P0533). All tumours from patient P0198 contained a HRAS G13R mutation whilst all 
tumours from patient P0533 contained a KRAS G12V. Mutations in the RAS genes and 
FGFR3 have been shown to be mutually exclusive. Compatible with this, the two 
patients with RAS mutations were wild-type for FGFR3. 
All patients had at least one hotspot mutation in one of their tumours (Table 3.2). Two 
tumours (P2065-S02 and P2291-S02) did not contain any hotspot mutations even 
though other tumours from the same patients carried mutations. Patient P2065 had two 
tumours, one of which contained a FGFR3 S249C mutation and a PIK3CA H1047R 
mutation (P2065-S01) whilst tumour P0265-S02 did not carry either of these mutations. 
A similar situation was seen in P2291 where tumour P2291-S01 contained a FGFR3 
S249C mutation whilst tumour P2291-S02 did not (Figure 3.11). 
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Figure 3.9: SNaPshot detection of hotspot mutations in FGFR3 in tumours from 
P1175. 
A) SNaPshot analysis of FGFR3 in tumours from P1175 identified a G372C mutation that was 
homozygous in tumour P1175-S01 (middle) and heterozygous in tumour P1175-S02 (bottom). 
Top panel is a representative wildtype control trace. Bases are represented by the following 
colours: A = green; C = black; G = blue; T = red. Orange peaks (S) represent the internal 
Genescan-120LIZ size standards. B) Plot of CN data for chromosome 4 in P1175-S01. 
Approximate location of FGFR3 is indicated by a red arrow. 
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3.2.7 CNAs and mutation status 
Previous studies have assessed the relationships between the mutation status of key 
bladder genes and CNAs125,259. To investigate any relationships between mutation 
status and CNAs in our cohort, GWFPs were created for tumours according to the 
mutation status of FGFR3, PIK3CA, the TERT promoter and the RAS gene family 
(Figure 3.12). 
Visual analysis of GWFP separating tumours according to FGFR3 mutation status 
identified that FGFR3 mutant tumours exhibit more losses of the whole of chromosome 
9 (Figure 3.12A). In the FGFR3 mutant tumours, 30/48 tumours had loss of the whole 
of chromosome 9 whilst only 3/19 tumours with wild-type FGFR3 contained this 
alteration. Loss of CDKN2A was similar in both groups with 34/48 mutant tumours and 
13/19 wild-type tumours containing this alteration. Gain of chromosome arm 8q 
appeared to be more frequent in FGFR3 wild-type tumours than in mutant tumours 
(4/19 WT, 3/48 mutant), however this alteration was present only in a single patient 
(P0198). 
Statistical comparisons undertaken using the Nexus software identified several regions 
exhibiting statistically significant differences in the frequencies of CNAs in FGFR3 
mutant and wild-type tumours. Interestingly a significant difference was identified at 
4p16.3, containing the FGFR3 gene. This region was gained in 29% of FGFR3 mutant 
tumours and included tumours from 5 patients, whilst no wild-type tumours contained 
gain of this region (p = 0.007, Fishers exact test, differential threshold 25%). 32 
significant regions of loss involving chromosome 9 were detected in the mutant 
tumours (p values ranging from 0.03 to < 0.0001). Visual inspection of the GWFPs 
identified that gain of the long arm of chromosome 8 was more frequent in FGFR3 wild-
type tumours compared to mutant tumours, but this frequency was not statistically 
significant at a 25% differential threshold. Two small regions on 8q that were identified 
as frequently gained in wild-type tumours compared to mutant tumours were located at 
8q24.22 and 8q24.3 (p = 0.004 for both regions). Wild-type tumours also exhibited 
more frequent loss of 13q13.3-q14.3 (p = 0.001, Fishers exact test, differential 
threshold 25%).  
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Figure 3.12: FGFR3, PIK3CA, TERT and RAS gene mutation status and genome-
wide copy number alterations 
Genome-wide frequency plots were generated for: A) FGFR3 WT (n=19) and FGFR3 mutant 
(n=48) tumours, B) PIK3CA WT (n=49) and PIK3CA mutant (n=18) tumours, C) TERT WT (n=6) 
and TERT mutant (n=61) tumours and D) RAS WT (n=58) and RAS mutant (n=9) tumours. 
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Analysis of FGA in mutant and WT tumours identified that FGFR3 mutant tumours had 
a higher median FGA than WT tumours, but this was not statistically significant (wild-
type median = 5.165 n = 19, mutant median = 7.015 n = 48, p = 0.2036, Mann-Whitney 
test). The higher FGA in the mutant tumours is likely due to the large number of mutant 
tumours with whole loss of chromosome 9. As these analyses were performed on 
multiple tumours from the same patient the results must be viewed with caution. 
Separating tumours by PIK3CA mutation status identified several differences (Figure 
3.12B). Loss of chromosome 9 was rare in PIK3CA mutant tumours with only 3/18 
tumours showing loss of the whole chromosome. This is interesting as 13/18 of these 
tumours also contained FGFR3 mutations, which was associated with chromosome 9 
loss in this study. Statistical analysis identified 55 regions on chromosome 9 that were 
more frequently lost in wild-type tumours than in PIK3CA mutant tumours (p value 
range: 0.05 to 0.0002). Loss of 7p was identified only in PIK3CA mutant tumours but 
this was not significant at the differential threshold of 25%. Loss of 17p.13.3 – p13.2  
and gain of 17q.22 – q25.3 were more frequent in mutant tumours (p = 0.0009 for both, 
Fishers exact test, differential threshold 25%). 
Tumours lacking a TERT promoter mutation were seen to have very stable genomes 
with only one tumour (P2291-S01) exhibiting CNAs on any of the autosomes (Figure 
3.12C). Of the 6 samples without a TERT mutation, 2 tumours (P2065-S02 and P2291-
S02) did not carry any mutations in any of the hotspots assessed. In addition, these 
two tumours did not share any genomic alterations with the other tumours from the 
same patient. The remaining 4 tumours all had a FGFR3 mutation (P0536-S01, P0536-
S02, P2065-S01 and P2291-S01) and 3 tumours also had a PIK3CA mutation (P0536-
S01, P0536-S02 and P2065-S01). 
Analysis of GWFP from patients with RAS mutations showed that these tumours have 
few CNAs (Figure 3.12D). All RAS mutant tumours had HD of CDKN2A. Interestingly, 
for chromosome 9, none of the RAS mutant tumours exhibited loss of the entire 
chromosome or loss of an entire chromosome arm. Statistical analysis identified that all 
CNAs identified in the RAS mutant tumours, except for alterations on chromosome 9, 
were statistically more frequent in the mutant tumours. Caution must be taken in 
interpreting these results as only two patients had tumours with RAS mutations and all 
tumours in these patients shared the same CNAs. Nevertheless, the lack of 9q loss is 
interesting as this has been observed in other RAS mutant tumours (Carolyn Hurst, 
personal communication).  
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3.2.7.1 Inclusion of hotspot mutation data in the assessment of clonality 
In section 3.2.5, tumours from each patient were assessed for clonal origins using 
CNAs. This identified a monoclonal origin for 15 of the 23 patients but could not infer a 
monoclonal origin for tumours from patients P0468, P0536, P0933, P0990, P2065, 
P2161, P2218 and P2291. It was thought that additional information from the hotspot 
mutation analysis may be able to assist in defining the relationships between tumours 
from these patients and confirm the monoclonal origin of the 15 patients identified as 
monoclonal by CN analysis. 
Mutation analysis suggested a monoclonal origin for 6 of the patients for whom CN 
data alone had been insufficient (P0468, P0536, P0933, P0990, P2161 and P2218). 
However, due to the prevalence of many of the mutations in bladder cancer, this data 
alone cannot be used to completely assume monoclonality. Tumours from patient 
P0468 shared TERT promoter mutations (-124 G > A) but were wild-type for all other 
hotspot mutations. As mutations in the TERT promoter are highly prevalent in bladder 
cancer it is possible that these occurred independently, and therefore a monoclonal 
origin cannot be assumed in this patient from this data alone. Tumours from P0990 
contained a FGFR3 Y375C and a PIK3CA E542K mutation whilst tumours from patient 
P2218 shared a FGFR3 R248C mutation. Tumours from both patients contained -124 
(G > A) TERT promoter mutations. Combined, this suggests a monoclonal origin for 
these patients. Tumours from patients P0933 and P2161 carried an FGFR3 S249C 
mutation as well as mutations in the TERT promoter. As these events are highly 
frequent in bladder cancer, it is again possible that these mutations developed 
independently. Tumours from patient P0536 shared FGFR3 S249C and PIK3CA 
E545K mutations but tumour P0536-S03 contained an additional mutation in the TERT 
promoter (-146 G > A) not seen in the other two tumours. Again, these mutations are 
highly prevalent in bladder cancer and the presence of the TERT promoter mutation in 
a single tumour means that monoclonality cannot be absolutely confirmed. More 
extensive mutation analysis was carried out to confirm monoclonality in the tumours 
from these 6 patients; P2161 and P2218 underwent whole exome sequencing whilst 
the remaining tumours (P0468, P0536, P0933 and P0990) underwent NGS-based 
targeted sequencing using a gene panel of 140 genes identified as being frequently 
mutated in bladder cancer. The results of these analyses are discussed in Chapter 5 
section 5.2.5.2. 
No evidence for monoclonality was identified for two patients; P2065 and P2291. Both 
tumours from patient P0265 had losses on chromosome Y, but these were different: 
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P0265-S01 had loss of the whole chromosome whilst P2065-S02 had loss of only a 
segment of the chromosome. Neither tumour had any other CNAs so monoclonality 
could not be attributed using CNAs. Further evidence for possible oligoclonality comes 
from the fact that the two samples did not share any mutations in the hotspot regions 
targeted by the SNaPshot assays; P2065-S01 had mutations in both FGFR3 (S249C) 
and PIK3CA (H1047R) whilst P2065-S02 had neither of these (Figure 3.11A). This 
evidence would suggest that the tumours are unlikely to be related. Unfortunately, 
P2065-S02 did not have enough DNA for NGS-based targeted exome sequencing to 
be carried out and therefore oligoclonality could not absolutely be confirmed. For 
patient P2291, each tumour had only one CNA and these were not shared. Tumour 
P2291-S01 also demonstrated an FGFR3 S249C mutation that was not detected in 
tumour P2291-S02 (Figure 3.11B). These tumours were further assessed for 
monoclonality using targeted sequencing. The results of this analysis are discussed in 
Chapter 5 section 5.2.5.2. 
3.2.8 Phylogenetic tree reconstruction 
When analysing multiple samples from the same patient the identification of shared 
and unique alterations can predict the order of alteration acquisition. This can be used 
to identify events that occur early during the cancer evolutionary process versus events 
that occur later and may be tumour or region specific. To assess the temporal order of 
CNAs, and thus the relationship between tumours from the same patient, the TuMult 
algorithm was employed. TuMult uses the shared and unique breakpoints in tumours 
from the same individual to reconstruct the hypothesised sequence of events giving 
rise to each tumour. This information is then used to create phylogenetic trees. A 
phylogenetic tree was created for all patients using the scored CN data and this was 
supplemented with the mutation status of genes assessed using the SNaPshot assays. 
Any trees not shown in this section can be found in Appendix G. For some patients 
there were only a few CNAs shared by all tumours after which individual tumours 
diverged and acquired unique CNAs of their own. In other cases, the majority of CNAs 
were shared and there was very little individual divergence seen between tumours.  
3.2.8.1 Linear and branching evolution 
Tree reconstruction showed different predicted evolutionary trajectories amongst 
patients. Linear evolution was predicted in patients P0536, P0926, P0933, P0990, 
P1175, P1870, P2104 and P2440. Trees from these patients are depicted as straight 
lines, with tumours gaining more CNAs in each consecutive tumour (Figure 3.13A). 
Branching evolution was predicted in patients P0712, P0960 and P2218 where some 
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CNAs were common to all tumours, but each tumour also had unique events resulting 
in branching (Figure 3.13B). For some patients there appeared to be a mix of 
branching and linear evolution (P0418, P0533, P0712 and P1485). In patient P0712, 
for example, tumours P0712-S01, P0712-S02, P0712-S03 and P0712-S04 are 
predicted to branch off from common precursors, but tumour P0712-S05 is predicted to 
have developed linearly from tumour P0712-S04 due to the presence of a single 
additional CNA (+1q32) having been identified in this tumour (Figure 3.14A). 
In some cases, all tumours from an individual were identical with respect to CNAs and 
hotspot mutations. For example, patient P0198 had 4 tumours, all of which shared 
identical CN events and hotspot mutations. Where there are no CNAs unique to an 
individual tumour TuMult depicts these as a linear tree in chronological TURBT order 
(Figure 3.14B&C). However, there is no way of knowing the order of events based on 
CNAs and hotspot mutation data alone in these cases. 
 
 
Figure 3.13: Phylogenetic trees for tumours from patients P1175 and P0960 
demonstrating linear and branching evolution. 
Trees were created using the TuMult algorithm which uses shared and unique breakpoints to 
reconstruct the evolutionary history of the tumours. A) Linear evolution was seen in tumours from 
patient P1175 according to CNAs and hotspot mutations. Tumour P1175-S01 is predicted to have 
evolved from tumour P1175-S02. B) Phylogenetic analysis of tumours from patient P0960 
generates a branching tree. Tumours share some events then branch off with additional unique 
events.  
 
A B 
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Figure 3.14: Phylogenetic trees for tumours from patients P0712, P0198 and 
P0533. 
Trees were created using the TuMult algorithm which uses shared and unique breakpoints to 
reconstruct the evolutionary history of the tumours. A) Patient P0712 has some CNAs shared by 
all tumours followed by significant branching of the tumours. Tumour P0712-S05 is predicted to 
evolve in a linear fashion from tumour P0712-S04. B) Tumours from patient P0198 share all CNAs 
and hotspot mutations. There are no events unique to any tumour resulting in an uninformative 
tree. C) Tumours from patient P0533 share the majority of CNAs. However two different PIK3CA 
mutations are present in tumours P0533-S02 and P0533-S04. MMC treatment was not 
associated with any CNAs. 
A 
B C 
  
96 
3.2.8.2 Chronology of tumour presentation 
In some cases, the chronology of tumour presentation was not reflected in the order of 
genetic aberrations. In patients P0418, P0933, P1175 and P2104 the primary tumour 
was predicted to be a genomic descendant of the recurrent tumour and contained more 
CNAs. For P1485 the second tumour (P1485-S02) was predicted to be the first tumour 
in the tree with the primary and most recent tumours, P1485-S01 and P1485-S03,  
predicted to descend from this via a common precursor (Figure 3.15).  
 
Figure 3.15: Phylogenetic tree for tumours from patient P1485. 
The chronology of tumour presentation for tumours from patient P1485 does not reflect the order 
of genomic alterations. According to phylogenetic reconstruction, tumour P1485-S02 is 
genomically ancestral to tumour P1485-S01 despite being resected at a later date. 
 
3.2.8.3 Recurrent trunk mutations 
All trees were analysed for events occurring on the trunk of the tree. As patients P2065 
and P2291 did not share any CNAs or hotspot mutations, and therefore had no truncal 
events, they were discounted from this analysis. The most frequent truncal event was a 
TERT promoter mutation which was seen on the trunk of the tree in 20/21 patients. 
Indeed, almost all hot-spot mutations were found on the trunk of the trees with the 
exception of one TERT promoter mutation identified in patient P0536 and the PIK3CA 
mutations identified in two of the tumours from patient P0533. FGFR3 mutations were 
always predicted to be on the trunk of the tree.  
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CN losses were more common on the trunk of trees than gains. Alterations involving 
chromosome 9 were the most common CN events occurring on the trunk of the tumour 
trees (Table 3.3). Where patients had loss of the whole of chromosome 9, this always 
occurred on the trunk of the tree, suggesting that this may be an early event in bladder 
cancer development. This early event was identified in almost half of the patients 
(10/21). Only 3 regions of gain were seen on two or more trunks. Gain of the entire q-
arm of chromosome 15 was seen on the trunk in two tumours; P1326 and P1485.  
3.2.8.4 Mitomycin C treatment and tumour evolution 
Sixteen of the patients in the cohort underwent a six-week course of MMC treatment 
(P0418, P0468, P0533, P0536, P0717, P0926, P0960, P0990, P1175, P1485, P1777, 
P1870, P2161, P2218, P2329 and P2440). Comparing the frequencies of CNAs in 
matched pre- and post-MMC treated tumours did not identify any regions of CNA that 
were differentially altered between the two groups. Likewise, no statistical difference in 
the FGA was identified between pre- and post-MMC tumours. We were interested to 
see whether placement of MMC treatment on the phylogenetic trees was associated 
with any recurrent alterations (Figure 3.16). 
The predicted genomic evolution did not follow the chronology of presentation for two 
patients (P1175 and P1485), consequently it was not possible to indicate MMC 
treatment on the trees for these patients. For three patients, no changes in CNAs were 
identified in the post-MMC tumours (P1870, P1777 and P2161). In other patients, 
treatment with MMC coincided with a predicted branching event (Figure 3.16). CNAs 
that were uniquely detected post-MMC treatment or CNAs that were detected pre-
MMC treatment but not post-MMC treatment were assessed for recurrent events. 
Tumours from 3 patients (P0468, P0926 and P2440) showed a loss of 9p21 containing 
CDKN2A/B after the MMC course compared to the tumours pre-MMC. For patients 
P0468 and P2440, tumours resected prior to MMC treatment contained loss of 9p21 
whilst post-MMC tumours contained HD of this region. For patient P0926, loss of 9p21 
was identified only in the post-MMC tumour. 
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Table 3.3: Recurrent events seen on the trunk of the phylogenetic trees. 
Events seen on the trunk of the tumour trees were examined and events occurring in more than 
one patient have been listed in the table. *The overall frequency is calculated from the 21 patients 
with a trunk event. 
Event Number of 
patients 
(n=21) 
Overall 
frequency 
(%)* 
Mutations   
TERT 20 95 
FGFR3 16 76 
PIK3CA 4 19 
RAS 2 9.5 
Losses   
-9 10 47.6 
--9p21 (HD CDKN2A) 7 33.3 
-9p21 (CDKN2A loss) 3 14 
-9p22 3 14 
-11p 3 14 
-Y 3 14 
-6p21 2 9.5 
-9p23 2 9.5 
-9q 2 9.5 
-12q24 2 9.5 
-17p 2 9.5 
Gains   
+7q11 2 9.5 
+15 2 9.5 
+16p13 2 9.5 
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Figure 3.16: Examples of MMC positioning on phylogenetic trees reconstructed 
for tumours from patients P1870, P2161 and P0418. 
A) MMC treatment was not associated with any changes in CN for patients P1870 and P2161. B) 
Tumours from patient P0418 were punctuated with many focal regions of CN gain that were 
shared between all tumours. MMC treatment coincides with tumour P0418-S03 branching off the 
common ancestor.  
A 
B 
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3.2.9 Hierarchical cluster analysis 
In previous studies, hierarchical clustering of multiple tumours from the same patient 
has demonstrated that these tumours tend to cluster close together163,167. In our cohort, 
the majority of tumours from the same patient share CNAs, therefore we hypothesized 
that these would likely cluster together. One-way unsupervised hierarchical cluster 
analysis of copy number data from all 67 tumours from this cohort  was performed. 
This identified two main subgroups of tumours; one characterised by loss of 
chromosome 9 and/or gain of chromosome 7, whilst tumours in the other group lacked 
these alterations (Figure 3.17). For the majority of patients, tumours tended to cluster 
next to each other. Seven patients (P0468, P0712, P0933, P960, P0990, P1485 and 
P1870) had one tumour cluster separately to the other tumours from that patient. This 
was due to CNAs not being shared by all tumours from an individual patient. For 
example, tumour P1870-S01 clustered separately to all the other tumours from this 
patient. This tumour did not contain loss of chromosome 18 which was identified in all 
other tumours from this patient. Similarly, tumour P0960-S01 clustered away from the 
other two tumours from this patient, likely due to a gain of chromosome 7 identified in 
tumour P0960-S01 but absent from the other tumours from that patient. In all seven 
cases, tumours clustered into the same main subgroup as the other tumours from the 
patient (Figure 3.17). 
In NMIBC, genomic subtypes have been identified using hierarchical clustering 
analysis of CNAs82,125. These studies identified two genomic subgroups of stage Ta 
tumours; one (GS1) characterized by no or few CN alterations and the other (GS2) 
characterized by loss of chromosome 9. We were interested to identify which of these 
subgroups tumours from our cohort would cluster with. 
One-way unsupervised hierarchical cluster analysis of copy number data from all 67 
tumours from this cohort and 133 of the tumours from Hurst et al.82 was performed. 
This produced the two main clusters (GS1 and GS2) as described by Hurst et al.82 
(Figure 3.18). The majority of tumours from our cohort clustered with the GS2 tumours. 
Only 11 tumours clustered into GS1, including all the tumours lacking a TERT promoter 
mutation. These tumours were all stage Ta grade 2 that were chromosomally very 
stable with few or no CNAs. The remaining 56 tumours clustered into GS2. 
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Figure 3.17: Unsupervised hierarchical cluster analysis 
Unsupervised hierarchical cluster analysis of CN data from all 67 tumours. Columns represent 
tumours and rows genomic position. Blue shading is CN gain, yellow is CN loss and black 
represents no CN change. Patient ID for each tumour is designated by colour.  
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Figure 3.18: Unsupervised hierarchical cluster analysis of CNAs with tumours 
from Hurst et al.82. 
Unsupervised hierarchical cluster analysis of CN data from the 67 tumours from this cohort and 
133 samples from Hurst et al.82. Columns represent samples and rows genomic position. Blue 
shading is CN gain, yellow is CN loss and black represents no CN change. Red bars indicate 
samples from Hurst et al. and orange bars represent samples from the current cohort of 67 
tumours. The two main clusters from Hurst et al, GS1 and GS2, are indicated. 
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Two patients had tumours that clustered into different genomic subgroups (P0933 and 
P0990). For patient P0933, tumour P0933-S02 clustered into GS1 whilst tumour 
P0933-S01 clustered into GS2. Both tumours demonstrated stable genomes with no 
CNAs identified in P0933-S02 and only one CNA, loss of 9q21.11 – q22.33, was 
identified in P0933-S01. In this case, the loss on chromosome 9 led to tumour P0933-
S01 clustering  into GS2. For patient P0990, tumour P0990-S01 had no CNAs and 
clustered into GS1 whilst tumours P0990-S04 and P0990-S05 clustered into GS2. 
Interestingly, neither P0990-S04 or P0990-S05 contained loss of chromosome 9 or 9q, 
the characteristic losses of this subgroup, but these two tumours were more 
chromosomally unstable, containing several whole chromosome gains. 
3.3 Discussion 
Shallow-pass whole genome sequencing was used to assess CNAs in 67 tumours 
from 23 patients. Using multiple tumours from one individual patient can make it 
difficult to assess important CN changes as many of the tumours from an individual 
patient will share CNAs. This may artificially inflate the frequency of certain events. 
Likewise, if only one tumour per patient is assessed important events may be missed. 
To compensate for this GWFPs were created for all tumours as well as just the first or 
last tumour from each patient. These showed very similar CNA profiles with no 
significant difference in the frequencies of CNAs identified. Additionally, analysis of the 
FGA demonstrated that there no statistically significant differences between the first 
and last tumours from each patient. This suggests that bladder tumours are relatively 
stable at the CN level between recurrences.  
Tumour stage and grade are key parameters used in the prediction of risk of 
recurrence and progression for NMIBC182,260. This cohort consisted of: 8 stage Ta G1, 
42 stage Ta G2, 7 stage Ta G3, 4  stage T1 G2, 2  stage T1 G3, 1 stage Ta(x) G3, 2 
stage T1(x) G3 and 1 possible low-grade urothelial carcinoma in which small, heavily 
diathermied fragments of tissue made grading difficult. Tumours with an (x) had 
insufficient sampling of the muscle layer and therefore invasion could not be ruled out. 
The one stage Ta(x) tumour was therefore omitted from the comparison of tumours by 
stage as it is possible that this tumour may have been of a higher stage. 
Separating tumours according to stage and grade identified that stage T1 tumours and 
grade 3 tumours are more chromosomally unstable than stage Ta or grade 1&2 
tumours. This is in agreement with previous observations125,126. We also used the 
fraction of genome altered (FGA) as a measure of chromosomal instability and this 
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showed that NMIBC with a higher stage or grade had a significantly higher median 
FGA (Mann Whitney U test, p<0.005 and p<0.05 for stage and grade, respectively). 
The number of tumours in each group was very different with the majority of samples 
being stage Ta grade 2 and this may have biased the results. However, the data 
presented here shows similarities to that of Hurst et al,125 who looked at over 100 
NMIBCs and also found that higher stage and grade tumours had a higher median 
FGA. 
Statistical comparisons of the frequencies of CNAs in tumours of stage Ta and T1 
identified many differences. Gains of 7p, 7q, 8q12.3 - q24.3 and 17q22 – q25.3 were 
more frequent in stage T1 tumours. Gains of 8q were reported as statistically more 
frequent in stage T1 tumours compared to stage Ta tumours in a study by Richter et 
al.126, who also identified deletions of 2q, 8p and 11p and gains of 1q, 3p, 3q 5p, 6p 
and 10p as significantly different in frequency between stage Ta and stage T1 tumours. 
Gains on 3p, 3q and 5p were also significantly more frequent in our stage T1 tumours, 
but the size of these regions were much smaller than those previously identified126. 
Again, these differences may be due to the low number of stage T1 tumours included 
in this study. 
Separation of CNAs in tumours according to grade showed a similar distribution to that 
generated when tumours were separated according to stage. Of the 8 stage T1 
tumours, 4 were G3 and 4 were G2. Interestingly, the chromosome 7 gains seen in 
stage T1 tumours were equally divided between G2 and G3 tumours. Whilst this could 
suggest that this alteration may be associated with stage it is important to note that 
chromosome 7 gains were present in 4 stage T1 tumours from 2 patients only, P0717 
and P0418. Analysis of the other tumours from these patients identified the presence of 
chromosome 7 gains in all tumours making it more likely to be a patient specific 
alteration rather than being associated with stage and grade. Within the literature there 
are conflicting reports on the relationship between chromosome 7 gain and stage and 
grade261,262. A correlation between chromosome 7 CN and increasing stage and grade 
was identified on one study261 but in other studies, this correlation has not been 
observed135,262. 
The most common CN event identified was loss of the CDKN2A locus at 9p21.3. This 
is a region that is commonly deleted in bladder cancer and has previously been 
associated an increased risk of recurrence in NMIBC132. In a recent review by Knowles 
and Hurst4, hemizygous deletion of CDKN2A was reported at 50-60% in both low stage 
Ta tumours and MIBC (≥T2) and HD was reported as being present in 15% of low 
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grade Ta tumours and 20-30% of MIBC. In our cohort of 67 tumours, 31 tumours had 
HD of CDKN2A; 22 TaG2, 5 TaG3, 2 T1G2 and 2 T1G3. On a per-patient basis, 10 
patients had HD of this region in at least one of their tumours corresponding to 43.5% 
of patients overall. This is a higher rate of HD than previously reported for either 
NMIBC or MIBC. When assessing only the first and last tumours from each patient, HD 
of CDKN2A was present in 34.7% and 43.5% of tumours, respectively, suggesting that 
the high level of CDKN2A loss is reflective of this group of tumours, and not because of 
multiple recurrences containing the same CN event. This data therefore further 
supports the association between CDKN2A HD and increased risk of recurrence132. 
Meeks et al173 identified an increased frequency of loss of the CDKN2A locus in high-
risk NMIBC patients that progressed compared to non-progressors, however this was 
non-significant (p=0.54). They suggested that loss of the CDKN2A locus may be a late 
event during invasion and may be important for progression. In our cohort, where loss 
of CDKN2A occurred in a patient it was usually present in all tumours from that patient 
which may suggest that it might actually be an early event. Indeed, loss of CDKN2A 
(either as a focal loss or part of a whole chromosome loss) was seen on the trunk of 
the phylogenetic trees in 14 out of 15 patients. HD of the region was a trunk event in 
7/10 patients. This may suggest that whilst loss of CDKN2A is an early event, HD of 
the region can occur later on and this may be the important event for progression. Our 
study looked specifically at recurrent tumours, with the majority of patients being of an 
intermediate risk of progression. It is therefore unsurprising that loss of CDKN2A was a 
common event. 
In the current study, two patients’ (P0926 and P0990) had progression from stage Ta 
to stage T1 disease and two patients (P0717 and P2440) later progressed to 
metastatic disease (see patient timelines in Appendix A). For patient P0926, loss of 
CDKN2A was identified only in the recurrent tumour. In this case the initial tumour was 
stage Ta grade 1, whilst the recurrence analysed was stage Ta grade 3. However this 
patient also had a T1G3 tumour between these two which did not have enough DNA 
for analysis. There was no loss of CDKN2A observed in any of the tumours analysed 
from patient P0990, but both patients with metastatic disease showed HD of CDKN2A; 
for patient P0717 this was present in all tumours from the patient whereas for patient 
P2440 only the recurrent tumour showed HD of this region. Whilst these observations 
are interesting, this study does not include enough patients with disease progression to 
confirm the association between CDKN2A loss and progression reported by Meeks et 
al.173. Interestingly both patients with metastatic disease had upper tract disease; 
  
106 
patient P0717 additionally had transitional cell carcinoma of the right renal pelvis and 
patient P2440 had bilateral nephrectomies due to transitional cell carcinoma of the 
renal pelvis. This could be an alternative route for progression. Clonality between 
bladder tumours and tumours in the renal pelvis has been identified by NGS174. It 
would be interesting to study these upper tract tumours to see if these were also 
clonally related to the bladder tumours. 
CDKN2A HD has been associated with muscle invasion in FGFR3-mutated urothelial 
BC263. This could be a progression pathway for FGFR3 mutant tumours. In this cohort, 
out of the 31 tumours with CDKN2A HD, 20 tumours from 7 patients (P0712, P0717, 
P1175, P1485, P1777, P2218 and P2440) carried an FGFR3 mutation, including the 
two patients that progressed to metastatic disease. It would be interesting to analyse 
the metastatic tumours (as well as the upper tract tumours) to see if CDKN2A HD was 
present. Again, the lack of patient numbers makes it impossible to draw any firm 
conclusions concerning CDKN2A loss, FGFR3 mutation and progression. 
Amplifications detected in the current study were distributed throughout the genome 
whilst all HD events except for one were located on chromosome 9. These were all 
focal events ranging from 0.6-2.9 Mb in size except for one broad region of 
amplification of a 14Mb region on chromosome 18 seen in tumours from patient P0418. 
It is thought that focal CNAs are the product of errors in DNA repair whilst broader 
CNAs are the result of incorrect chromosome segregation during mitosis264. Focal 
amplifications in stage Ta BC have been associated with high-grade and 
recurrence250,265 whilst HD are more frequent in patients with multiple tumours250. In this 
data set amplifications were only found in 5 tumours; 1 TaG2, 1 Ta(x)G3, 1 T1G2 and 
2 T1(x)G3. 
A single tumour from patient P1485 contained an amplification of 11q13.3, tumour 
P1485-S01. This is a region that is recurrently amplified in bladder cancer135,250,266 and 
contains the Cyclin D1 (CCND1) gene as well as fibroblast growth factors (FGFs) 3, 4 
and 19. CCND1 is often found to be dysregulated in cancer and forms part of an active 
complex that can phosphorylate the retinoblastoma (RB1) tumour suppressor protein, 
driving progression to S-phase267. The FGFs are the activators of FGF receptors, 
including FGFR3, and have roles in proliferation, migration, differentiation, 
angiogenesis and wound healing268, all of which are frequently dysregulated in cancer. 
Amplification of this region has been shown to correspond with increased expression of 
CCND1 mRNA but not FGFs despite the genes being within the same amplicon265. It 
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would be interesting to follow this up with further analysis of these candidate genes at 
the mRNA and/or protein levels.  
P0468-S01 exhibited an amplification at 13q33.3 and part of this region was also 
gained in tumour P0468-S03. The region of gain in P0468-S03 included 3 of the 12 
genes present in the amplified region seen in tumour P0468-S01 (LINC00676, IRS2 
and COL4A1). This could suggest that one, or all, of these three genes are the 
target(s) for this amplification. The concomitant focal deletions around this amplification 
in tumour P0468-S01 are suggestive of significant rearrangement occurring in this 
region. It is possible that this region was gained in a clone, then in a subclone there 
was significant chromosomal rearrangement leading to amplification of the region with 
deletions at the breakpoints. This potentially gave the subclone a survival or growth 
advantage, thus making it the first tumour to be detected. Of the 12 genes located in 
the amplification, insulin receptor substrate 2 (IRS2) is an interesting candidate. IRS2 
is an intracellular signalling adaptor protein involved in insulin signalling which can 
activate both the PI3K and ERK signalling pathways269. IRS2 has been identified as a 
candidate driver oncogene in colorectal cancer270 and overexpression plays a role in 
many cancers269. Analysis of the TGCA MIBC dataset81 in COSMIC identified 7 
patients with a gain of this gene and further inspection identified that this gain was 
actually a focal amplification in 3 of the patients, according to our criteria. However, 
IRS2 was only found to be overexpressed in one of these patients (data not shown). It 
would be interesting to see if IRS2 is indeed upregulated in the tumours from patient 
P0468 as this might implicate IRS2 as a driver event in bladder cancer. 
The majority of HD events were located on chromosome 9, with the CDKN2A locus 
being the most commonly deleted region as discussed previously. In patient P0533, a 
region containing protein tyrosine phosphatase delta (PTPRD) was focally deleted in all 
tumours in a separate event to HD of CDKN2A, which is on the same chromosome 
arm (9p) less than 12 Mb away. PTPRD is a tumour suppressor gene that is frequently 
inactivated in glioblastoma and other cancers271,272. This gene was also identified as a 
target of HD in bladder cancer in a recent study by Beoth et al.250. They investigated 
solitary, multifocal and recurrent tumours and identified that HD of PTPRD occurred 
more frequently in patients with multiple tumours as did HD at 9p22.3-p22.2, a region 
harboring the C9orf93, BNC2 and CNTLN genes. This HD at 9p22.3-p22.2 was also 
identified in our cohort in all five tumours from patient P0712. Combined, these data 
suggest a role for these regions in multifocal and recurrent disease and warrant further 
investigation. 
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A region on chromosome X containing the genes XIAP, STAG2, SH2D1A and TENM1 
was HD in tumour P0712-S03 and there was CN loss in the same region in tumour 
P0712-S02. Of these genes, STAG2 has been seen as frequently inactivated by 
mutations in bladder cancer273,274. STAG2 forms part of the cohesin complex which is 
required to ensure correct chromosome segregation by maintaining sister chromatid 
cohesion following DNA replication275. Deletion of Xq25, the region that contains 
STAG2, has been reported in other cancers276,277 and inactivation of this gene by 
mutation has been shown to cause aneuploidy277. Correlating with this, the two 
tumours with loss of STAG2 have a higher FGA than the average in this cohort (18% in 
P0712-S02 and 24% in P0712-S03 compared to 6.08% median overall). Studies 
investigating the role of STAG2 in bladder cancer have reported conflicting results 
regarding aneuploidy170,274,278. The knockdown of  STAG2 by small interfering RNA 
(siRNA) resulted in an increase in aneuploidy in normal human bladder cells278 but 
investigations into bladder tumours report few CNAs170 and a lower FGA than WT 
tumours274. As our study contained only 2 tumours from one individual patient with loss 
of STAG2 there is insufficient  data to contribute to either argument as it is possible 
that that these tumours would be outliers in a larger study of STAG2 CN loss in 
NMIBC.  
Loss of STAG2 expression is associated with low-stage and low-grade 
tumours170,274,279,280. In NIMBC, loss of STAG2 is associated with  a good prognosis and 
reduced risk of recurrence and progression170,273,279,280. Conversely in MIBC, loss of 
STAG2 was associated with an increased risk of recurrence and cancer specific 
mortality273. The biological basis for this difference is currently unknown. In our cohort, 
loss of STAG2 was only identified in two of the recurrent tumours from patient P0712 
and these were both stage Ta of G2 or G3. Despite having many recurrences, this 
patient did not display any stage progression. With such low numbers in our cohort, no 
conclusions can be drawn regarding STAG2 loss. Analysis of more recurrent tumours 
would help confirm or refute the observations regarding recurrences.  
Patient P0712 is male and therefore only has one copy of STAG2, yet in tumour 
P0712-S02 the gene has not been completely deleted. This could suggest that it 
represents a sub-clonal loss in this tumour as it was highly pure. Taylor et al. 274 found 
that expression of STAG2 was frequently chimeric suggestive the involvement of intra-
tumour genomic evolution.  
As part of their treatment a subset of patients underwent a 6-week course of 
intravesical MMC therapy. MMC has been seen to cause a variety of aberrations in 
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vitro including the induction of sister chromatid exchanges281, giant cell formation with 
nuclear fragmentation194, the formation of micronuclei200 and non-random interchange 
breakages199. More recently, an in vivo study using the model organism C.elegans 
identified that MMC treatment mainly causes deletions205. We therefore hypothesised 
that there might be an increase in the number of CNAs detectable after treatment and 
these were more likely to be deletions rather than gains. It was thus interesting that no 
significant difference in CNAs from pre- and post-MMC treated tumours was identified.  
Analysis of the CNAs surrounding MMC treatment identified a single region of CNA 
potentially associated with MMC treatment in multiple patients. This was loss of the 
9p21 locus containing CDKN2A seen in post-MMC tumours from patients P0468, 
P0926 and P2440. For patient P0926 this was a change from CN neutral to loss of the 
region and for the other two patients it was a change from loss to HD of the region. 
Despite the fact that this occurred post-MMC treatment in all 3 cases, it is impossible to 
say that this was a direct result of MMC treatment. Patients P0468 and P0926 had a 
gap of 12 and 3 years respectively between tumours pre- and post-chemotherapy. 
Within this period they both also received rounds of BCG treatment.  It is therefore not 
possible to say if this aberration is due to MMC, BCG or just down to tumour evolution 
over time.  
Many of the early in vitro studies into the effects of MMC treated peripheral blood 
leukocytes with different concentrations of the drug before making cytological 
preparations to assess breaks and exchanges in metaphase spreads. One of the major 
findings of these early studies was that chromosomes 1, 9 and 16 were the most 
affected, specifically in areas of secondary constriction196-199. These regions of 
secondary constriction are the peri-centromeric regions of heterochromatin found 
specifically on these three chromosomes. These regions are gene-poor and have yet 
to be properly annotated with a sequence and therefore are not covered by NGS. This 
means that aberrations such as deletions, SNVs etc. cannot yet be identified in these 
regions. Another possible cause for the lack of an increase in CNAs after treatment is 
that any chromosomal interchanges occurring could be CN neutral and would therefore 
not be detectable by CN analysis. It is also possible that the large exchanges could be 
more lethal to tumour cells in vivo or that these do not provide a growth advantage and 
therefore do not grow out to form a significant clonal population detectable by shallow-
pass WGS. The deletions identified by Tam et al. in C.elegans were also small, ranging 
from 2-318,826 bp in length. This could mean that any CNAs being generated by 
treatment may be smaller than can be identified with the resolution of this data.  
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Despite the lack of findings at the CNA level, it is still possible that MMC can affect the 
DNA. Studies have used sequencing to interrogate mutations caused by MMC in vitro 
and have identified a large proportion of substitutions and single base deletions201,202. 
WES performed on tumours pre- and post-MMC treatment should be able to identify 
any differences in the number and type of SNVs in the two groups. It may also provide 
an increased resolution for the analysis of CNAs in the coding regions, allowing smaller 
events to be discovered. 
Bladder cancer has well characterised hotspot mutations in FGFR3, PIK3CA, the 
TERT promoter and the RAS gene family. These regions were probed using SNaPshot 
assays to detect the presence of any SNVs. Over 71% of samples were FGFR3 
mutant. FGFR3 mutation has been associated with favourable disease parameters and 
a better prognosis259-282. Previous studies have seen a lower overall FGA in tumours 
with an FGFR3 mutation compared to FGFR3 wild-type tumours125,259. In this study 
there was no significant difference in FGA in FGFR3 mutant verses WT tumours with 
mutant tumours having a slightly higher median FGA than WT tumours. This remained 
true even when separating the tumours by stage and grade, and when a single mutant 
and/or wild-type tumour from each patient only was analysed. The likely cause for the 
discrepancy in this data is the high frequency of chromosome 9 loss seen in the 
FGFR3 mutant tumours. This study also specifically selected for patients with 
recurrences and for patients undergoing a treatment course of MMC. These patients 
tend to have a higher risk of recurrence and progression so it may be that this has 
selected for patients with a higher level of genomic instability than previous studies. It 
would be interesting to follow patients who had both FGFR3 wild-type and mutant 
tumours to see which tumours recurred and if there was any progression within these 
patients. Analysis of the subsequent tumours would identify if wild-type tumours or 
tumours harbouring an FGFR3 mutation led to the recurrent/progressed tumours. 
Interestingly, 29% of FGFR3 mutant tumours demonstrated gain of 4p16.3, the region 
harbouring the FGFR3 gene. It is possible that these tumours are heavily reliant on 
signalling through FGFR3, making this a possible therapeutic target for these patients. 
Mutations in RAS genes were identified in only two patients; P0198 and P0533. 
Mutations in RAS genes and FGFR3 are mutually exclusive events142,143,283. Consistent 
with this, none of the tumours with a RAS mutation carried an FGFR3 mutation in this 
cohort. This mutual exclusivity is thought to be due to the two genes signaling through 
the same pathway in bladder cancer146. GWFP and WGPs of RAS mutant tumours 
showed that these tumours have relatively stable genomes with conserved CNAs 
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between tumours from the same patient. Neither of the patients had loss of the whole 
of chromosome 9, yet both had HD of CDKN2A. Interestingly, tumours harbouring RAS 
mutations frequently lack deletions of 9q (Carolyn Hurst, personal communication). 
Loss of 9q has been associated with upregulation mTORC1 signalling, likely through 
the loss of TSC1, a negative regulator of mTORC182. Both RAS and mTORC signaling 
result in an increase in cell survival, proliferation and motility and the two pathways 
have been demonstrated to cross-talk and regulate one-another284. This could suggest 
that activation of both pathways is redundant in cancer, and may provide a possible 
explanation for the mutual exclusivity of these events. 
The TERT promoter was the most frequently mutated hotspot region with 21/23 
patients containing a mutation in at least one of their tumours. Other studies have 
demonstrated TERT promoter mutations in 56-83% of bladder tumours156,157,285. 
Restricting analysis to the first tumour from each patient identified that 87% (20/23) of 
patients carried TERT promoter mutations, a similar level to that reported previously. 
Only 6 tumours did not contain TERT promoter mutations and all of these tumours 
showed very stable genomes with loss of chromosome Y being the only recurrent 
event. Work by others has previously identified that bladder tumours with TERT 
promoter mutations have a significantly higher CNA burden and mutational load burden 
than wild-type tumours286. This correlates with our observations but the low sample 
size of wild-type tumours in our cohort means that results should be reviewed with 
caution. The lack of CNAs in tumours that do not carry TERT mutations suggests that 
mutation of the TERT promoter is an early event that precedes the acquisition of 
CNAs. This idea is reinforced by the observation that TERT promoter mutations are 
seen on the trunk of the phylogenetic tree in 20 out of 21 patients.  
Some tumours did not share the same mutations with other tumours from the same 
patient. Patient P1175 had one tumour that was heterozygous and one tumour that 
was homozygous for an FGFR3 G372C mutation. Analysis of the CN status at the 
FGFR3 gene locus indicated no alterations in the region suggesting that tumour 
P1175-S01 may have undergone CN neutral LOH compared to tumour P1175-S02. It 
is also possible that tumour S02 contained more contaminating normal cells resulting in 
the detection of the wild-type allele in the mixture. However, the sample was 
macrodissected and consequently should have been close to 100% pure making this 
unlikely. It is possible that the LOH event is subclonal in this tumour, which would 
explain the observation of the wild-type allele in the SNaPshot analysis. 
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In patient P0533 two different PIK3CA mutations were identified in two tumours. These 
were the E542K and E545K hotspot mutations found in the helical domain of the 
protein233. These appeared to be later events in the carcinogenesis process in this 
patient occurring on the branches of the tree. These mutations have previously been 
linked to APOBEC mediated mutagenesis83, especially when present subclonally287 
and they tend to occur later in carcinogenesis288. This might suggest that the PIK3CA 
mutations found in this patient are a result of APOBEC mutagenesis. 
The prevalence of hotspot mutations in bladder cancer has resulted in studies 
attempting to use this information to create non-invasive urine-based tests for 
diagnosis and identification of recurrences. Bladder tumours routinely shed cancer 
cells and tumour DNA into the urine and this can be used as a target for tests that 
detect hotspot mutations143,156. Mutations in the TERT promoter have been assessed in 
the urine of bladder cancer patients for the detection of disease recurrence156,289,290. A 
recent prospective study used the detection of TERT promoter mutations in the urine 
as a marker of bladder cancer290. This study found that TERT promoter mutation 
detection was more sensitive than cytology with a high specificity when detecting 
bladder cancer. They also reported that TERT promoter mutations were a dynamic 
marker of recurrence as detection of these mutations mirrored the cytoscopic 
presentation of recurrent tumours in several patients. However, there are limitations to 
the efficacy of such urine tests and one such limitation is highlighted by the 
identification of recurrent tumours in our cohort that did not contain the hotspot 
mutations detected in the primary tumours. Relying on mutation detection in the urine 
alone would not have identified these tumours. To combat these issues, groups are 
investigating the use of panels of markers to improve sensitivity and specificity291,292. A 
recent systematic review of urine biomarkers reported that these multi-target panels 
have better diagnostic performance compared to single target biomarkers293. 
Whole genome plots were generated to enable comparison of CNAs between tumours 
from the same patient. CNAs were also used to reconstruct phylogenetic trees for all 
tumours from a given patient using the TuMult algorithm35. This uses the breakpoints of 
related tumours to infer relationships between the tumours. Events seen in multiple 
tumours are likely to have occurred earlier whilst events unique to certain tumours are 
likely to have occurred later in the evolutionary process. This data was supplemented 
with data from the single gene mutation analysis to aid in tree reconstruction. 
The majority of patients shared at least some CNAs suggestive of a monoclonal origin. 
For patients P0198, P0536, P1326 and P1777, all tumours shared all CNAs with no 
  
113 
divergence seen, making tree building difficult. This shows a lack of inter-tumour 
heterogeneity with respect to CNAs for these tumours. It would be interesting to 
investigate whether these tumours had any unique mutations in order to assess 
whether the lack of heterogeneity is restricted to CNAs or if this is reflective of SNVs as 
well. For example, hotspot mutation analysis showed that tumour P0536-S03 
contained an additional TERT mutation compared to the other tumours from this 
patient. 
Cancer can follow different types of evolution. In the linear evolution model, a selective 
sweep follows the acquisition of a driver mutation, resulting in a dominant clone which 
can be seen at the time of profiling. Some patients (patients P0926, P0933, P0990, 
P1175, P1870, P2104 and P2440) showed apparent linear evolution where one tumour 
appears to be the direct descendant of another tumour, having acquired additional 
aberration(s). Interestingly, this linear evolution pattern was not always chronologically 
linear in terms of tumour resection. For example, for patients P0933, P1175 and 
P2104, the primary tumour was predicted to be a direct descendant of the recurrent 
tumour.  
This lack of genomic evolution reflecting the chronological presentation of the tumours 
was not restricted to tumours displaying apparent linear evolution. Indeed almost 50% 
of cases in this study showed fewer CNAs in the recurring tumour compared to the 
primary tumour. This has been observed before in bladder cancer; a study profiling 
recurrent tumours with CGH showed that despite the tumours sharing some 
aberrations, others were different between the tumours and these were not compatible 
with a simple progression model where the recurrent tumour is directly descended from 
the primary tumour167. Other studies have also reported that the chronology of tumour 
presentation does not necessarily reflect the genomic evolution of bladder cancer265. A 
study looking at recurrences spanning periods of up to 17 years identified a clonal 
relationship in all the patients studied and also observed that the chronological order of 
tumour presentation did not parallel the genetic evolution of the tumour163. 
This reduction in genomic complexity as tumours are chronologically resected is likely 
a consequence of field change seen in bladder cancer. Once a tumour is detected it is 
resected using TURBT. The earliest tumours to be detected are the fastest growing 
ones and it stands to reason that these are likely to be the ones with the most genomic 
alterations. Once these have been resected the slower growing clones may be left 
resulting in a tumour with fewer genomic alterations than the previous tumour. This 
may also explain why recurrent tumours can be of a lower grade than the preceding 
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tumours4. The slower growing clones may be left due to incomplete resection, re-
implantation or due to the spread of early clones throughout the urothelial layer, or 
potentially all three. Improvements in resection, such as the implementation of 
hexylaminolevulinate (HAL) photodynamic diagnosis (PDD) which is a procedure that 
uses a photoreactive molecule to identify neoplastic cells with blue light, will likely be 
instrumental in reducing recurrences. If all cancerous cells can be detected and 
removed then recurrence rates should drop. These practices are currently being trialed 
with promising results294. 
In two cases, no evidence for clonality was detected. These were patients P2065 and 
P2291. In each case the tumours from these patients did not share any CNAs or 
hotspot mutations at all. Tumour P2065-S02 was impure and required enrichment for 
tumour cells using LCM. In this case the stroma was removed from the slide leaving 
the tumour cells which were then scraped into a microcentrifuge tube for DNA 
extraction. This would have resulted in a highly pure DNA sample so it is unlikely that 
the hotspot mutations could have been missed due to contamination with normal cells. 
Tumour P2291-S02 had an estimated tumour content of 75% at the start of sectioning, 
but as cutting progressed, this purity dropped to approximately 60%. It was accepted 
that overall the purity of the cut sections would be around 70% so DNA was extracted 
from the two tubes that had been cut. Therefore, it is unlikely that the lack of clonality 
seen in these tumours are an artefact of tumour impurity. 
Previous studies have identified synchronous and metachronous tumours that do not 
appear to be clonally related. Lindren et al.167 used CGH, LOH and mutation profiling to 
analyse recurrent tumours and this indicated a clonal relationship in all but two 
patients. In one of the patients the tumours did not share any CNAs or regions of LOH 
but did share the same TP53 mutation suggestive of a clonal relationship. The other 
patient’s tumours did not share any events except for LOH in the region of CDKN2A. 
However these were likely independent events as different alleles were lost, 
suggesting that the samples were not clonally related. 
Despite providing a good overview of the relatedness of the tumours from the same 
patient there are some flaws to the TuMult algorithm. For patient P0712 for example, 
TuMult predicted that gain of chromosome 21 occurred in a common precursor to 
tumours P0712-S01, P0712-S04 and P0712-S05 followed by loss of some regions of 
chromosome 21 in tumour P0712-S01. TuMult also separated the loss of 8p, seen in 
all tumours except P0712-S01, into two separate branches. It is much more likely that 
the loss of 8p was a common event whilst the loss of the different regions of 
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chromosome 21 were more likely different events. This suggests that the prediction of 
common breakpoints within the algorithm could be refined to make more biological 
sense. 
Another limitation of the TuMult algorithm is that is uses the discretized data to infer the 
breakpoints. In most cases this is not a problem, as for most break points there is a 
change in the discretized CN status. However, in some cases there are CN changes 
present in multiple tumours from the same patient but in one of the tumours the change 
is not as great and does not change the discretized status. For example, tumours from 
patient P0418 shared 3 focal gains on chromosome 7. Additionally, two of the tumours 
(P0418-S01 and P0418-S02) demonstrated gain of the whole of chromosome 7. The 
whole chromosome gain likely resulted in two of the focal gains being classified as 
amplifications at 7p21.1 and 7q34 thus altering their discretized CN value. However, 
the third focal gain at 7q11.23 remained classified as a gain rather than an 
amplification resulting in no change in the discretized CN. As the algorithm cannot 
distinguish that this region is different from the whole chromosome gain it does not get 
automatically included as shared with tumour P0418-S03 and this alters the tree. This 
was corrected manually, but it represents a flaw in the algorithm. 
Hierarchal clustering of the 67 tumours revealed that the majority of tumours from the 
same patient cluster together. This correlates with previous studies clustering multiple 
tumours from the same patient by CNAs163,167, demonstrating that tumours from the 
same patient are relatively stable at the CN level. A lack of divergence at the CN level 
has also been demonstrated in muscle invasive and metastatic bladder cancer where 
tumours from the same patient tended to cluster into the same group despite 
containing some private CNAs62. Combined, this could suggest that the CN landscape 
of bladder tumours is set relatively early in cancer development, with only a small 
amount of evolution occurring between tumours. 
Hierarchal clustering of the 67 tumours with tumours from Hurst et al.82 showed that the 
majority of tumours from this cohort clustered into the more genomically unstable 
subgroup, GS2 whilst tumours with few-to-zero CNAs clustered into the GS1 subgroup. 
In the study by Hurst et al. more tumours clustered into the GS1 subgroup than the 
GS2 subgroup. They included only primary stage Ta tumours, the majority of which 
were of grade 1 or 2. Our cohort of 67 tumours contained some tumours of a higher 
stage and grade; 7 TaG3, 4 T1G2, 2 T1G3, 1 Ta(x)G3 and 2 stage T1(x)G3. This could 
explain why these tumours clustered into GS2 as tumours of a higher stage and grade 
often contain more CNAs125,135. Only 11 TaG2 tumours (from 6 patients; P0536, P0933, 
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P0990, P2065, P2161 and P2291) clustered into GS1 whilst 31 TaG2 and 8 TaG1 
tumours clustered into GS2. The high number of tumours clustered into GS2 could 
suggest that recurrent tumours are more genomically unstable or contain a high 
frequency of chromosome 9 or 9q loss. Interestingly, Hurst et al.82 identified a trend 
towards decreased recurrence free survival for patients in GS2, but this was not 
formally significant (p = 0.25). It would be interesting to profile more recurrent tumours 
to see how they cluster. 
Sample selection for CNA may have introduced some biases into the data. Patients 
were initially selected as they had multiple recurrences but obtaining sufficient DNA 
from many of the recurrent tumours proved challenging due to the small size of the 
tumours. Additionally, tumours that were heavily infiltrated or were difficult to 
microdissect were excluded from the analysis as their CN profiles would have been 
heavily influenced by the contaminating normal cells. This means that the tumours in 
the CN cohort were biased towards larger tumours that contained few contaminating 
normal cells. It is possible that smaller tumours may have displayed different 
characteristics; it would be interesting to compare larger and smaller tumours to see if 
there are any alterations associated with tumour size.  
Infiltration of bladder tumours by lymphocytes has been identified as prognostic in 
muscle-invasive and metastatic bladder cancer, with heavy infiltration being associated 
with a longer overall survival295-297. However, in non-muscle-invasive tumours the 
relationship is less clear with dense tumour infiltrating lymphocytes having been shown 
to predict progression in an early study295 but in other studies, a lack of correlation with 
clinical outcomes has been observed296,298. These differences may have been 
influenced by the scoring methods used in each study. It would be interesting to look at 
the mutation load in the heavily infiltrated tumours to see if it is different to the tumours 
included in our cohort. However the presence of the infiltrating lymphocytes means that 
the sequencing depth would need to be much higher to be able to identify variants with 
a low VAF. 
In the subset of patients that underwent a course of MMC treatment, all 10 patients that 
had a tumour available both pre- and post-MMC treatment underwent CN analysis. 
Patients for whom a tumour was not available post-MMC treatment were not included 
and this subset included those patients whose disease did not recur after treatment. 
This patient subgroup would be interesting to investigate as it may be possible to 
identify features associated with a full response to a course of MMC chemotherapy. 
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CNAs were detected using shallow-pass WGS and a read depth approach. A pseudo-
CGH algorithm, ngCGH (https://github.com/seandavi/ngCGH), was used. This 
algorithim uses a window size of 1000 reads to compare read depth between the 
tumour and normal, from which the log2 ratio is calculated. Each window can therefore 
be thought of as similar to a probe used in array CGH (aCGH) and the method 
produces a data set similar to that produced using aCGH methodologies. Previous 
work performed by the lab has demonstrated that the profiles generated by aCGH and 
the NGS pipeline display the same major features, however the NGS method has an 
improved resolution compared to aCGH due to the increased probe number and a lack 
of space between probes (see Appendix E).  
A benefit of using shallow-pass WGS is that it can provide a higher resolution than 
aCGH: in aCGH the resolution is limited to the distance between probes and probe 
size (arrays used in our lab had a 1-Mb resolution and contained ~4000 probes125) 
whilst in WGS the resolution correlates with the depth of coverage. For the shallow-
pass WGS, the raw depth of coverage was ~0.7x, and this equated to an average of 
~12700 probes per patient. As coverage is not uniform in NGS data the algorithm uses 
a set number of reads for windowing rather than a set distance as this produces CN 
estimates that should have similar variance at each location. The limitation of this 
method is that window sizes can vary meaning that the resolution is not set and this 
makes it difficult to assign a value to the resolution granted. This makes it difficult to 
predict the size of CNAs that may be missed by the method, as these will be bigger in 
regions of low coverage. An alternative method would be to use a set window size (e.g 
10 kb) but this would have its own challenges in low coverage regions. 
Comparisons of profiles for the same tumour generated by shallow-pass WGS or 
aCGH suggests that shallow-pass WGS may be more sensitive than aCGH in 
detecting shallow CNAs (see Appendix E). However, it is also possible that intratumor 
heterogeneity and a lack of a matched normal may have affected analysis in the aCGH 
data set. As the shallow gain detected by WGS was detected in an additional tumour 
from the patient it would suggest that this event is likely to be real. A limitation of both 
aCGH and shallow-pass WGS is that they provide estimates of the relative CN, not 
absolute CN. Additional information from B-allele frequencies is required to estimate 
absolute CN. This could be improved with increased depth of sequencing for the WGS 
method or could be provided by using SNP arrays. 
Another limitation of both methods is that other structural rearrangements, such as 
inversions or chromosome fusions, cannot be identified. Alternative methods such as 
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multicoloured Fluorescence In Situ Hybridization (FISH) could be used to identify 
rearrangements, but this would not be able to detect inversions. These could be 
detected by an alternative method such as directional genomic hybridization299. 
Information on structural rearrangements could also be generated by using deeper 
WGS and using information provided by mate-pairs257. However, this increased level of 
coverage would significantly increase the cost of the sequencing meaning that fewer 
samples could be assessed. 
Overall, the shallow-pass WGS method employed for the detection of CNAs is an 
improvement on previous methods such as aCGH but it still has some limitations. If the 
price of WGS continues to fall, these could be countered by an increase in sequencing 
depth.  
3.4 Summary 
Overall, tumours from the same patient tend to share most CNAs and cluster together 
suggesting that the generation of CNAs is an early event in bladder cancer 
tumorigenesis. Some tumours will then go on to develop private CNAs. No difference in 
the frequency of CNAs or the fraction of genome altered was identified between 
tumours resected before and after MMC treatment. The majority of tumours from the 
same patient were predicted to be clonally related as they share many CNAs despite 
being separated by time and space. This supports the idea of the field change in 
bladder cancer where much of the urothelium contains aberrations4. The presence of 
the tumours that are potentially oligoclonal also suggests that the urothelium can have 
different genetic damage in spatially separated regions.  
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Chapter 4  
Analysis of matched pre-MMC and post-MMC treatment 
tumours by whole exome sequencing 
4.1 Introduction 
The primary focus of this project was to investigate genomic alterations in bladder 
tumours associated with a course of mitomycin C (MMC) treatment. MMC is a potent 
DNA alkylator with the potential to form DNA-MMC monoadducts as well as intra- or 
inter-strand crosslinks. Next-generation sequencing studies investigating other DNA-
alkylating chemotherapies have shown that these therapies generate mutations that 
can be identified in post-treatment tumours176,300. In glioma, treatment with the 
alkylating agent temozolomide has been shown to induce C:G > T:A transitions 
predominantly at CpC and CpT dinucleotides70 whilst in MIBC, treatment with cisplatin-
based chemotherapy was associated with an increase in C > T and C > A mutations176. 
Early in vitro molecular studies identified MMC-induced mutations, predominantly in 
GC rich regions, with C > A transversion substitutions occurring most 
frequently201,202,204. Additionally, an in vivo study identified an increased number of 
tandem substitutions in MMC treated mice203, and this has also been identified in 
vitro201,203. To investigate the possible mutagenetic effect of MMC treatment, paired 
pre- and post-MMC treatment tumours from 8 patients were subjected to whole-exome 
sequencing to identify somatic variants. 
Accurately calling somatic variants is inherently difficult301. Cancers are often impure 
and can contain rare subclones resulting in low frequency variants. These are therefore 
challenging to disambiguate from sequencing artifacts that are often present in low 
frequencies. There are now numerous variant callers available with a recent review 
identifying 46 publicly available callers302. Choosing the correct variant caller(s) 
depends on the type of variant that is of interest (SNV, indel) and expected allele 
frequency range. 
Outputs of different variant calling pipelines can be highly divergent. This divergence is 
reflected by the results of a study that compared 4 major variant-calling methods. They 
identified that only 31% of the SNVs were identified by all 4 methods and there were 
numerous SNVs that were either unique to one caller, or missed by only one caller303. 
  
120 
To attempt to identify the most accurate variant-calling methodologies the International 
Cancer Genome Consortium (ICGC)-TCGA Dialogue for Reverse Engineering 
Assessments and Methods (DREAM) Somatic Mutation Calling Challenge was 
launched (https://www.synapse.org/#!Synapse:syn312572/wiki/ ). This effectively 
crowdsourced the running and fine-tuning of algorithms. Overall, a clear trade-off was 
seen between precision (fraction of predicted SNV’s that are true) and recall (number 
of SNVs detected)304. Using an ensemble of the variant-calling methodologies to create 
a consensus outperformed any individual method, especially when assessing more 
complex genomes304. As this data suggests that variant calling should perhaps be 
made using multiple variant callers, we decided to use an ensemble of three variant 
callers to identify variants. In this chapter we tested five different variant callers, in 
every possible combination of three callers, to identify the best combination.  
The best practices in variant calling have so far focused on reducing the number of 
false positives. Analysing multiple tumours from the same patient has additional 
challenges as it is important to be able to identify mutations shared between tumours. 
Mutations that are present at a low level in one tumour yet are expanded in a second 
can give insight into genetic events contributing to progression, recurrence and 
resistance. Misidentifying a variant as unique to one tumour when it was actually 
present in both would alter the perceived evolution of those tumours allowing incorrect 
conclusions. It is therefore important in these samples to ensure that these shared 
variants are not filtered out. Droop et al.242 describe a method to improve variant calling 
across multiple samples from the same patient. They reason that having multiple 
tumours from the same patient creates a type of internal validation for shared 
mutations: if a variant is seen as shared between samples then these are likely to be 
true variants regardless of the strength of evidence of any one call. The identification of 
shared mutations can therefore be completed at a lower stringency to ensure that all 
shared mutations can be identified. A second round of more stringent variant calling 
follows to identify variants found in only one sample. Using this method they were able 
to identify many more biologically relevant shared mutations. As our tumour samples 
are paired we investigated using this methodology in our variant identification pipeline. 
By combining both shared mutation identification and ensemble calling, a two-stage 
variant calling pipeline was devised. This aimed to improve identification of shared 
variants whilst maintaining high specificity for unique variants. This pipeline was used 
to call somatic variants from whole-exome sequencing of paired tumours resected 
before and after a six week course of intravesical MMC treatment from 8 patients with 
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matched peripheral blood serving as a germline control. Individual tumours were 
assessed for mutation burden, base substitutions and mutational signatures and 
comparisons were made between pre-MMC and post-MMC treated tumours. 
In this Chapter, tumour nomenclature follows that of Chapter 3. However, each tumour 
also has an additional identifier after the tumour number: BX - before MMC, PX – post-
MMC, UX – unique variants post-MMC.  
Two patients had more than one tumour at a timepoint: P2218 had two tumours pre-
MMC and P0960 had two post-MMC. To avoid skewing the data through the inclusion 
of multiple tumours with similar genomes, only one tumour from each patient was 
included at a timepoint for comparisons. Tumour P0960-S03-PX was used as the post-
MMC tumour for patient P0960  and tumour P2218-S1A-BX was used as the pre-MMC 
tumour for patient P2218 for Figure 4.6 A-E, Figure 4.7, Figure 4.8, Figure 4.9D and 
Table 4.3 
Throughout this thesis, the terms ancestral/founding clone, subclone, subclonal and 
clonal are used. The ancestral/founding clone refers to the cluster of mutations that are 
present in every cancer cell of every tumour from a patient. They are found on the 
trunk of the cancer evolutionary tree. Subclone refers to a cluster of mutations that 
have branched off the ancestral clone whilst subclonal refers to mutations that are only 
present in some, not all, of the cancer cells of a tumour. Subclone and cluster therefore 
mean the same thing and are used interchangeably. Clonal means that the mutation is 
found in all the cancer cells of a particular tumour. A subclone can therefore be clonal, 
present in all cells of a tumour after making a clonal sweep, or subclonal with only 
some cancer cells containing the mutation(s). 
 
4.2 Results 
4.2.1 Variant calling pipeline 
As discussed above, there are many caveats to variant calling. To create a variant 
calling pipeline, pre-MMC and post-MMC treated tumours from two patients were 
analysed initially; P0418 and P2161. Whole exome sequencing (WES) data for these 
two patients was initially used to determine the best way to identify the shared variants 
and determine which variant callers performed best for consensus calling. 
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4.2.1.1 Identification of shared variants 
One of the most important processes in analysing paired tumours is the identification of 
shared variants. MuTect2 was selected to initially investigate the identification of 
shared variants due to its popularity within the literature and its ability to call low 
variant-allele frequency (VAF) variants. The raw data (i.e. all variants identified prior to 
filtration) can also be extracted from MuTect2 and this data can aid the identification of 
shared variants.  
Shared and unique variants from the VCF files created by MuTect2 were identified 
using the “dplyr” package within the R software environment (Figure 4.1A). To ensure 
that unique variants were correctly annotated as such, the raw MuTect2 data was 
interrogated. This identified 6 variants in patient P2161 and 14 variants in patient 
P0418 that were actually shared between tumours but had been filtered out for one of 
the tumours. As these variants are present in both tumours these are likely to be real 
despite not being called in one of the tumours. The most common causes for filtering 
out of variants were “t_lod_fstar”, which is where the tumour event does not meet the 
likelihood threshold for a variant to be called usually due to an insufficient number of 
reads, or “clustered_events”. Visual inspection using the Interactive Genome Viewer 
(IGV) showed that these “clustered_events” were due to artefacts in the sequencing 
data around the variant site but the variants themselves were clearly real. 
Droop et al.242 used VarScan2 to identify their variants. The default parameters on 
VarScan2 are quite stringent and it requires a minimum allele frequency of 20% when 
run in somatic mode. This means that low allele frequency variants are missed. To 
combat this, Droop et al. used modified parameters changing the minimum coverage to 
10 and setting the minimum VAF to 3.5%. To see if using VarScan2 with the adjusted 
parameters improved the identification of shared mutations, variants were called using 
both the default parameters and the adjusted parameters (Figure 4.1B). Adjusting the 
parameters led to an increase in the total number of variants identified for each tumour 
as expected. Counterintuitively, the number of variants identified as shared between 
tumours from patient P2161 was actually less than the number identified using the 
default parameters although a small increase in the number of shared variants was 
observed for tumours from patient P0418.  
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Figure 4.1:Variant calling optimisation. 
A) Variants were called using MuTect2. Venn-diagrams show the shared and unique variants for 
pre-MMC and post-MMC tumours from patients P0418 and P2161. The unique variants for each 
tumour were checked against the raw MuTect2 data to identify any shared variants that may have 
been filtered out. These were included in the Venn diagrams. B) Variants were called using 
VarScan2 with either the default or less stringent parameters as described in Droop et al.242 and 
compared to variants called by MuTect2. Bars show the number of variants identified by each 
method.  
A 
B 
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Overall MuTect2 outperformed VarScan2 with more variants identified for each tumour 
(compared to default) and more shared variants identified than either VarScan2 
approach. Using the shared variant method, a further 20 variants were identified that 
may be important in the predicting the inferred evolution of the cancer. This method of 
identifying shared variants was therefore included in the pipeline.  
4.2.1.2 Multiple variant callers 
It has been shown in many studies that different variant callers will generate different 
outputs from the same sequencing data. This means that relying on just one variant 
caller may lead to variants being missed and false positives being called. Using the 
consensus from multiple callers is a way to improve specificity and recall. For this study 
it was decided that variants should be taken forward when reported by at least two out 
of three variant callers. Five variant callers were tested and the best combination of 
three of these was selected. 
Variants were called using five variant calling algorithms; MuTect2301, VarScan2240, 
Strelka2238, EBCall239 and MuSe241. Strelka2 called the most variants whilst VarScan2 
and MuSe called the least (Figure 4.2A). Of the five variant callers only MuSe does not 
call indels. It was noticed that indel calling appeared to be skewed for two of the variant 
callers; Strelka2 appears to call more deletions and MuTect2 more insertions. 
VarScan2 and EBCall appear to call both insertions and deletions fairly evenly (Figure 
4.2B). 
Shared mutations are internally validated so they do not need to be called by more 
than one caller. Shared mutations were therefore used to evaluate the 5 callers. As 
with MuTect2, VarScan2 and MuSe both generate pre-filtering variant data, facilitating 
the checking of unique variants against the raw data as described above. This 
identified a total of 4 extra shared variants for VarScan2 (2 per patient) and 3 extra 
shared variants for MuSe all in patient P2161.  
We were interested to see if any of the “unique” calls made by a variant caller were 
called as a “shared variant” by an alternative variant caller (Table 4.1). Over 50% of the 
unique variants identified by VarScan2 were seen as shared by an alternative caller 
making it the lowest performer of the 5 callers. Strelka2 and MuTect2 performed best 
with fewer than 1% of calls being incorrect.  
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Figure 4.2: Variant detection by multiple callers. 
Five variant callers (MuTect2, VarScan2, Strelka2, EBCall and MuSe) were used to detect 
variants from pre-MMC and post-MMC treated tumours from patients P0418 and P2161. A) 
Numbers of variants detected by each caller. Bars show both the unique mutations and shared 
mutations for each tumour pair. The x-axis identifies the results for each variant caller used for 
both patients, the y-axis shows the number of variants. B) Types of variants detected by each 
caller. The numbers of SNVs (blue bars), insertions (orange bars) and deletions (grey bars) are 
shown. Pre-MMC and post-MMC tumours are separated for each variant caller. The y-axis 
denotes the number of variants. 
A 
B 
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Table 4.1: Evaluation of unique variants using 5 different variant callers. 
The unique variants identified by each variant caller for each tumour were interrogated to see if 
they had been identified as shared by a different caller. aTotal number of variants identified as 
unique for both tumours from both patients P0418 and P2161. bDenotes the total number of those 
unique variants that were actually identified as shared variants by an alternative variant caller.  
Variant Caller Total no. of unique variantsa 
No. of variants 
incorrectly 
identified as 
uniqueb 
% of incorrect 
variant calls 
MuTect2 307 3 0.98 
VarScan2 99 50 50.51 
Strelka 755 7 0.93 
EBCall 311 5 1.61 
MuSe 77 4 5.19 
 
 
Next, we wanted to identify the best three variant callers to be used in the pipeline. All 
10 possible combinations of three variant callers were used to generate consensus 
calls using the vcftools function “vcf-isec” with “-n +2” specified so that only variants 
present in two or more input VCFs were kept. The combination of MuTect2, Strelka2 
and EBCall identified the most variants and combinations involving VarScan2 and 
MuSe identified the least (Figure 4.3). 
As the shared variants are internally validated it would be expected that these are all 
non-artefactual regardless of which variant caller identified them. Therefore, all the 
shared variants identified by each caller were added together to get the total possible 
number of shared variants for each patient. For patient P2161, a total of 161 variants 
were identified as shared and 560 were identified for patient P0418. Each combination 
of variant callers was then assessed for the number of shared mutations they each 
identified. The combination of MuTect2, Strelka2 and EBCall gave the most shared 
variants with 160/161 for patient P2161 and 557/560 for patient P0418. Further 
investigation into the variants not shared by this group of callers revealed that none of 
these were exonic. 
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Figure 4.3: Consensus calling. 
Variants were called with five variant callers. Each possible combination of 3 variant callers was 
used to generate a consensus with variants required to have been called by at least 2 of the three 
callers. Shared variants were included even if they were only called by one variant caller as these 
have internal validation. The use of a caller within a combination is denoted by a “+” in the table. 
All 10 possible combinations were tested for each patient. 
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Overall the best combination of callers was considered to be MuTect2, Strelka2 and 
EBCall. Each of these performed well individually with low false-unique call rates and 
when combined they gave the best identification of variants. The variant calling pipeline 
described here therefore consists of consensus calling using these three variant callers 
followed by the addition of any variants that were identified as shared by any one 
variant caller. Unique variants were checked against the raw MuTect2 data and any 
shared variants that may have been filtered out in one tumour were added back into 
the dataset. 
4.2.2 Exome sequencing analysis 
Whole exome sequencing was performed on a total of 18 tumours from 8 patients who 
underwent a course of MMC treatment. Matched pre- and post-chemotherapy biopsy 
tissue was sequenced for each patient with peripheral blood used as a germline 
control. Tumour DNA was sequenced to an average depth of 80x (range 70-90x) and 
matched germline DNA was sequenced to an average depth of 69X (range 48-88x). 
Variant calling was performed as described above. An average of 348 SNVs (99-636) 
were identified per sample within the covered regions as well as an average of 19 (10-
24) indels per sample, corresponding to mean and median total somatic mutation rates 
of 5.90 and 5.75 mutations per Mb respectively. Of these, an average of 140 (64-241) 
SNVs and 6 (2-10) indels per tumour were non-synonymous (missense, nonsense, 
frameshift or mutations of the invariant dinucleotide at splice junctions) (Figure 4.4A). 
The number of variants did not correlate with sequencing depth (data not shown). A 
breakdown of this information per tumour can be seen in Table 4.2.  
4.2.2.1 Changes in mutational load after chemotherapy 
As MMC is a DNA damaging chemotherapy, it was hypothesized that treatment with 
this agent might lead to an increased number of mutations. Indeed 5 out of 8 patients 
showed an increase in the number of mutations after MMC treatment (Figure 4.4B) 
with a mean change of +74 mutations post-MMC. However this was not statistically 
significant (paired two tailed t-test, p=0.1086) (Figure 4.4C). A high proportion of 
mutations were shared between the two tumours of most patients (Figure 4.4D). When 
restricting analysis to non-synonymous mutations, a significant increase in the number 
of mutations post chemotherapy was observed (two-tailed paired t-test, p=0.0333) 
(Figure 4.4E). 
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Figure 4.4: Overview of the number of mutations and mutational load. 
A) Total number of mutations per tumour; dark blue indicates the number of potentially functional 
protein coding variants and light blue indicates the number of non-coding and synonymous 
variants. B&C) Changes in total mutational load per patient from pre-MMC to post-MMC 
treatment. There is no statistically significant change in mutation load after treatment (mean 
change = +74, paired t-test p = 0.109). D) Breakdown of mutations per patient. Private mutations 
for both pre-MMC and post-MMC tumours and mutations common to both tumours are shown. E) 
Boxplot showing the median and range of potentially functional mutations in pre-MMC and post-
MMC tumours. There is a statistically significant increase seen post-MMC (paired t-test *p =  
0.0333).  
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Table 4.2: Details of tumours and information regarding variants identified by 
whole-exome sequencing. 
Grading is according to the 1973 World Health Organisation (WHO) guidelines. Variants were 
included if they were identified by at least two of the three variant callers. Additional variants that 
were seen in both tumours but were only called by one variant caller, or only passed the filtering 
for one tumour were also included. aPotentially functional variants include missense, nonsense, 
frameshift or mutations of the invariant dinucleotides at splice junctions. 
Tumour ID Stage Grade 
Total variants 
Potentially 
functional 
variantsa 
SNVs Indels SNVs Indels 
P0418-S02-BX Tx(a at least) G3 556 15 190 2 
P0418-S03-PX Tx(1 at least) G3 654 16 234 2 
P0533-S3B-BX Ta G2 210 17 96 3 
P0533-S04-PX Ta G3 491 24 192 3 
P0960-S01-BX Ta G2 305 24 128 7 
P0960-S03-PX Ta G1 379 26 166 8 
P0960-S04-PX Ta G2 377 27 166 9 
P1175-S01-BX Ta G2 423 23 140 4 
P1175-S02-PX Tx G2 360 23 126 3 
P1870-S2A-BX Ta G2 340 21 127 3 
P1870-S03-PX Ta G2 394 24 148 4 
P2161-S01-BX Ta G2 174 21 65 5 
P2161-S02-PX Ta G2 175 12 63 5 
P2218-S1A-BX Ta G2 114 23 55 9 
P2218-S1B-BX Ta G2 136 25 58 10 
P2218-S02-PX Ta G3 166 23 74 9 
P2329-S02-BX Ta G2 441 21 160 9 
P2329-S03-PX Ta G1 606 24 231 10 
 
 
All patients had some private mutations in both pre-MMC and post-MMC tumours 
alongside mutations that were shared (Figure 4.4D). To account for differences in 
mutation number between patients, the number of mutations in each group (pre-MMC 
unique, post-MMC unique and shared) were presented as a percentage. The average 
percentage of mutations that were shared was 54% (24-81%). Overall, the average 
percentage of mutations seen as unique pre-chemotherapy was 17% (range 2.2-42%), 
whilst for post-chemotherapy unique mutations this was 29% (range 13.7-60.1%).  
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4.2.2.2 Mutational Profile 
To gain an insight into the mutational landscape of these tumours the top 50 mutated 
genes were identified (Appendix H). The most frequently mutated genes were FGFR3 
(75%), PIK3CA (56%), TTN (56%), DNAH2 (38%), KDM6A (38%) and TSC1 (31%). A 
subset of genes with potentially functional (frameshift, nonsense or mutations of the 
invariant dinucleotides at splice junctions) or missense mutations predicted as 
potentially deleterious by SIFT and PolyPhen-2 is presented in Figure 4.5. 
Interestingly, divergent mutations in TSC1 and KMT2C were identified for patients 
P2218 and P2161 respectively. This could represent possible convergent evolution 
within paired tumour samples.  
Mutations in several chromatin modifier genes were identified including KDM6A, 
KMT2C, KMT2D, CREBBP, EP300, ARID1A, and STAG2 (Figure 4.5, B-C). These 
mutations tended to be inactivating, as has been seen in previous studies82,157,164. 
KDM6A has previously been shown to have a female gender bias82, but in this limited 
cohort KDM6A mutations were only seen in the males. 
Overall, C:G > T:A transitions were the most common substitution, accounting for 
48.8% of substitutions in pre-MMC tumours and 44.6% of substitutions in post-MMC 
tumours. Histograms showing the full mutation spectrum of substitutions were created 
to enable visualisation of the overall substitution patterns and look for asymmetry in the 
substitution spectrums of pre-MMC and post-MMC samples (Figure 4.6, A-B). Pre-
MMC and post-MMC histograms showed very similar distributions with no signs of 
asymmetry.  However there was a suggestion of an increase in C:G > A:T 
transversions in the post-MMC tumours. In order to focus on possible MMC related 
events, the post-MMC unique variants were extracted. These show a divergent 
mutation spectrum compared to the pre-MMC variants (Figure 4.6C) with a reduction in 
the number of C:G > T:A transitions from 48.8% to 36.7%, alongside an increase in the 
number of C:G > A:T transversions from 12.3% in pre-MMC variants to 32.4% in post-
MMC unique variants.  
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Figure 4.5: Oncoplot showing the distribution of potentially functional mutations 
identified in selected genes by whole exome sequencing. 
A subset of the top 15 frequently mutated genes with loss-of-function mutations (frameshift, 
nonsense or mutations of the invariant dinucleotide at splice junctions) or missense mutations 
predicted as potentially deleterious by SIFT and PolyPhen-2 are shown. A) Clinical details for 
each sample. B) The top 15 mutated genes with potentially functional mutations from pre-MMC 
and post-MMC tumours. C) Potentially functional mutations in chromatin modifier genes not 
represented in (B) that are also frequently mutated in NMIBC.  
A 
B
 
C 
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Figure 4.6: Base substitutions in pre-MMC and post-MMC samples. 
Base substitutions were identified using the bcftools package with the “stats” command. A-C) 
Histograms of the substitution spectrum for each variant group (pre-MMC,  post-MMC and post-
MMC unique variants respectively). Substitutions are depicted as a mean proportion ± SEM. D) 
Substitutions categorised by the pyrimidine of the mutated base pair. Lines represent the median 
and range. The y-axis depicts the proportion of mutations with that event. Comparisons between 
the 3 groups of variants show a significant difference in the number of C > A, C > G and C > T 
substitutions in the post-MMC unique variants compared to the pre-MMC variants (two-way 
ANOVA with Tukey’s correction for multiple comparisons: **** p = <0.0001, *** p = 0.006,  * p = 
0.0354). E) Boxplot showing the number of transitions and transversions identified in each variant 
group. Boxes show the median and interquartile range (IQR) with the lines showing the absolute 
range. There is a significant difference in both transitions and transversions between pre-MMC 
variants and post-MMC unique variants (two-way ANOVA with Tukey’s correction for multiple 
comparisons, ***p =0.0010 for both). F) Sample specific mutation spectrum. The relative 
frequency of each substitution type (designated by the pyrimidine base) is shown for each sample. 
A B
F 
C
D E
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To assess the extent of these changes, substitutions were categorised by the 
pyrimidine base and comparisons were made between the three groups using a two-
way ANOVA with multiple comparisons. A significant decrease in the number of C > T 
transitions was observed between pre-MMC and post-MMC unique variants. Post-
MMC unique variants showed a significant increase in the number of C > A 
transversions compared to both pre-MMC and post-MMC variants. A slight reduction in 
the number of C > G transversions was also seen in the post-MMC unique variants and 
this was significant compared to the post-MMC group (Figure 4.6D, two-way ANOVA 
with Tukey’s correction for multiple comparisons: **** p = <0.0001, *** p = 0.006,  * p = 
0.0354). Despite the decrease in C > G transversions in the post-MMC unique variants, 
a significant difference was observed in the overall proportion of transitions and 
transversions between pre-MMC and post-MMC unique variants (Figure 4.6E, two-way 
ANOVA with Tukey’s correction for multiple comparisons, p =0.0010 for both).  
To ensure that the changes seen in the bulk analysis were representative of all the 
patients, the sample specific mutation spectrum was plotted (Figure 4.6F). For all 
patients except patient P2218 an increase in the number of C > A transversions and 
decrease in the number of C > T transitions can be seen in the post-MMC samples, 
and this change is exaggerated when looking at the post-MMC unique variants. Patient 
P2218 is the only exception to this rule.  
Tandem substitutions, specifically at GpG bases, have been linked to MMC intrastrand 
crosslinks. Quantification of the number of tandem substitutions showed that post-
MMC tumours had significantly more tandem substitutions than pre-MMC tumours 
(paired t-test,  p = 0.0158). Overall, pre-MMC tumours exhibited a total of 8 tandem 
substitutions (per-sample median = 1, range = 0-2), whilst post-MMC tumours exhibited 
a total of 70 tandem substitutions (per-sample median = 7 range =2-19). Sixty-two of 
the post-MMC tandem substitutions were unique post-MMC events. To ensure an 
accurate representation, the numbers of mutations involved in tandem substitutions 
were converted to proportions (Figure 4.7). This confirmed that the proportion of 
tandem substitutions was significantly higher in the post-MMC group (p = 0.0441) and 
post-MMC unique group (p =  0.0224) compared to the pre-MMC group (repeated 
measures one-way ANOVA). Tandem substitutions predominantly occurred at GpG or 
CpC dinucleotides in the post-MMC unique variants (97%), whilst pre-MMC tandem 
substitutions occurred at these bases in only 63% of cases (Table 4.3). The increased 
proportion of tandem substitutions seen in the post-MMC unique events (mean = 
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10.78%, range: 1.10-26.95%) along with the specificity of GpG or CpC dinucleotides 
suggests that these are a MMC-related occurrence. 
 
 
Figure 4.7: Tandem substitutions. 
The number of tandem substitutions was identified within each variant group. The boxplot shows 
the median proportion of tandem substitutions for each group with the IQR and absolute range.*p 
< 0.05. There is a significant increase in the number of tandem substitutions in the post-MMC 
variants (p = 0.0441) and post-MMC unique variants (p = 0.0224) compared to pre-MMC variants 
(repeated measures one-way ANOVA with Dunnett’s multiple comparisons test).  
 
Table 4.3: Tandem substitutions. 
Variants were combined into pre-MMC, post-MMC or post-MMC unique variant groups. The 
number of tandem substitutions in each group was identified. This was multiplied by 2 to give the 
total number of variants involved in tandem substitutions, and from this a percentage of variants 
involved in tandem substitutions was calculated. 
  
Mutation 
group 
No of 
tandem 
substitutions 
Total 
variants 
Variants 
involved in 
tandem 
substitutions 
(%) 
Tandem 
substitutions at 
GpG or CpC 
dinucleotides (%) 
Pre-MMC 8 2535 0.63 62.5 
Post-MMC 70 3139 4.38 92.9 
Post-MMC 
unique 62 1165 10.64 96.8 
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4.2.2.3 Mutational Signatures 
To further characterise the mutational processes and evaluate mutational signatures 
within the tumour samples the 5’ and 3’ nucleotides surrounding each SNV were 
extracted (Figure 4.8). All 3 variant groups show a similar context distribution of C > G 
and C > T mutations with a high proportion of these mutations occurring at TpCpA and 
TpCpT sequences, consistent with APOBEC mutagenesis. In the post-MMC unique 
variants an increase in C > A substitutions is observed with peaks at ApCpG, CpCpA, 
GpCpG and TpCpC sequences whilst in the pre-MMC group, the few C > A mutations 
are primarily at TpCpA, TpCpC and TpCpT sequences. The mutational context per 
patient for pre-MMC, post-MMC and post-MMC unique variants can be seen in 
Appendix I.  
The mutational context was used to create mutation signatures that were decomposed 
into the 30 signatures described by COSMIC using the mutation-signatures package 
from MSKCC (https://github.com/mskcc/mutation-signatures). In both pre- and post-
MMC tumours, the most common signatures were signatures 2 and 13, both of which 
are APOBEC-related signatures (Figure 4.9A). Overall 49% of all variants had an 
APOBEC signature. Signature 1 was the next most common signature. This 
corresponds to spontaneous deamination of 5-methylcytosine and correlates with age 
at cancer diagnosis. The percentage contribution of the age signature did not correlate 
with age (data not shown), but the age range at diagnosis differed by only 9 years 
(range 67-76). Interestingly signature 7, which is associated with ultraviolet (UV) light 
exposure, was amongst the top signatures in both pre- and post-MMC tumours but this 
was not observed within the top signatures in the post-MMC unique variants (Figure 
4.9A). An overview of all the mutation signatures identified in each sample can be seen 
in Figure 4.9B. 
Using the results from the signature analysis, tumours were classified by the 
contribution of APOBEC signatures, where “high APOBEC” denotes tumours for which 
the combined contribution of APOBEC signatures 2 and 13 was greater than 30%, as 
reported in Lamy et al61 (Figure 4.9C). Interestingly only one patient, P2218, had a “low 
APOBEC” score and this was for both pre- and post-MMC tumours. All other tumours 
had a “high APOBEC” score. When focusing on post-MMC unique variants, only 50% 
of tumours had a “high APOBEC” score. For patients P0418, P0960, P1175 and P2161 
a “low APOBEC” score was seen in the post-MMC unique variants despite these 
tumours having an overall “high APOBEC” when looking at all variants. A reduction in 
APOBEC score was also seen in patients P1870 and P2329. However these patients 
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still had a high level of APOBEC contribution to post-MMC unique variants. This 
suggests that APOBEC mutagenesis was less prevalent for these tumours post-MMC 
compare to pre-MMC. 
For two patients the APOBEC score increased post-MMC. For patient P0533 an 
increase in APOBEC contribution from 35% pre-MMC to 56% post-MMC was seen. 
Indeed 65% of post-MMC unique variants likely came from APOBEC derived 
mutagenesis for this patient. Most interestingly, for patient P2218 a “high APOBEC” 
score was seen in the post-MMC unique variants despite this patient having a “low 
APOBEC” score overall. This suggests that for these two patients APOBEC activity 
increased over time. 
Signatures that contributed to more than 4% of the mutational spectrum for each group 
were compared using a two-way repeated measures ANOVA with multiple 
comparisons (Figure 4.9D). A significant reduction in the contribution of signatures 1 
and 13 was seen in the post-MMC unique variants. Most interestingly, a very significant 
increase in the contribution of signature 24 to the mutational signature was seen in the 
post-MMC unique variants (p = <0.0001). Overall for pre-MMC variants, signature 24 
contributed to only 4.5% of variants and this increased to 31% for post-MMC unique 
variants. Analysis of the contribution of each signature per patient shows an increase in 
the contribution of signature 24 in post-MMC unique variants for every patient except 
patient P2218. This large increase seen in post-MMC unique variants suggests that 
this could reflect the MMC mutagenic process. Signature 24 has been seen in a subset 
of liver cancers and has been linked to exposure to aflatoxin and is characterised by C 
> A mutations. Signature 4 also increased in contribution when analysing the post-
MMC unique variants. Signature 4 is present at a low level in pre-MMC tumours, 
contributing an average of 4.1 % of mutations in this group and in post-MMC unique 
variants this contribution increased to 12%, but this increase is not statistically 
significant.  
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Figure 4.8: Mutational context in pre-MMC, post-MMC and post-MMC unique 
variants and COSMIC signatures. 
A) Variants were grouped into pre-MMC variants, post-MMC variants and post-MMC unique 
variants. The 5’ and 3’ nucleotides surrounding each SNV were extracted and the sequence 
context plotted. B) COSMIC signatures identified within the samples (taken from 
https://cancer.sanger.ac.uk/cosmic/signatures).  
  
A 
B 
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Figure 4.9: Mutational signature analysis. 
Mutational signatures identified in the patient cohort. A) Signatures contributing to more than 4% 
of variants were assessed in the different variant groups. B) The contribution of each signature is 
shown per sample as well as for the post-MMC unique variants. Samples are grouped by patient. 
C) The contributions of the two APOBEC signatures were combined to create an APOBEC score. 
A score greater than 30% was designated “high APOBEC”. High and low scores have been 
differentiated further for greater clarity. D) Changes in contribution of the signatures were 
assessed using a two-way ANOVA with repeated measures by both factors. Post-MMC and post-
MMC unique contributions were compared to pre-MMC contributions and Dunnett’s test was used 
to correct for multiple comparisons (* p = 0.0106, ** p = 0.0047, **** p < 0.001). 
A 
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4.3 Discussion 
This chapter investigated the mutational changes seen in paired tumours after a 
treatment course of mitomycin C (MMC) with the aim of identifying MMC 
chemotherapy-associated genomic changes. A variant calling pipeline was developed 
and used to identify somatic variants from 18 matched pre-MMC and post-MMC 
treatment tumours. These have been assessed for changes in mutational load after 
therapy, the types of base substitutions seen and mutational signatures, and frequently 
mutated genes have been identified. 
4.3.1 Variant calling pipeline 
The aim of best-practice bioinformatic pipelines is to decrease the number of false-
positive and false negative variants detected in order to increase precision242. 
However, for the analysis of paired tumour data these practices can be too stringent 
and cause the filtering out of important low-frequency variants, often from only one 
tumour. To circumvent this problem an adapted variant calling methodology was 
adopted for the identification of shared variants. This methodology was an adaption of 
that described by Droop et al.242 who suggest a two-stage approach with a round of 
reduced stringency calling for the identification of shared variants followed by a round 
of high stringency calling to identify unique mutations. To ensure adequate detection of 
shared variants, all variants that were identified as shared by a single caller were 
included and unique variants were checked against raw variants (variants detected 
prior to filtering) identified by the MuTect2 algorithm. Initial studies with the output from 
MuTect2 identified an additional 20 mutations for the two patients assessed. 
Five variant callers were investigated to identify the best combination of three callers 
for consensus calling. Overall, VarScan2 was the least suited for this type of data 
analysis. VarScan2 is a high-stringency variant caller which uses a heuristic threshold 
methodology. It will identify potential variants that pass the thresholds (at least 4 
supporting reads and 20% VAF) and employs a Fisher’s exact test on the read counts 
between tumour and normal in a 2 x 2 contingency table to filter out any germline 
variants302. These settings are designed to filter out artifacts present at low levels but 
this will also filter out any variants with a low VAF that arise from subclones or as a 
result of impure input material. In our hands, relaxing the thresholds did not increase 
shared variant discovery so the default settings were used. This inability to identify low-
frequency variants is the probable reason why so many of the unique variants identified 
by VarScan2 were actually called as shared by another caller. With appropriate 
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threshold settings, VarScan2 has been shown to be able to achieve sensitivity as low 
at 5% VAF305, however this was with high coverage and requires optimization. 
Of the remaining four variant callers, MuSe identified the fewest variants and had the 
highest percentage of incorrect calls. MuSe is also the only variant caller that does not 
identify indels. As the literature has suggested that an increase in indels may be 
observed in MMC treated samples, it is important that such variants are identified. A 
combination of MuTect2, Strelka2 and EBCall was therefore selected as this set of 
callers had the lowest incorrect unique call percentage and identified the most variants 
in combination. 
MuTect2, Strelka2 and EBCall all use an allele frequency analysis approach which 
allows the discovery of minor subclones301,302. This makes them particularly useful for 
the investigation of intra-tumour heterogeneity or impure tumours. However, this ability 
to call low variant alleles may increase the number of false-positives due to the miss-
calling of sequencing noise. By using consensus calling the number of false positives 
should be reduced as variants need to be called by at least two of the variant callers 
and are thus more likely to be real. 
It is unlikely that there is a single “best” caller303 and the type of variant caller to use 
largely depends on the question being asked. Benchmarking studies have shown that 
using an ensemble approach gives good results even when poor performing pipelines 
are included304,306,307. For this study it is important to be able to identify the shared 
variants as well as the variants unique to each tumour. The two-pronged method we 
have devised should increase the number of shared variants identified and reduce the 
number of false-negatives, whilst the ensemble calling should reduce the number of 
false positives in the unique data. 
4.3.2 Mutation burden  
In this cohort the total mutation rate (5.90 mutations per Mb) was higher than that 
reported previously for NMIBC by Hurst et al.82. In their study, Hurst et al. reported the 
clustering of low-stage low-grade tumours into two distinct groups using CNAs. These 
clusters were denoted genomic subtypes 1 and 2 (GS1, GS2). GS1 was characterized 
by no or few CNAs whilst GS2 was more genomically unstable with characteristic loss 
of chromosome 9. An overall mean somatic mutation rate of 2.41 mutations per Mb 
was identified. However, when assessing the individual subtypes, a higher mutation 
rate of 3.75 mutations per Mb was noted for GS2 tumours compared to only 1.85 
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mutations per Mb for tumours from GS1. In Chapter 3, tumours from our cohort were 
clustered by their copy number profiles alongside the tumours from Hurst et al.82. 
Tumours from this exome panel mostly clustered with tumours in GS2 . Only 2 tumours 
clustered with tumours from GS1. This higher mutation rate seen in GS2 tumours is still 
not as high as the mutation rate identified in our cohort. This may be partially due to the 
stage and grade of the tumours analysed: Hurst et al. assessed only primary, low-
grade Ta tumours  (though a handful of tumours were re-classified as high-grade when 
assessed by a single pathologist), whilst this cohort contained recurrent tumours of 
mixed stages and grades, including a stage T1 grade 3 tumour as well other grade 3 
tumours. Additionally, Hurst et al. used a more stringent variant calling methodology 
which may have missed some low allele frequency variants leading to an 
underestimate of tumour mutational burden. 
This difference in overall tumour mutation burden between our study and that of Hurst 
et al.82 could be interesting. Few studies have specifically compared the mutation rate 
of high-grade and low-grade tumours. The study by Pietzak et al.157 contained tumours 
with a mix of stages and grades; including stage Ta, stage T1 and muscle-invasive 
tumours. They identified a median mutation rate of 9 mutations per Mb in high-grade 
NMIBC compared to a mutation rate of 7 mutations per Mb in low-grade tumours. 
These values are much higher than previously reported, higher even than those 
reported for MIBC81. This may be due to the use of a targeted gene panel of cancer 
associated genes compared to a whole exome panel. These conflicting results identify 
the need for sequencing larger cohorts of NMIBC to gain insight into the mutational 
landscape of tumours of all stages and grades and exemplify the need for adjusting 
mutation rates identified by targeted gene panels. It would be interesting to see if 
somatic mutation rates follow a similar picture to that of CNAs, where more of the 
genome is altered by CNAs in tumours of a higher stage and grade125. 
All tumours contained a significant proportion of private mutations. However, most 
patients had a higher proportion of shared variants compared to private mutations. The 
average proportion of mutations private to pre-MMC tumours was 17% compared to 
29% in post-MMC tumours. A significant increase in the number of non-synonymous 
mutations was also identified despite no significant increase in the total number of 
mutations. This is in contrast to what has been observed in MIBC treated with cisplatin 
where a reduced number of private variants was seen after treatment. This correlated 
with an overall reduction in variant number seen after treatment but this was not 
significant176. This could suggest that cisplatin is a less mutagenic chemotherapy agent 
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or that it is more toxic, resulting in an increased cell death and thus leaving fewer cells 
in which new mutations can be induced.  
The significant increase in non-synonymous mutations after MMC treatment could be a 
reflection of the CpG specificity of MMC as CpGs are enriched in exons and promoter 
regions relative to the rest of the genome206. It would be interesting to use WGS to see 
if new mutations after MMC treatment cluster in the promoter and coding regions 
compared to the rest of the genome to confirm this pattern suggested by WES. 
4.3.3 Mutational profile 
FGFR3 and PIK3CA were the most frequently mutated genes and these were mutated 
at a level similar to that reported in other sequencing studies82,157. KDM6A mutations 
were seen at a lower level than in previous sequencing studies of stage Ta tumours. In 
those studies, the mutation frequency ranged from 50-65%82,157,164, whilst in this study it 
was 38%. In previous studies, splitting stage Ta tumours into low and high-grade 
identified that whilst 52% of low grade tumours contained a KDM6A mutation82,157, only 
38% of high-grade tumours contained a mutation157. This is the same level as seen in 
our exome cohort. KDM6A mutation has previously been identified as having a female 
gender bias82, but in this cohort mutations were only seen in the males. This could be 
due to the very low patient number in this cohort. 
TSC1 was frequently mutated with 31% of patients carrying a mutation. This is much 
higher than seen previously across all stages and grades81,82,157,164. Hurst et al. saw a 
higher frequency of TSC1 mutations in their GS2 subgroup (19%) compared to their 
GS1 subgroup (4%). As all but two of the tumours in this cohort clustered with the GS2 
tumours this could go some way to explaining the high occurrence of these mutations. 
TTN was also seen to be frequently mutated with all missense mutations identified in 
this gene predicted to be potentially deleterious by SIFT and PolyPhen-2. TTN codes 
for a very large protein, Titin, which contains over 34000 amino acids. Its large size 
combined with its presence in late replicating regions of the genome contribute to an 
increased likelihood of DNA repair error and mutations in this gene are usually 
considered passenger events308. However, mutation frequencies of TTN differ amongst 
different cancers and mutually-exclusive mutation patterns have been identified, 
suggesting that the role of TTN still remains to be evaluated in cancer progression309. 
Investigations into the substitutions occurring in the samples showed some interesting 
results. C > T transitions followed by C > G transversions have been shown to be the 
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most common substitutions in both MIBC81 and NMIBC61,82,164 with C > T transitions 
accounting for approximately 51% of mutations in MIBC81 and 47% in NMIBC82. In this 
data set, C > T transitions accounted for approximately 46.7% of substitutions overall, 
comparable to previous NMIBC studies82. C > G transversions were the second most 
common event overall. When analysing the post-MMC unique variants, C > T 
transitions remained the most common substitution, but the proportion of mutations 
with this substitution was significantly less, and a significant increase in the number of 
C > A transversions was seen. In this group C:G > A:T mutation was the second most 
common substitution event. A significant reduction in the proportion of C > T transitions 
was also seen by Lamy et al. when comparing the initial vs latest tumours from patients 
with NMIBC with progressive disease61. In their patients, an increase in C > G 
transversions accompanied this change but this was non-significant. No change in the 
proportion of C > A transitions was seen in that study. This suggests that different 
mutational mechanisms may be at play in tumours from Lamy et al.61 compared to our 
dataset. This may be because they looked at progressive disease or because the 
tumours were treated differently. No treatment information was available for tumours in 
that study. 
Only a few studies have characterised the mutations induced by MMC. In the study of 
Srikanth et al.201, base substitutions accounted for 76% of the mutations identified. The 
majority of these (84%) were transversions, 69% of which were C:G > A:T. 
Transversions were also the most common substitution event in the study of 
Maccubbin et al.202. Again, C:G > A:T transversions were most common, but the overall 
contribution of such transversions was reduced compared to the level seen by Srikanth 
et al. making up only 29.3% of all substitutions. This evidence would suggest that the 
large increase in C:G > A:T transversions seen here in the post-MMC unique variants 
is likely due to MMC-induced mutagenesis. 
Interestingly, 30% of the base substitutions seen by Srikanth et al. were tandem 
substitutions, all of which were identified at GpG dinucleotides. Takeiri et al.203 also 
identified tandem substitutions, primarily at GpG dinucleotides, in their MMC treated 
mice. A significant increase in tandem substitutions, specifically at GpG or CpC 
dinucleotides was identified in the post-MMC unique events in our tumours. The 
tandem substitutions seen after treatment with MMC are thought to be the product of 
the intrastrand crosslinks202. Given the specificity of this adduct for GpG dinucleotides, 
combined with the observation that 97% of post-MMC unique tandem substitutions 
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were observed in a GpG or CpC, it is highly likely that these variants are caused by 
MMC-chemotherapy and may serve as a marker for MMC-related events. 
It is interesting that the mutations identified in these tumours more closely reflect 
results from previous in vitro studies than in vivo studies. SNVs were not identified as 
increased compared to controls in two in vivo studies203,205.  However both studies did 
see an increase in deletions. In Takeiri et al.203 these ranged from 110 bp to 8 kb in 
length whilst Tam et al.205 identified deletions ranging from 2 bp to 318.8 kb in length. 
This increase in deletions was not identified here in the MMC-treated tumours. This 
could be due to the size of the deletions as somatic variant callers tend to only be able 
to call short indels302. Indeed, Strelka2 will only detect indels up to a pre-defined value 
of 49 bp238, and for Mutect2 and EBCall this value is not defined. It is therefore possible 
that we missed the majority of deletions caused by mitomycin-C due to their size being 
above the maximum detection limit of our exome pipeline, yet below the minimum 
detection limit for our shallow-pass whole genome sequencing (WGS) pipeline. 
4.3.4 Mutational context and signatures 
The sequence context of variants provides an insight into the mutagenetic processes 
that have taken place within a cancer. These can be delineated into signatures 
characteristic of each mutational process and multiple signatures may be identified 
within a tumour. By counting the number of mutations that contribute to each signature, 
a level of exposure to each mutational process can be determined73. Analysis of 
individual tumours can only give a historical overview of the mutagenic processes that 
have occurred and cannot tell which processes are still ongoing. Assessing multiple 
tumours over time and specifically analysing the “new” mutations can give important 
information about ongoing processes. 
Six signatures were identified that contributed to more than 4% of variants in the pre- 
and post-MMC tumours. APOBEC related signatures, signatures 2 and 13, were the 
most prevalent with 49% of all variants coming from an APOBEC signature. In NMIBC, 
enrichment of APOBEC mutations has been associated with high risk tumours61,310. 
Lamy et al.61 compared tumours from patients with progressive disease to those with 
non-progressive disease and saw that two thirds of patients with progressive disease 
were classified as “high APOBEC” compared to only a third of patients with non-
progressive disease. Hurst et al.82 also identified that APOBEC mutagenesis was 
increased in GS2 tumours relative to GS1 tumours. Out of the 8 patients analysed 
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here, 7 of them had “high APOBEC” scores in both tumours.  However, the tumours 
with “low APOBEC” scores clustered into GS2.  
When focussing on the unique mutations post-MMC treatment, half of the patients had 
a “low APOBEC” score despite all of these patients having a high score overall. This 
implies that fewer of the new variants were due to APOBEC mutagenesis. This may 
suggest that APOBEC mutagenesis could have been an early event in these tumours 
that was reduced or switched off later on, or that a different mutational process is 
contributing more to the process than APOBEC mutagenesis. Indeed, in the 4 patients 
for whom a change from high to low APOBEC scores were seen in post-MMC 
samples, a large induction in variants attributed to signature 24 was seen. Another 
possible contribution to the reduction in APOBEC mutations could be due to the short 
time frame between tumours. For a mutation to be identified, sufficient time is required 
for the cells containing the mutation to proliferate and become present in large enough 
numbers for detection in bulk sequencing. With the maximum time frame between 
tumours assessed in this cohort being 13 months, and with some patients having other 
tumours resected in-between analysed tumours, this leaves a relatively short time for 
new mutations to both occur and expand to a detectable level. This would also explain 
the reduction in the contribution of the age signature to the post-MMC unique events.  
Previous studies have reported conflicting results regarding the timing of APOBEC 
mutagenesis61,180. Lamy et al.61 suggested that it is a later tumour-specific event, whilst 
data from synchronous multifocal tumours identified more APOBEC mutations shared 
between tumours compared to tumour unique events, suggesting an early event180. 
Despite 50% of the patients in our study having a “low APOBEC” score in their post- 
MMC unique variants, 50% still had a high “APOBEC” score and for two patients the 
APOBEC score increased in the post-MMC unique variants. This data set therefore 
implies that APOBEC mutagenesis is a tumour/patient specific event that can follow 
multiple paths. It can occur early and reduce in prevalence over time as seen in the 
patients for whom APOBEC scores were reduced post-MMC (P0418, P0960, P1175 
and P2161). It can occur early and remain active over time, as seen in the tumours 
from patients that maintained or increased their APOBEC scores (P1870, P2329, 
P0533) or it can be a later event, as seen in patient P2218. The evaluation of more 
tumours is required to understand if the timing of APOBEC mutagenesis has any links 
to prognosis. 
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Signature 1 was the next most common signature and was identified in all tumours. 
Signature 1 has been demonstrated to correlate with age of diagnosis in both adult and 
childhood cancers70,311,312. The mutational process underlying the signature is thought 
to be deamination of 5-methylcytosine at CpG dinucleotides creating C > T 
transitions311. In our data set no correlation between the age at diagnosis (or at 
resection of the pre-MMC tumour if this was not the diagnostic tumour) and the 
contribution of the age signature was identified. This could in part be due to the small 
age range in the patients, but could also be due to the recurrent nature of these 
tumours: some of the tumours are not the primary tumour and previous resections may 
have reduced the number of these mutations in later tumours. Indeed, the number and 
proportion of signature 1 mutations reduces in the post-MMC tumours from almost all 
patients. Additionally, few unique mutations post-MMC treatment (-UX) demonstrate an 
age signature and this could be a reflection of the short period of time between pre- 
and post-MMC tumours for the generation of new mutations.  
The age signature is reported to be prone to artefacts; the deamination of 5-
methylcytosine can be observed after formalin fixation of tumour samples313,314, can 
occur during DNA isolation315 and can be accelerated by heating316. As none of the 
samples in this cohort underwent formalin fixation, only errors caused during DNA 
extraction and library preparation are of concern. The presence of these errors in the 
dataset could contribute to the lack of correlation between the contribution of signature 
1 and the age of the patient. With this in mind, it may be prudent to check low VAF C > 
T mutations at CpG dinucleotides with an orthogonal method to ensure that these are 
not artefacts from the sequence preparation procedure. 
Signature 24 was found to contribute to significantly more mutations in the unique post-
MMC variants compared to pre-MMC. Signature 24 was first discovered in 5 liver 
cancer samples by whole-exome sequencing and verified using ICGC and TGCA WES 
data which identified 6 further tumours with this signature317. All patients were African 
or Asian with six tumours containing a somatic TP53 p.R249C. This mutation is typical 
of aflatoxin B1 exposure318  and suggested that aflatoxin B1 may be the cause of 
signature 24. This has since been confirmed through the sequencing of a larger 
cohort319, sequencing of a cohort from a high aflatoxin risk area320 and experimentally 
using cell lines and mouse models321. 
Aflatoxin B1 is a common contaminant of foods such as peanuts, corn and rice322. It 
has long been known to be a carcinogen and it targets guanine bases323 creating G:C 
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> T:A transversions324. Aflatoxin preferentially binds at GGG sequences but will also 
bind at XpGpY where X is G or C and Y is G or T324. Aflatoxin exposure of these 
patients was unknown, and for seven out of eight patients, signature 24 only became a 
major mutational contributor post-MMC treatment. It is unlikely that all patients were 
exposed to aflatoxin at this time.  
Signature 4 was also seen at a higher level in post-MMC unique variants compared to 
pre-MMC variants. Signature 4 is associated with tobacco smoke and whilst it is 
commonly seen in lung, liver and head and neck cancers it is not usually seen in 
bladder cancer4,81,325. Signature 4 exhibits transcriptional strand bias for C > A 
mutations and is also associated with CC > AA dinucleotide substitutions 
(https://cancer.sanger.ac.uk/cosmic/signatures ).  
MMC also targets guanine bases creating G:C > T:A transversions primarily at GpG or 
CpG sites and can cause CC > AA dinucleotide substitutions. Therefore it is 
unsurprising that mutational signature analysis has extracted signatures 4 and 24 as 
key contributors in the post-MMC variants. Indeed, comparisons of the peaks of C > A 
mutations within their trinucleotide context show that many of the peaks are at the 
same place. Signature 24 has peaks of C > A substitutions at GpCpC, CpCpA and 
TpCpC sequences, signature 4 has peaks at CpCpC, TpCpC and CpCpA sequences 
and in the post-MMC unique variants there are also peaks at CpCpA, and TpCpC 
sequences. However, there are some differences; the post-MMC unique variants also 
show peaks at ApCpG and GpCpG sequences, neither of which are large contributors 
to signatures 4 or 24. C > A mutations in a GpCpA context are also contributors to both 
signatures 4 and 24, but mutations were very infrequently seen in this context in the 
post-MMC unique variants. Perhaps with a greater sample number it would be possible 
to separate the MMC signature from signatures 4 and 24.  
The are several limitations to the signature analysis performed in this study. One of the 
limitations is the use of WES sequencing data; whilst some of the tumours contained 
up to 654 mutations many contained much fewer, especially when looking at the 
unique post-MMC mutations. Indeed, patient P2161 had fewer than 30 post-MMC 
unique mutations making signature analysis unreliable for this particular mutational 
group (P2161-S0-UX). As the exome is a small percentage of the genome, only a 
fraction of the mutations present in a tumour may be identified. Whole genome 
sequencing on the other hand produces many more mutations, providing an increased 
power for signature decomposition resulting in a more reliable signature determination; 
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Alexandrov et al. 312 were able to detect a much larger number of signatures from a 
much smaller number of whole-genomes compared to exomes. Additionally, codon 
usage in exons may be constrained and this could mean that some signatures are less 
likely to be identified in exons whilst others may be more likely326 and some mutations 
may be under selection327, potentially skewing the results generated from WES. A 
study comparing the signatures identified from the whole-genomes of 323 liver cancers 
with signatures identified using only the mutations from the exomes of those samples 
demonstrated that use of only the exome mutations resulted in the identification of 
fewer signatures with a higher background noise. These signatures also differed from 
those identified using the whole genome data, questioning the validity of using exome 
sequencing for mutational signature analysis327. 
As the sample set was small, with relatively small numbers of mutations, signatures 
were identified using a signature fitting method from Memorial Sloan Kettering Cancer 
Centre (MSKCC). The package, mutation-signatures, extracts the sequence context for 
each mutation creating a mutation profile per sample. The algorithm then attempts to 
identify the mutational signatures underlying the observed mutational profile using the 
30 signatures described by COSMIC as a reference and an iterative multiple linear 
regression strategy328. This restricts the analysis to known signatures, excluding the 
chance of identifying new signatures. This decomposition method used has limitations 
highlighted by the identification of the UV signature as well as the likely 
misclassification of MMC-related mutations to signatures 4 and 24 as discussed above. 
It is highly unlikely that mutations identified within a bladder tumour are caused by 
exposure to UV. A separate signature fitting decomposition method, deconstructSigs 
implemented through mSignatureDB329 (available at 
http://tardis.cgu.edu.tw/msignaturedb/), demonstrated the same signature identification 
as the MSKCC method including signature 7 (data not shown). Additionally, evaluation 
of the TCGA bladder cancer data using this portal also demonstrated the presence of 
signature 7. This data could suggest that there may be a signature present in bladder 
cancer similar to signature 7. However, a known limitation of signature fitting methods 
is that mutational profiles arising from a combination of signatures may be best fitted by 
an alternative single signature that resembles the mutational profile but does not 
actually contribute to the process. This is particularly applicable to C > T transitions as 
a third of the signatures in COSMIC are mostly composed of these transitions328 
An alternative approach to identifying mutational signatures would be to use the non-
negative matrix factorisation (NMF) method as described by Alexandrov et al. 70. 
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Signatures identified using NMF can be compared to the known signatures using 
cosine similarity, allowing for the identification of both known and novel signatures. 
However, using NMF for the identification of mutational signatures requires a large 
number of variants, either from a large sample number with few variants or from a 
small sample number with a large amount of variants. For example, 25,000-50,000 
mutations are needed to decipher 5 mutational signatures depending on the number of 
mutations per sample330. With fewer than 4000 different mutations identified in total in 
our cohort (some mutations were present in multiple tumours so have only been 
counted once in this instance) this significantly limited the potential for identifying any 
but the strongest mutational signatures within our cohort using NMF methods, 
therefore the signature fitting method was used. 
Since performing the analysis new methods have been published including a package 
called MutationalPatterns that combines NMF and signature fitting methods to identify 
both new signatures and quantify the contribution of previously known signatures331. 
Perhaps a greater sample number and WGS combined with a more accurate signature 
identification using both NMF and signature fitting would enable the identification of a 
MMC signature that can be distinguished from signatures 4 and 24.  
Despite the wealth of information generated by the computational analysis of cancer 
genomes in the detection of mutational signatures, it is clear that further analysis is still 
required to fully elucidate the mutation spectrum and delineate partially correlated 
signatures. The work presented in this Chapter has highlighted that different mutational 
processes can produce similar signatures. The Pan-Cancer Analysis of Whole 
Genomes network (PCAWG) has recently used over 84 million somatic mutations from 
23,829 samples of different cancer types in the largest analysis to date. They have 
identified 49 single base substitution, 11 doublet substitution, 4 clustered base 
substitution and 17 indel mutational signatures. The data is as-yet unpublished, but the 
paper is available as a pre-release312. It would be interesting to see if this increased 
power would delineate the MMC signature further. 
Further validation of this signature of MMC chemotherapy is required through the 
analysis of more tumours with exposure to the drug. With the advances in technology 
since the studies of Maccubbin et al.202 and Srikanth et al.201, further experimental 
analysis of the mutation signature should also be attempted to confirm the activity of 
MMC. This could be done on cancer cell lines or in mouse models. This is important as 
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similar signatures could be generated by several different mutagenic processes and 
confirmation that the MMC signature is similar to the aflatoxin signature is important. 
4.4 Summary 
Overall the data presented in this Chapter has shown that a 6-week course of MMC 
into the bladder can induce new mutations unique to post-treatment tumours. Analysis 
of these mutations has identified a mutational signature consisting of an increase in the 
number of C > A transversions and an increase in tandem substitutions, specifically at 
CC or GG bases. These mutations identified in the post-MMC treated tumours match 
mutations reported in early studies investigating the effect of MMC on DNA making it 
highly suggestive that these mutations are reflections of MMC induced mutagenesis. In 
the next Chapter the evolutionary path of the cancers will be determined and the 
clonality of the MMC-induced mutations will be assessed.
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Chapter 5  
 Subclonal composition of pre-MMC and post-MMC tumours 
and targeted sequencing of additional tumours for the 
determination of clonality 
5.1 Introduction 
Cells within a tumour are constantly competing for space and resources, following a 
Darwinian based evolutionary model17. This often results in tumours which consist of 
multiple cell populations that are genotypically distinct53,332,333. The comparison of 
shared and unique mutations provides key information about differentially altered 
genes across samples and may identify key genes that are mutated in a certain 
subgroup of samples, such as after treatment. However, this does not provide 
information on the frequency of a mutation which could be present in all the tumour 
cells or just a subpopulation. Analysis of mutations that have expanded from a 
subclonal to clonal prevalence can provide an understanding of genetic events that 
contribute to progression, recurrence and resistance242. Likewise, clonal populations 
that have been eradicated after treatment can provide information about alterations that 
confer sensitivity to treatment. Measuring the prevalence of a clone over time or space 
therefore provides an indication of the fitness of that clone334. In Chapter 4, we 
identified shared and unique mutations in each pre-MMC and post-MMC tumour pair as 
well as mutations associated with MMC treatment. In this chapter, we analyse those 
mutations to identify potential clonal and subclonal populations present within the 
tumours.  
Mutations can be classified as clonal or subclonal through the analysis of the variant 
allele frequency (VAF)110. The VAF is the fraction of reads supporting the variant allele 
rather than the reference allele and this can provide an estimate of the proportion of the 
cells containing the mutation335. Clustering mutations with a similar VAF can identify 
tumour subclones as mutations present at similar proportions in a population are likely 
to be present in the same cells335. Additionally, using multiple related samples can 
further delineate clusters through the identification of mutations that shift together when 
comparing tumours246. Unfortunately, the VAF can be affected by changes in copy 
number (CN) or regions of loss of heterozygosity336 as well as contaminating normal 
cells110, meaning that analysis of VAF alone can only provide a rough estimate of 
subclonal populations within tumours.  
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There are many algorithms available for the identification of subclones and intratumour 
heterogeneity from bulk tumour sequencing246,336-338, yet many of these do not take 
copy number alterations (CNAs) into account. To provide a more accurate 
measurement of subclonal populations, some algorithms incorporate CN data and 
tumour purity estimates into their predictions. In this project, clonal clustering was 
performed using PyClone246. This is a Bayesian clustering method that groups somatic 
mutations into putative clonal clusters whilst accounting for both CN and tumour 
purity246. To enable accurate clonal clustering PyClone requires allele-specific CN 
estimations for each mutation. Allele-specific CNAs cannot be identified using shallow-
pass whole genome sequencing (WGS) therefore we utilized the whole exome 
sequencing (WES) data from Chapter 1 to generate allele-specific CN data for each of 
the tumours and these results were compared with CNAs from the shallow-pass WGS. 
In this Chapter, the VAF and allele-specific CN of each SNV was used as the input 
data for PyClone246 in order to estimate the proportion of cells harbouring a mutation 
(referred to as “cancer cell fraction (CCF)”). Mutations with similar CCFs were clustered 
to identify clones present within each tumour. Temporal ordering of the clones was 
performed using ClonEvol247 to infer the order of evolution. This data was then used to 
understand the evolutionary dynamics of each tumour and examine the clonality of 
MMC-associated events. 
Four of the eight patients in the WES cohort had additional tumours available for 
analysis; patients P0418 and P2329 both had an additional tumour prior to the pre-
MMC tumour, patient P0533 had 3 additional tumours prior to the pre-MMC tumour and 
patient P1870 had one tumour before the pre-MMC tumour and one tumour after the 
post-MMC tumour. To supplement the information obtained from WES, these tumours 
underwent next-generation-based targeted sequencing of a panel of 140 genes that 
have previously been identified as mutated in either muscle-invasive or non-muscle-
invasive bladder cancer82,100,164,170-172,325. A list of the genes can be found in Appendix 
D. 
In Chapter 3, single gene mutations and CNAs were used to assess clonality between 
tumours from the same patient. However, for 8 patients this data was insufficient to 
accurately discern a monoclonal or oligoclonal origin of their tumours. In this Chapter, 
we used targeted sequencing of the gene panel described above to provide a more in-
depth examination of clonality for these patients.   
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5.2 Results 
5.2.1 Allele-specific copy number estimation 
Mutations found in regions of CN loss, CN gain or CN neutral LOH will have an altered 
VAF which needs to be considered during clonal clustering and ordering. Clonal 
clustering programs, such as PyClone, are more accurate when used with allele-
specific CN information but shallow-pass WGS does not provide enough depth for the 
detection of allele-specific CNAs. In order to accurately reconstruct the clonal evolution 
of the tumours the package FACETS245, an allele-specific CN analysis tool, was utilized 
with the whole-exome sequencing data. The output from FACETS was compared with 
the output from the shallow-pass WGS CN data generated by Nexus to ensure that all 
major CNAs were detected by the FACETS package. The allele specific CN data from 
FACETS was then used for clonal clustering. 
Overall FACETS identified significantly more regions of CNAs than were detected by 
analysis of the shallow pass sequencing using Nexus (Figure 5.1A). This included 
regions of subclonal CN change, CN neutral LOH and regions of smaller CNAs that are 
below the limit of detection with shallow-pass WGS. Comparisons of the size of the 
CNAs identified by Nexus and FACETS showed that shallow WGS rarely identifies 
CNAs less than 500 kb in size whilst FACETS can detect CNAs as small as 10 kb 
(Figure 5.1:B-C).  
In order to understand the types of CNAs that were called by FACETS but not Nexus, 
the CNAs identified uniquely by FACETS were investigated. These unique CN calls 
were subdivided into clonal and subclonal CNAs where clonal CNAs had an estimated 
cellular fraction greater than 0.75 whilst subclonal CNAs had a cellular fraction less 
than 0.75. Clonal regions of CNA identified uniquely by FACETS tended to be smaller 
in size, often below the lower limit of detection of the shallow-pass WGS (Figure 5.1D). 
Subclonal regions of CNA showed greater variance of size distribution with both large 
and small subclonal events detected (Figure 5.1E). Some larger CNAs were uniquely 
identified by FACETS that were clonal but many of these were CN neutral LOH events 
that shallow-pass WGS cannot detect. Very few CNAs were identified by Nexus that 
were not also detected by FACETS, indeed only 19 of the 247 CNAs identified by 
Nexus were not also identified by FACETS.  
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Figure 5.1: Comparison of copy number analysis carried out on shallow-pass 
WGS and WES data. 
Shallow-pass WGS CNAs were called using the Nexus software whilst CNAs from WES data 
were called by FACETS. A) The number of CN events detected per sample was significantly 
higher using WES and FACETS (paired t-test, p = 0.0023). B-E) Size distribution histograms of 
CNAs. The x-axis is a log10 scale of CNA size and the y-axis is the frequency (no. of events). B) 
Size distribution of CNAs called by Nexus in the shallow-pass WGS data. Shallow-pass WGS 
identifies larger CNAs. C) Size distribution of CNAs identified by FACETS in the exome data. 
FACETS identifies CNAs of all sizes. D) Size distribution of clonal CNAs uniquely identified by 
FACETS. CNAs with a cellular fraction estimate greater than 0.75 were designated clonal. The 
size distribution is skewed towards smaller CNAs. E) Size distribution of subclonal CNAs uniquely  
identified by FACETS. CNAs with a cellular fraction estimate less than 0.75 were designated 
subclonal. FACETS identifies subclonal CNAs of all sizes. F) The Fraction of Genome Altered 
(FGA) was calculated for each method per sample. There was no significant difference in FGA 
seen between pre-MMC tumours and post-MMC tumours in either dataset (2-way ANOVA with 
Sidak’s multiple comparisons test).  
A 
B 
C 
D 
E 
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CN analysis of the shallow-pass WGS data had previously shown that there was no 
significant difference in the fraction of genome altered (FGA) between pre- and post-
MMC tumours (see Chapter 3, section 3.2.4.3). To investigate whether this was also 
the case with the allele-specific CNAs, the FGA was calculated for each sample using 
the FACETS CN data. FGA was calculated by dividing the sum of size of the CNAs per 
sample by the size of the genome and multiplying by 100 to get a percentage. No 
significant difference was identified between pre- and post-MMC tumours for either CN 
method (2-way ANOVA with Sidak’s multiple comparisons test) (Figure 5.1F). 
However, a much higher FGA was identified in patients P1175 and P2161 when it was 
calculated using the WES data with FACETS as compared to the shallow-pass data 
analysed by Nexus. In the pre-MMC tumours, there was a 22% increase in FGA 
detected in P1175 and a 44% increase in FGA detected in P2616. In the post-MMC 
tumours these increases were 32% and 21% respectively. Analysis of these additional 
events showed them to be largely subclonal and therefore not identifiable by shallow-
pass CN analysis. For the other tumours, the difference was not as pronounced with an 
average increase in FGA of 5.3% as detected by FACETS. This data correlates with 
the increase in CNAs identified by FACETS. 
Overall, FACETS appears to identify the vast majority of CNAs identified by the 
analysis of shallow-pass WGS data using Nexus and its use with whole-exome 
sequencing data also enabled the identification of smaller regions of CNA as well as 
CN neutral LOH and subclonal events. The use of this CN data was therefore 
considered suitable for subclonal deconvolution .  
5.2.2 Identification of subclonal populations using kernel density 
plots  
In CN neutral regions of the genome the VAF can be used to provide an estimate of 
clonal dynamics within a tumour. If clusters of mutations are identified with different 
VAF within these CN neutral regions then this is evidence of multiple clones present 
within the tumour. To identify the presence of subclones, CN neutral SNVs were 
extracted for each tumour and a kernel density plot of the resultant VAFs was 
generated within R using the ggplot2 package. Clonal heterozygous mutations have a 
VAF greater than 0.25 usually with a peak near 0.5 whilst subclonal mutations have a 
VAF of less than 0.25. All tumours in this cohort were estimated to have a purity of at 
least 70% tumour cells and should therefore demonstrate this distribution.  
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Figure 5.2: Assessment of intratumour heterogeneity using kernel density plots 
of tumour variant allele frequencies. 
Variants from CN neutral regions were extracted for each tumour and kernel density plots were 
generated. The VAF (x-axis) is plotted against the density of the VAF (y-axis) generating a curve, 
the area under which is equal to 1. A single peak around a VAF of 0.5 would suggest a lack of 
subclonal populations whilst the presence of more than one peak is indicative of populations with 
different genotypes and therefore intratumour heterogeneity. The top row shows the pre-MMC 
tumour plots, the middle row shows the post-MMC tumour plots and the bottom row shows the 
post-MMC unique variants for each tumour. 
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An example of kernel density plots for tumours from 3 patients (P0533, P1175 and 
P2218) can be seen in Figure 5.2. Plots for all other patients can be found in Appendix 
J. All tumours showed at least two separate peaks suggestive of at least two distinct 
clonal populations. Patient P1175 shows an interesting pattern with a high density of 
subclonal mutations identified in the pre-MMC tumour. This was the only patient to 
display more subclonal mutations pre-MMC than clonal mutations. The post-MMC 
tumour had almost equal densities of clonal and subclonal mutations but when focusing 
on the post-MMC unique variants, almost all of these were subclonal. Overall, patient 
P1175 had a reduction in mutational load post-MMC. Taken together the data suggest 
that it was the subclonal mutations from the pre-MMC tumour that were lost and these 
were replaced by a smaller set of subclonal mutations post-MMC. This high level of 
subclonal mutations in this patient is reflective of the high level of subclonal copy 
number changes identified in this patient. The high number of subclonal mutations may 
also be indicative of neutral evolution within this patient. 
Patients P0533 and P2218 both had more clonal mutations than subclonal. For these 
patients a mix of clonal and subclonal mutations were observed in the post-MMC 
unique variants (Figure 5.2). Only patients P1175 (Figure 5.2) and P0418 (see 
Appendix J) had very low levels of clonal mutations generated post-MMC treatment 
whilst the remaining patients had a mix of clonal and subclonal mutations. Some 
patients showed more than 2 peaks suggestive of multiple subclone clusters.  
5.2.3 Subclone analysis and tumour evolution 
To understand patterns of clonal selection related to MMC treatment, subpopulations of 
potentially functional variants were inferred from the paired tumours using PyClone-
0.13.0246. PyClone can account for changes in CN state, including LOH, and uses this 
information to assign cellular prevalence estimates to individual mutations. Mutations 
with a similar cellular prevalence are then grouped together as a clonal cluster in which 
each clone is defined as a set of mutations. The package ClonEvol247 was then utilized 
for clonal ordering and tree reconstruction. 
An ancestral clone (set of mutations) was identified that was present in all cells of all 
tumours for each patient. Each tumour also contained additional subclones with a 
median of 2 additional subclones per tumour (range 1-4). The ancestral clones carried 
mutations in several genes that have been identified as cancer driver genes47. Potential 
driver events in ancestral clones included mutations in FGFR3, PIK3CA, KDM6A, 
CDKN1B, KMT2D, ARID1A and KRAS. Some tumours demonstrated a very simple 
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subclone structure such as patient P1175. Kernel density analysis had shown that both 
tumours from this patient had many subclonal mutations as well as some clonal 
mutations. Plotting the raw VAF of the variants as a scatterplot indicated that the 
variants present in both tumours ranged in VAF from approximately 0.25 to 0.9 whilst 
variants unique to either tumour had VAFs of less than 0.4 with clusters around 0.125 
(Figure  5.3A). This correlates well with the CN neutral variants shown in the kernel 
density plots (Figure 5.2). The scatterplot shows three variants that were likely to be 
homozygous in both tumours; FGFR3 p.G372C, HTT p.Q659E and MICA p.I116S. 
These were all in regions of CNA and therefore were omitted from the kernel density 
analysis. 
For patient P1175, PyClone analysis grouped the variants into 3 clusters (Figure 5.3B). 
The mutations shared between the two tumours were clonal in both tumours 
suggesting that these mutations likely represent the ancestral founding clone. Each 
tumour also contained a single subclone derived from the ancestral clone (Figure 3C) 
and these were different between the pre- and post-MMC tumours. A representative 
diagram of each tumour illustrates the proportion of the tumour that is made up by each 
subclone (Figure 3C). 
Overall the data suggests that for patient P1175, cluster 1 represents the ancestral 
trunk of the tree from which the two tumours branched off with different subclonal 
events (Figure 5.3D). This implies that the selective pressures of resection and/or MMC 
treatment may have eradicated cluster 2, whilst additional mutations that arose 
between resections generated cluster 3. This can be visualized in Figure 5.3E, where 
cluster 2 is not present after resection whilst cluster 1 retains its high prevalence. 
Cluster 3 is a new small subclone derived from cluster 1. Clusters were assessed for 
the presence of potential driver gene mutations using a list of 299 genes identified as 
drivers in various types of cancer47. Only mutations that had a predicted effect on 
protein composition (frame-shift, nonsense, splice-site) or missense mutations 
predicted as deleterious by SIFT and/or PolyPhen were included on the tree. Potential 
driver events were identified in both the ancestral branch and the pre-MMC subclone 
(clusters 1 and 2 respectively). The event affecting the potential driver gene AJUBA in 
cluster 3 was a tandem substitution hitting two separate codons; one variant was silent 
(p.P192P) and the other predicted to be tolerated (p.A193S). Despite the lack of a 
prediction for a detrimental effect, these mutations were included on the tree as they 
were likely a MMC specific event. 
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Figure 5.3: Clonal clustering and ordering for patient P1175. 
A) Scatterplot of the variant allele frequency (VAF) of mutations found in the pre- and post-MMC 
tumours. Shared mutations can be identified in the middle of the graph with mutations unique to 
a tumour found at x or y =0. Variants were plotted at 30% opacity to show where mutations are 
clustering. VAF has not been adjusted for CN. B) PyClone was used to cluster mutations with a 
similar cancer cell frequency (CCF). Three clusters were identified; cluster 1 which is a clonal 
cluster common to both tumours, cluster 2 which is a subclonal cluster found only in tumour 
P1175-S01-BX and cluster 3 which is a subclonal cluster found only in tumour P1175-S02-PX. 
Points were plotted with a reduced opacity and jitter for better visualisation. C) ClonEvol was used 
for clonal ordering. Bell plots can be seen showing the development of each tumour with a 
representative depiction of the clonal makeup of each tumour. D) Clonal evolution tree depicting 
the evolution of the two tumours. Cluster ID can be found within the circles at each node. Branch 
colour reflects cluster composition. E) Fishplot bringing together the clonal models for the two 
tumours. * represents tumour events for which fresh-frozen material was not available. Clonal 
composition between the two time points is unknown and therefore represented by a line. Grey 
fill = cluster 1, green = cluster 2 and blue = cluster 3. 
A B 
C D 
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Patient P2161 also had a simple subclone structure. The raw VAF plot suggests that 
there was a clonal cluster shared between the two tumours then a subclonal population 
unique to the pre-MMC tumour and two subclonal populations unique to the post 
chemotherapy tumour (Figure 5.4A). One mutation appears to be potentially 
homozygous for both tumours and this was the FGFR3 p.S249C hotspot mutation. 
SNaPshot analysis suggested this was a heterozygous mutation due to the presence of 
a wild-type allele. Reanalysis of the SNaPshot profiles indicates that this allele peak 
was very small and therefore consistent with the VAFs identified by WES. Clonal 
clustering performed by PyClone identified 5 different clusters, two of which were 
common to both tumours. Of these, cluster 1 was likely the ancestral clone as this 
remained at a stable high cellular prevalence in both tumours (Figure 5.4B). Cluster 2 
was near-clonal in both tumours but increased in prevalence slightly after treatment. 
Cluster 3 was a subclonal cluster unique to tumour P2161-S01-BX, the pre-MMC 
tumour, and clusters 4 and 5 were subclonal clusters unique to tumour P2161-S02-PX, 
the post-MMC tumour. Clonal ordering suggested that both tumours evolved in a linear 
fashion (Figure 5.4C) and tree reconstruction indicated that divergence occurred from 
cluster 2 (Figure 5.4D). Cluster 5 was the first cluster to grow out after therapy, rising to 
be prevalent in about 75% of cancer cells. Interestingly no potential driver gene 
mutations were identified in this cluster but a mutation in KMT2C (p.L975P) was 
identified in cluster 4, and this was different to the pre-MMC KMT2C mutation 
(p.S1480*) identified in tumour P2161-S01-BX. 
For some patents, multiple possible evolutionary trajectories were identified. Patients 
P0533, P1870, P2218 and P2329 each had two possible evolutionary trajectories. For 
patient P0533 an ancestral cluster, cluster 1, was identified from which tumour P0533-
S3B-BX developed in a linear fashion with two subclones (Figure 5.5A). Both of these 
subclone clusters were eradicated post-MMC treatment. A new major clonal cluster, 
cluster 7, developed from the ancestral cluster post-MMC treatment and became 
present in almost all cells of tumour P0533-S04-PX. Clusters 6 and 8 were subclones 
of cluster 7 however it could not be determined if these developed linearly or if they 
were separate branches from cluster 7 (Figure 5.5A).  
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Figure 5.4: Clonal clustering and ordering for patient P2161. 
A) Scatterplot of the variant allele frequency (VAF) of mutations found in the pre- and post-MMC 
tumours as per Figure 5.3. B) PyClone was used to cluster mutations with a similar cancer cell 
frequency (CCF). Three clusters were identified; cluster 1 which is a clonal cluster common to 
both tumours, cluster 2 which is a subclonal cluster in tumour S01 which rises to be almost clonal 
in tumour S02, cluster 3 which is a subclonal cluster unique to tumour S01 and clusters 4 and 5 
which are subclonal clusters unique to tumour S02. Points were plotted with a reduced opacity 
and jitter for better visualisation. C) ClonEvol was used for clonal ordering. Bell plots can be seen 
showing the linear development of each tumour. D) Clonal evolution tree depicting the evolution 
of the two tumours. Cluster ID can be found within the circles at each node. Brach colour reflects 
cluster composition. 1nonsense mutation p.S1480*, 2missense mutation p.L975P. E) Fishplot 
bringing together the clonal models for the two tumours. * represents tumour events for which 
fresh-frozen material was not available. Clonal composition between the two time points is 
unknown and therefore represented by a line. The ancestral clone is grey whilst the subclones 
are coloured as per B. 
A B 
C D
E
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Interestingly, both major subclones found within the two tumours from patient P0533 
(cluster 4 and cluster 7) carried mutations in the RB1 gene. Cluster 4 carried a splice 
site mutation affecting the splice donor site (p.X565_splice at c.1695+1G>A) whilst 
cluster 7 carried a nonsense mutation (p.S576*, c.1727C>G). Both of these mutations 
would lead to non-functional proteins. As all tumours from patient P0533 carried a 
deletion of the part of chromosome 13 that contains RB1 this would have eradicated 
RB function in both tumours. The convergence of mutations on the RB1 gene could 
suggest that loss of this pathway was critical for tumour outgrowth in this patient. 
The CCF of two subclonal clusters from tumour P1870-S03-PX, clusters 4 and 5, made 
it impossible to determine if these subclones developed linearly or branched off 
separately from the ancestral cluster (Figure 5.5B). Interestingly neither of these 
clusters contained a potential driver gene mutation. For cluster 5, the lack of driver 
combined with the low CCF of this cluster could suggest that it developed neutrally. 
Cluster 4 was present in over 75% of the cells from the post-MMC tumour suggestive 
of an increased fitness despite the lack of an identifiable driver gene mutation. This 
could either suggest the presence of a driver gene that has yet to be identified, that a 
non-coding mutation drove growth of this cluster or that the ancestral mutations were 
sufficient for tumour recurrence. 
Tumours from patient P2329 demonstrated simple clonal architectures (Figure 5.5C). 
An ancestral cluster, cluster 4, was identified in all cells. In tumour P2329-S02-BX an 
additional subclone containing just 2 coding variants was identified (cluster 3). In 
tumour P2329-S03-PX two additional subclones were identified; clusters 1 and 2. 
Again it was impossible to determine if the two subclones developed linearly, with 
cluster 2 developing as a subpopulation of cluster 1, or if they branched off the 
ancestral cluster (cluster 4) separately, resulting in two possible evolutionary trees 
(Figure 5.5C). 
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Figure 5.5: Clonal clustering and ordering for patients P0533, P1870 and P2329. 
PyClone was used to cluster mutations with a similar cancer cell frequency (CCF). These are 
plotted as a scatter graph with pre-MMC tumours on the x-axis and post-MMC tumours on the y-
axis. Clusters compromising of a single mutation were removed from the analysis. Clusters unique 
to pre-MMC tumours can be found where y=0 and clusters unique to post-MMC tumours can be 
found at x=0. Clusters were plotted with added jitter and increased transparency to give distinction 
between clusters containing many variants and clusters containing few variants. ClonEvol was 
used to order the clusters. Two trees are possible for the post-MMC tumours for each patient and 
the branching or linear evolutionary paths that could have been followed are shown in each case. 
Ovals are drawn around branching subclonal clusters that are present in the same tumour. A) 
Results for patient P0533. B) Results for patient P1870. C) Results for patient P2329.  
A
 
B
 
C
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Patient P2218 had two multifocal tumours prior to MMC treatment and a single tumour 
post-MMC treatment. All three tumours contained cluster 8 which likely represented the 
ancestral clone. The pre-MMC tumours shared a small cluster that made a clonal 
sweep (cluster 7), from which the other tumour specific subclones evolved. Tumours 
P2218-S1B-BX and P2218-S02-PX followed a linear evolution pattern however the 
evolutionary pattern for tumour P2218-S1A-BX could not be determined resulting in two 
possible evolutionary trees (Figure 5.6). Parallel evolution was displayed with tumours 
P2218-S1A-BX and P2218-S02-PX showing independent mutations of the tumour 
suppressor gene TSC1 (p.E174K fs*36 and p.Q55*) (Figure 5.6). Interestingly tumour 
P2218-S1B-BX contained an additional FGFR3 mutation to the R248C hot-spot 
mutation identified in all 3 tumours. This was a frameshift insertion (p.V245R fs*36). 
Two patients, P0418 and P0960, had complex genetic structures which made clonal 
ordering difficult. For patient P0418 the presence of a cluster that transitioned from 
subclonal to almost clonal confounded ordering of the clusters (Figure 5.7A). This 
cluster, cluster 1, contained 6 variants including the PIK3CA p.E545K hot-spot 
mutation. Investigations into the CN status of these 6 variants identified that they were 
in regions of subclonal CN loss that was not present in the post-MMC tumour. It was 
hypothesised that the subclonal nature of these CN events confounded the calculation 
of CCF and that these variants were actually part of the ancestral cluster. Removing 
the subclonal CNAs by restoring them to a CN neutral state resulted in these mutations 
being clustered together with the ancestral cluster and reduced the number of clusters 
identified (Figure 5.7B). Using this data for clonal ordering with ClonEvol generated 4 
possible evolutionary trees. These all differ with respect to cluster 6 which has a very 
low CCF that makes it impossible to determine where this cluster branches off the tree 
(Figure 5.7C). 
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Figure 5.6: Clonal clustering and ordering for patient P2218. 
PyClone was used to cluster mutations and scatterplots were generated as per Figure 5.3. As 
patient P2218 has multiple tumours all possible combinations have been plotted. ClonEvol was 
used to order the clusters. Two trees were possible for P2218 as branching or linear evolutionary 
paths for tumour P2218-S1A-BX could have been followed. Ovals are drawn around branching 
subclonal clusters that are present in the same tumour.   
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Figure 5.7: Clonal clustering for patients P0418. 
PyClone was used to cluster mutations and scatterplots were generated as per Figure 5.3. 
Parallel coordinate graphs have also been generated for each patient showing the mean cellular 
prevalence for each cluster with the standard deviation. A) Clonal clustering for patient P0418 
with all CN events identified by FACETS. Cluster 1 does not appear to make evolutionary sense. 
These variants are all in regions of subclonal CN identified by FACETS B) Clonal clustering for 
patient P0418 with subclonal CN events identified by FACETS returned to a normal CN status. 
Cluster 1 from A now clusters with cluster 2, the ancestral cluster. C) Tumour evolution tree for 
patient P0418 using clustering from B for clonal ordering with ClonEvol. Cluster 6 has a very small 
prevalence and therefore the branching point of this cluster cannot be identified. All possible 
positions for cluster 6 have been indicated with an arrow. Ovals have been drawn around 
branching subclonal clusters that are present in the same tumour..  
A 
B 
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Clonal ordering was difficult for patient P0960 as cluster 3 did not follow a cellular 
prevalence pattern that fitted with the evolution of the other clusters (Figure 5.8). 
Cluster 7 is a new cluster that becomes clonal post-MMC meaning it cannot be a 
subclone of cluster 3. However, this means that cluster 3 should not theoretically be 
present at the high clonal prevalence it is found to be in the post-MMC tumours. Clonal 
ordering of the post-MMC tumours with ClonEvol places this cluster as a subclone of 
cluster 7, however this is unlikely as cluster 3 was present in the pre-MMC tumour. 
Cluster 3 contained 11 coding variants making it an important cluster that cannot be 
overlooked but there were no mutations identified in potential driver genes. Removing 
any subclonal CNAs from the analysis did not change the cluster dynamics observed 
(data not shown). Cluster 2 was likely the ancestral cluster and this contained several 
mutations in potential driver genes including missense mutations predicted to be 
deleterious in NCOR1 (p.K835I), MGA (p.E1337K) and TSC1 (p.M142V) as well as a 
hot-spot mutation in FGFR3 (p.Y375C). No other clusters contained mutations 
predicted to affect protein function in any driver genes, however a tandem substitution 
in KMT2C (p.G2213L) was identified in cluster 9. This had a MMC signature mutation 
of CC > AA however this was predicted to be benign using PolyPhen-2. 
5.2.4 Mitomycin C associated mutations are predominantly 
subclonal 
In Chapter 4, a number of mutation characteristics were associated with a course of 
mitomycin C treatment. These included: an increase in the number of C > A 
substitutions, a decrease in the transition/transversion (Ts/Tv) ratio and an increase in 
the number of tandem substitutions, specifically at CC or GG dinucleotides. Kernel 
density analysis identified the presence of both clonal and subclonal mutations in the 
unique post-MMC variants (see Figure 5.2 and Appendix J). Clustering of the coding 
mutations with PyClone identified clonal post-MMC unique clusters in 6 patients and 
subclonal post-MMC unique clusters in all patients. We were interested to identify if the 
MMC-associated variants were clonal, subclonal or a mix of the two. 
The bcftools “stats” command was used to investigate the base-substitution pattern of 
post-MMC unique clonal and subclonal variants. Clonal clusters contained C > T or C > 
G substitutions whilst the subclonal clusters contained predominantly C > A 
substitutions (Figure 5.9A and B). The clonal variants had a Ts/Tv ratio of 0.92 whilst 
the subclonal variants had a Ts/Tv ratio of 0.25. These data suggest that the mutations 
associated with mitomycin C treatment tended to be subclonal. 
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Figure 5.8: Clonal clustering for patient P0960. 
Clonal clustering for patient P0960. Clusters with 3 mutations or fewer were removed. Scatterplots 
comparing the CCF for each post-MMC tumour against the pre-MMC tumour, as well as 
comparing both post-MMC tumours were generated. The results have been displayed on a line-
chart to visualise the changes in CCF between tumours. Clonal ordering was attempted by 
ClonEvol however no consensus trees could be identified due to cluster 3.  
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A large increase in the number of tandem substitutions was identified post-MMC 
treatment. These are highly likely to be MMC-induced events and can therefore be 
used to represent such events. Of the 62 post-MMC unique tandem substitutions, 36 
were in coding regions. All coding, post-MMC unique tandem substitutions from CN 
neutral regions were plotted in a kernel density plot of VAF against density (Figure 
5.9C). This shows that the majority of these tandem substitutions were subclonal. 
Analysis of the clonal and subclonal clusters for each patent identified only 2 tandem 
substitutions within a clonal cluster and these were both from patient P0533. Overall 
the data suggests that variants induced by MMC treatment were mostly subclonal. 
 
5.2.5 Targeted next generation sequencing 
Targeted next generation sequencing was used to supplement the WES data 
described in Chapter 4. A panel of 140 genes (Appendix D) was sequenced in 
additional tumours from patients who previously had selected tumours included in the 
WES cohort. Targeted sequencing was also used to discern clonality of tumours from 
patients for whom tumour clonality could not be determined by CN and single gene 
mutation analysis alone. 
5.2.5.1 Targeted sequencing of additional tumours from patients in the 
WES cohort 
Four patients from the WES cohort had material available from tumours additional to 
those immediately surrounding treatment. These were patients P0418, P0533, P1870 
and P2329. It was considered that analysis of these tumours could provide additional 
information about shared and unique mutations identified within the exome cohort. 
These additional tumours underwent targeted sequencing using the bladder cancer 
gene panel described above. Summary data of the variants identified can be seen in 
Table 5.1. 
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Figure 5.9: Mutation spectrum of clonal and subclonal post-MMC unique 
variants. 
Summary of mutation spectrum data for clonal and subclonal variants unique to the post-MMC 
tumours. A) Base substitutions were identified using the bcftools package with the “stats” 
command.  Histograms of the substitution spectrum for clonal and subclonal SNVs can be seen. 
Substitutions are depicted as a mean proportion ± SEM. B) Substitutions categorised by the 
pyrimidine of the mutated base pair. Lines represent the median and range. The y-axis depicts 
the proportion of mutations with that event. Comparisons between clonal and subclonal variants 
show a significant difference in the number of C > A, C > G and C > T substitutions (two-way 
ANOVA with Sidak’s correction for multiple comparisons: **** p = <0.0001, ** p = 0.0090). C) 
Kernel density plot of coding tandem substitutions from the post-MMC unique variants. The VAF 
(x-axis) is plotted against the density of the VAF (y-axis). The majority of post-MMC unique 
tandem substitutions tend to be subclonal. 
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Patient P0533 had 3 additional tumours available for targeted sequencing all of which 
were resected prior to MMC treatment: P0533-S01 resected almost 12 years prior to 
MMC treatment, P0533-S02 resected 8 months prior to MMC treatment and P0533-
S3A resected 2 months prior to MMC treatment, at the same time as tumour P0533-
S3B-BX. Analysis of the three tumours identified 8 variants that were shared between 
all 3 tumours: BRCA2 (p.E3152Q), CREBBP (p.Y1539*), FAT1( p.Q3929*), KRAS 
(p.G12V), KRAS (p.A146T), NAT10 (p.D90N), STAG2 (p.Q573*) and ZFHX3 
(p.P2282L). These variants were also shared with both tumours from the exome 
sequencing data and were part of the ancestral clonal cluster. These variants included 
all the key driver variants depicted on the branch of the tree in Figure 5.5A which were 
nonsense mutations in CREBBP (p.Y1539*), FAT1 ( p.Q3929*) and STAG2 (p.Q573*), 
and missense mutations in KRAS (p.G12V and p.A146T) and ZFHX3 (p.P2282L).  
All tumours from patient P0533 analysed by targeted capture also contained many 
unique non-synonymous variants (range 5-21). Tumour P0533-S02 was an interesting 
tumour as it shared a missense variant in KLF5 (p.D418N) with P0533-S3A and a 
nonsense mutation in RB1 (p.S576*) with tumour P0533-S04-PX, neither of which were 
identified in any other tumours. P0533-S02 also contained a unique mutation in 
PIK3CA (p.E452K). This suggests that tumour P0533-S02 contained at least 3 
subclones, each of which went on to found separate tumour events.  
Table 5.1: Summary of targeted sequencing results. 
Variants were included if they were identified by at least two of the three variant callers. The 
number of unique variants are variants identified for that tumour that were not shared by all the 
other tumours from that patient. Potential driver mutations for these additional variants have been 
highlighted. aVariants in ARID1A are different for each tumour; P0533-S01 contains a missense 
mutation (p.I2282T) predicted to be deleterious and P0533-S3A contains a nonsense mutation 
(p.Q944*). bUTY  has not been identified as a driver gene but it is the Y-chromosome homolog of 
KDM6A. cNonsense mutation shared with tumour P0533-S04-PX. dShared missense variant 
(p.D418N). eKDM6A (p.V558E fs*36) mutation is shared with tumours P1870-S2A-BX and P1870-
S03-PX. 
Patient Tumour No. 
variants 
identified 
No. of 
unique 
variants 
Additional driver events 
P0418 P0418-S01 11 4 PIK3CA 
P0533 P0533-S01 34 26 ARID1Aa, ATM, KMT2C, UTYb 
P0533-S02 18 10 RB1c, KLF5d, NFE2l2, PIK3CA 
P0533-S3A 27 18 ARID1Aa, KMT2D, KLF5d, 
MECOM 
P1870 P1870-S01 7 0  
P1870-S05 14 7 CDKN1A, KDM6Ae 
P2329 P2329-S01 16 3 FBXW7 
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Patient P1870 had an additional 2 tumours available for targeted sequencing; tumour 
P1870-S01 resected 44 months prior to MMC treatment and tumour P1870-S05 
resected 30 months after MMC treatment (25 months after tumour P1870-S03-PX). 
Analysis of the tumours identified 5 variants common to all four tumours. This included 
the hot-spot mutation in FGFR3 (pS249C), a missense PIK3CA mutation (p.R88Q) as 
well as the missense mutation in RHOB (p.N94Y) predicted to be an ancestral driver 
event. Interestingly the mutation in KDM6A (p.V558Efs*36), predicted to be an 
ancestral event by exome sequencing, was not present in tumour P1870-S01. This 
suggests that tumour P1870-S01 branched off prior to this event. Neither of the other 
ancestral driver genes, MTOR or PSIP1, were included in the targeted gene panel. 
Two additional events were identified as being present in only tumours P1870-S01 and 
P1870-S05. These were mutations hitting the intronic regions of NOTCH2 and HMCN1. 
However, investigations into these variants in the Interactive Genome Viewer (IGV) 
showed the presence of these mutations in all four tumours, yet the variants were not 
called in the exome samples. For the intronic NOTCH2 mutation this was likely due to 
its presence in a region with low mapping quality whist for HMCN1 this was likely due 
to strand bias present in the exome sequencing data. 
Patient P0418 had a single additional tumour which underwent targeted sequencing; 
tumour P0418-S01 resected 4 months prior to MMC treatment. This identified 11 
variants, of which 7 were shared with all other tumours including the frame-shift 
insertion mutation in ARID1A (p.Q802V fs*32). Of the four unique variants identified in 
tumour P0418-S01 only one affected a coding region. This was an additional PIK3CA 
mutation (p.E726K).  
Patient P2329 also only had a single additional tumour; P02329-S01 resected 13 
months prior to MMC treatment. Targeted exome sequencing identified 16 variants in 
this tumour. Of these, 13 were identified as shared with both the exome sequenced 
tumours and included the three ancestral driver mutations in PIK3CA (p.E545K), 
FGFR3 (p.S249C) and KDM6A (p.S1114Ifs*37). Tumour P2329-S01 had 3 additional 
variants that were unique to that tumour only, one of which was a missense mutation in 
FBXW7 (p.R479G), a potential driver gene.  
5.2.5.2 Determination of clonality based on next generation sequencing 
data 
In Chapter 3, recurrent tumours from 23 patients were assessed for copy number 
alterations using shallow-pass WGS. This data was supplemented with mutation 
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analysis of hot-spot regions in 6 key genes; FGFR3, PIK3CA, HRAS, KRAS, NRAS 
and the TERT promoter region. This identified a clear monoclonal origin for 15 of the 
patients. However, for 6 patients (P0468, P0536, P0933, P0990, P2161 and P2218) 
despite a suggestion of monoclonality, this could not be confirmed due to the shared 
events being very common in bladder cancer and therefore possibly independent. A 
further 2 patients (P2065 and P2291) showed no evidence for a monoclonal origin. In 
order to confirm or refute a monoclonal origin of tumours from these patients, tumours 
were further analysed by targeted sequencing.  
Tumours from patients P2161 and P2218 underwent WES as part of the MMC 
treatment cohort. This identified numerous shared variants between tumours (Chapter 
4, Figure 4.4) and mutation clustering and clonal ordering identified the presence of an 
ancestral cluster common to all tumours for each patient (Figure 5.4 and Figure 5.6), 
consistent with a monoclonal origin. Tumours from patients P0468, P0533, P0536, 
P0933, P0990 and P2291 underwent targeted sequencing using the bladder cancer 
targeted gene panel. Unfortunately, a lack of available DNA excluded patient P2065 
from analysis. 
Mutations shared by all tumours from an individual patient were found in patients 
P0468, P0536, P0933 and P0990 (Table 5.2) suggestive of a monoclonal origin for 
tumours from these patients. Two mutations were shared by all 3 tumours from patient 
P0468 including a frameshift insertion in CDKN1A (p.L37L fs) and an inframe insertion 
in EGFR (p.P772PH). Tumours P0468-S03 and P0468-S05 shared an additional 2 
mutations both in FAT1: one frameshift insertion (p.F330F fs) and one missense 
(p.P329S). The missense mutation is likely to be a mapping error as it occurs close to 
the frameshift mutation and is always present on the same reads. Tumour P0468-S01 
had 8 unique mutations, including three nonsense mutations in FAT1 (p.Q725*, 
p.S1908* and p.Q2304*) and a nonsense mutation in CDKN1A (p.R48*). All 3 FAT1 
mutations were different to those seen in tumours S03 and S05. P0468-S03 contained 
a unique missense mutation in AHNAK2 (p.V1789L) predicted to be benign whilst 
P0468-S05 had 10 unique mutations including two tandem substitutions within 
SPTAN1, both of which hit separate codons (p.L9L & p.E10* and p.L1036L & 
p.E1037*), and a frameshift insertion in FOXA1 (p.T46 fs). 
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Targeted sequencing identified only 2 variants that were shared between all three 
tumours for patient P0536 and these were the hot-spot mutations in FGFR3 (p.S249C) 
and PIK3CA (p.E545K) identified previously by SNaPshot analysis. Tumours P0536-
S01 and P0536-S03 additionally shared 4 variants not seen in tumour P0536-S02 
including a nonsense mutation in STAG2 (p.W743*), a missense mutation in ATM 
(p.E2164Q), a frameshift deletion in KDM6A (p.D934 fs) and a missense mutation in 
HMCN1 (p.W3746C). Tumour P0536-S02 also contained missense variants in ATM 
(p.D1548H and p.G2765S) and a frameshift deletion in KDM6A (p.QR117-118 fs) but 
these were alternative events to those seen in tumours P0536-S01 and P0536-S03. 
Tumours P0536-S01 and P0536-S02 both contained 4 unique mutations and P0536-
S03 contained 2 unique mutations. Overall tumours P0536-S01 and P0536-S03 had a 
clear monoclonal origin. However, the origin of tumour P0536-S02 remains unclear.  
Hot-spot mutation analysis had identified that the two tumours from patient P0933 
shared FGFR3 S249C and -124 G>T TERT promoter mutations, but P0933-S02 
contained an additional PIK3CA E542K mutation not seen in P0933-S01. CN analysis 
identified a large loss of a region of 9q in tumour P0933-S01. This CN loss was not 
present in P0933-S02 which contained no detectable CNAs. A monoclonal origin could 
not be determined from this data alone so the tumours underwent targeted sequencing. 
This identified an additional 7 variants that were shared including a splice-donor 
mutation in ELF3 (c.805+1 G>A), a missense mutation in RHOA (p.D67H) and 
nonsense mutations in ARID1A (p.Q585*), EP300 (p.Q2141*) and KDM6A (p.S1154*). 
This would suggest a monoclonal origin for these tumours. Both tumours also 
contained unique mutations with P0933-S01 containing 3 unique mutations (STAG2 
p.R216*, PHF p.P506P and ZFHX3 p.Q1857*) and P0933-S02 containing 9 (including: 
RARG p.R116Q and a splice donor variant in EP300 (c.3671+1 G>A) as well as a 
PIK3CA hotspot mutation (p.E542K). 
Analysis of the tumours from patient P2291 did not identify any variants shared 
between the two tumours (Table 5.2). Tumour P2291-S01 contained 7 variants: 
ARID1A (p.P1592 fs), KMT2D (p.L448 fs, p.C1103G and p.D3411N), CREBBP 
(p.R386*), FGFR3 (p.S249C) and an intronic mutation in SYNE2. Tumour P2291-S02 
contained 8 variants: ELF3 (p.L342 fs, p.236-237 fs and p.254-255 fs), ZFP36L1 
(p.137-138 fs), ACAN (p.P59S), RHOB (p.E47K), CACNA1D (p.A66V) and KDM6A 
(p.1081-1082 fs). All sites were investigated in the Interactive Genome Viewer (IGV). 
One variant in P2291-S01 (SYNE2) was found to be false as all SNVs occurred at the 
end of reads only, with very few reads covering the variant. The two ELF3 frame-shift 
mutations in close proximity (p.236-237 fs and p.254-255 fs) were never present on the 
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same read, suggestive of two separate events and inactivation of both alleles of the 
protein. All other variants were verified to be unique to their respective tumour but two 
variants did show a single read in the other tumour; FGFR3 p.S249C, unique to S01, 
contained 1 read with the variant allele in tumour S02 and CACNA1D (p.A66V), unique 
to S02, contained 1 read with the variant allele in S01. For FGFR3 this was one read 
out of a total of 345 reads covering the base and for CACNA1D this was one read out 
of a total of 789. It is possible that these were detected in very minor subclones within 
the two tumours, however the presence of only a single read despite high coverage 
may also suggest that cross contamination or error could be the likely cause. Overall, 
the evidence would suggest that the tumours from patient P2291 were oligoclonal in 
origin. 
 
5.3 Discussion 
Detailed knowledge of the clonal composition and mutational heterogeneity of NMIBC 
and the changes associated with the use of therapy would aid in the design of new 
therapies or therapeutic regimes. By gathering a detailed understanding of the 
molecular alterations present within tumours and identifying variants that frequently 
occur on the trunk of the evolutionary tree, new therapeutic targets that are present in 
all cancer cells from a patient can be identified. Following clonal dynamics and the gain 
and loss of mutations post-therapy could identify constraints in tumour evolution that 
can be exploited. This Chapter focused on deconvoluting the clonal structure of the 
individual tumours used in this study and inferring the order of mutation gain.  
Accurate clonal ordering requires the input of allele-specific CN data. The shallow-pass 
WGS data does not provide enough depth for the estimation of B-allele frequencies 
and therefore cannot be used to generate allele-specific CN data. Due to the popularity 
of WES as a method to study genomic variation, there are now several packages that 
can identify CNAs from WES data245,339,340.  
The FACETS245 package was used to extract CN data from the WGS data. FACETS 
was able to detect substantially more CNAs than shallow-pass WGS, including 
subclonal CNAs as well as clonal CNAs and regions of CN neutral LOH. Shallow-pass 
WGS gave an average coverage of 0.7x. Whilst this gives enough coverage to identify 
larger CNAs present in the majority of cells, and can give a good indication of the level 
of genome instability within a tumour, it is not enough for the identification of smaller 
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CNAs, CN neutral LOH or CNAs that are subclonal. Subdividing the unique CNAs 
identified by FACETS into clonal and subclonal CNAs showed that the majority of 
clonal CNAs, which hypothetically can be detected by shallow-pass WGS, were below 
the size limit of detection for shallow-pass WGS. Those that were larger tended to be 
regions of CN neutral LOH, again undetectable by shallow-pass WGS. 
The ability of FACETS to identify subclonal CNAs helped disambiguate the SNaPshot 
analysis result for the FGFR3 mutation in patient P1175. In Chapter 3, tumour P1175-
S01-BX displayed a homozygous SNaPshot profile for FGFR3 p.G372C, whilst tumour 
P1175-S02-PX displayed a heterozygous profile. WES identified a VAF of 0.89 for 
tumour P1175-S01-BX and 0.84 for tumour P1175-S02-PX, suggesting that both 
tumours are homozygous for this mutation. Analysis of the CN for this mutation with 
FACETS identified that it was in a region of subclonal LOH for both tumours. For 
tumour P1175-S01-BX, this was a region of CN neutral LOH with an estimated CCF of 
0.65, whilst for tumour P1175-S01-PX this region of LOH had an estimated CCF of 0.3 
but it was also precited to contain a single copy gain, producing 3 copies of the mutant 
allele. Unfortunately, FACETS only provides one estimate for a region, so it is not 
possible to identify if all cells with LOH of FGFR3 in tumour P1175-S02-PX had the 
additional gain, or if this was a subpopulation of cells with LOH. Nevertheless, this 
subclonal nature explains why the wild-type allele could be identified in P1175-S02. It 
is interesting that no wild-type allele was identified in tumour P1175-S01 during 
SNaPshot analysis, however this could have been at the lower limit of detection or 
sampling of the DNA may have been uneven. 
Prior to running clonal clustering algorithms, it was desirable to first identify if there 
were likely to be any subclones present. In CN neutral regions of the genome the 
variant allele fraction (VAF) is a readout of the proportion of cells containing the 
mutation91. For example, heterozygous mutations present in all cells of a pure tumour 
would have a VAF around 0.5 in a CN neutral region. If a tumour contains clusters of 
mutations with dissimilar VAFs this is evidence of intratumour heterogeneity and is 
suggestive of the presence of clusters of cells with different genotypes53,341. Kernel-
density analysis was used to quickly visualise the spread of the VAFs341 to see if it was 
worth proceeding with clonal clustering and ordering. At least two peaks of different 
VAFs within the CN neutral regions of each tumour was identified providing evidence 
for the presence of subclones. This suggested that further analysis of the tumours to 
identify the number and contents of the subclones was worthwhile. 
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The subclone composition of the tumours was assessed using PyClone, a CN-aware 
Bayesian clustering method for grouping sets of mutations246. PyClone uses 
information on allele imbalances resulting from changes in copy number and the 
normal cell contamination along with the observed VAF to provide an estimate of the 
cellular presence of each mutation. Mutations with similar cellular prevalence are 
grouped together to form clusters. Analysis of multiple tumours from the same patient 
allows the identification of mutations that change in cellular prevalence together and 
this helps to refine clusters.  
Correlating with the kernel density analysis, PyClone analysis identified all tumours to 
be heterogeneous. In all 8 patients an ancestral origin was identified consisting of a set 
of shared mutations present at a high cellular prevalence. These were designated the 
founding clones. Each tumour then contained subclones with a median of 2 subclones 
observed per tumour (range 1-4). Previous studies identified a similar small number of 
subclones for NMIBC with 1 to 2 private subclones identified per tumour61,164. 
Tumours from patients P1175 and P2161 showed very simple clonal dynamics with 
only a single subclone identified for each tumour producing a single possible 
evolutionary tree for each patient. For all other tumours at least two evolutionary trees 
were possible due to the prospect of either linear or branched evolution of the minor 
subclones. Sequencing of bulk tumour tissue makes these types of events very difficult 
to disambiguate as there will always be an amount of noise and error in the data342. To 
be able to explicitly determine the type of evolution occurring and refine the 
evolutionary tree, single cell sequencing would need to be implemented. This would 
provide the exact genotype of a cell, from which the true evolutionary path could be 
deducted through the analysis of multiple cells343. Single cell sequencing has been 
applied to many cancers54,344,345 including MIBC169, but as yet it has not been used in 
the sequencing of NMIBC. 
Patient P0960 showed a complicated clustering of mutations from which an 
evolutionary tree could not be generated using the ClonEvol package. This was due to 
the incompatible cellular prevalence of cluster 3 across the tumours. The similar 
presence of this mutation in the two post-MMC tumours suggests that this is a real 
event. This would also make contamination of the post-MMC tumours unlikely as it 
would have to happen twice. Targeted deep sequencing would need to be employed to 
try to disambiguate the clusters further. This highlights that a limitation of this study is 
the relatively low level of coverage. Tumours were sequenced to an average depth of 
80x; a heterozygous mutation in a subclone consisting of 10% of the total tumour mass 
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would therefore only have 4 reads covering the mutation in a pure tumour. This may 
mean that important subclones present at very low VAFs may not have been detected 
or biases in the sequencing may have distorted the VAF of certain variants. 
This low coverage could mean that it is possible that some of the post-MMC unique 
variants may have been outgrowths of undetected subclones in the pre-MMC tumours. 
As the identified MMC-related signature is very specific and correlates highly with the 
in vitro literature, it is unlikely that these mutations were present in the pre-MMC 
tumour. The majority of these mutations were subclonal. It is possible that some of the 
other mutations, such as those derived from APOBEC mutagenesis, that became 
highly prevalent post-MMC may have been present at very low VAFs pre-treatment. 
This can be evidenced by the observation that the nonsense mutation of RB1 identified 
uniquely in tumour P0533-S04-PX was also identified in P0533-S02 by targeted 
sequencing. Again, ultradeep sequencing of selected variants would provide validation 
of the MMC-associated events and allow for better separation of subclones. Due to 
time and resource constraints, targeted re-sequencing could not be performed as part 
of the current project but would be a key follow up experiment in later projects. 
PyClone makes several assumptions during analysis. It assumes that all cells of a 
clonal population have the same CN status, that no site mutates more than once in its 
evolutionary history and that mutations do not disappear246. These assumptions are 
easily violated especially as CNAs or LOH events could occur before and/or after the 
mutational event resulting in loss of variants. These limitations are highlighted with the 
results from patient P0418 for whom cluster 1 produced a result that was incompatible 
with the evolutionary model (Figure 5.8A). Cluster 1 increased from subclonal to clonal 
after MMC treatment, whereas other clusters that were clonal pre-MMC treatment 
became subclonal. This made clonal ordering impossible due to incompatible CCFs 
between the two tumours. Cluster 1 contained 6 mutations including the PIK3CA 
E545K hotspot mutation. Further analysis of these variants showed that they were in 
regions of subclonal CN deletions in P0418-S02-BX yet at a normal CN in P0418-S03-
PX. It was thought that the subclonal nature of the CNAs may be confounding the 
clustering. Removing the subclonal CN estimation by returning these variants to a 
normal CN estimation did indeed make these variants cluster with the ancestral 
variants as expected. The use of a clustering algorithm that considers subclonal CNAs 
and incorporates CNAs as events into the subclonal deconvolution, such as Canopy336, 
would likely improve the clustering and delineate more subclonal populations. This 
could provide interesting results as highlighted by the FGFR3 mutation in patient 
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P1175, which clearly shows subclonal diversity with respect to CNAs. Unfortunately 
there was not enough time to perform this analysis during the project. 
In Chapter 3, phylogenetic trees were drawn for each patient using CN alterations 
whilst in this chapter trees have been created using the subclonal clusters of 
mutations. Comparing the trees from the two methods shows similar results in patients 
that have tumours with several CNAs. For example, phylogenetic ordering of CNAs for 
patient P0418 identified that tumours P0418-S02-BX and P0418-S03-PX shared many 
alterations before branching occurred. After branching both tumours gained private 
CNAs, but tumour P0418-S03 gained more CNAs than tumour P0418-S02. This was 
reflected in the mutation data with tumour P0418-S03-PX containing more private 
SNVs than tumour P0418-S02-BX. Similarly, for patient P2218, all tumours contained 
some CNAs that were shared. Tumours P2218-S1A-BX and P2218-S1B-BX then 
branched off together with an additional 2 shared CNAs between them before diverging 
(see Appendix G). This was also seen in the mutation data where these tumours 
shared additional mutations that were not present in tumour P2218-S02. Tree building 
using CNAs in tumours containing few CNAs was uninformative or showed very simple 
linear evolution of tumours. For example, tumours from patient P2161 contained only 
one CNA that was shared making tree building difficult. The addition of mutation data 
identified a simple evolution pattern for patient P2161, with a single branching event. 
This data shows that phylogenetic tress predicted from CN data appear to accurately 
reflect the evolution of tumours as determined by mutation data, but only if many CN 
events are present. Unsurprisingly, mutation data provides a deeper analysis of the 
evolution of the tumours, especially in tumours with few-to-zero CNAs. In all cases, the 
use of a clustering algorithim that can order both SNVs and CNVs would help 
subclonal reconstruction and identify the order of mutational gain. 
As sequencing was performed on bulk tumour tissue from a single region of each 
tumour it is possible that some subclones may have been missed due to spatial 
positioning. Lamy et al.61 performed multiregional exome sequencing on a single 
muscle-invasive tumour and found no mutations or subclones unique to any one 
region. However, the mean sequencing depth was 61.1x, so it is entirely possible that 
rare mutations were missed. Further studies investigating spatial heterogeneity would 
be of use, however the low numbers of subclones identified in NMIBC would suggest 
that spatial heterogeneity may not be highly prevalent in this disease.  
An ancestral clone was identified for all patients and this tended to contain the majority 
of driver mutations identified. Overall, 26 driver genes were identified as ancestral 
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events present in the trunk of the tumour evolutionary tree from both the WES and 
targeted sequencing panels (from a total of 12 patients with monoclonal disease). Of 
these, 6 were present on the trunk of more than one patient. These included FGFR3 (7 
patients), PIK3CA (5 patients), KDM6A (4 patients), ARID1A (2 patients), RHOA (2 
patients) and ELF3 (2 patients). Targeting of truncal driver mutations would ensure 
targeting of all tumour cells. In the case of activating mutations, this could be done 
through small molecule inhibitors. Inhibition of FGFR3 is being investigated for the 
treatment of bladder cancer346 as well as other cancers347. However, a common 
problem with small molecule inhibitors is the development of resistance through 
additional mutations348 or the activation of equivalent or downstream pathways349. 
Additionally, targeted treatment would need to be localized as systemic administration 
would likely cause unacceptable toxicity in these lower-risk patients that have a long-
life expectancy. 
Interestingly, targeted sequencing for patient P1870 identified that the driver mutation 
in KDM6A (p.V558Efs*36), predicted to be an ancestral event by exome sequencing, 
was actually a later event not present in tumour P1870-S01. This became clonal and 
remained dominant in tumours resected at a later date. These results identify the need 
to sequence all tumours from a patient for the accurate identification of the early truncal 
events before applying a personalised targeted therapy regime.  
Chromatin modifiers are frequently mutated in bladder cancer100 and these can be 
early events as evidenced by truncal mutations of ARID1A and KDM6A. Epigenetic 
changes have the ability to be manipulated using pharmaceuticals and therefore could 
represent a therapeutic option for bladder cancer350. However, the mutations in 
ARID1A and KDM6A are frequently inactivating, meaning that directly targeting the 
protein product of these genes is not possible. Recently, ARID1A deficiencies have 
been exploited through synthetic-lethal interactions351,352. Inhibition of aurora kinase A 
was shown to confer selective vulnerability in ARID1A deficient colorectal cancer 
cells351 and inhibition of EZH2, a methyltransferase, was shown to be synthetically 
lethal in ovarian clear cell carcinoma cells and caused regression of ARID1A mutated 
tumours in a mouse model352. EZH2 inhibition has also been shown to be effective in 
KDM6A-null bladder cancer cell lines. Ler et al.177 showed that cell lines with loss of 
KDM6A were sensitive to EZH2 inhibition whilst a cell line with wild-type KDM6A did 
not respond to EZH2 inhibition at all. Additionally, EZH2 inhibition inhibited growth of 
KDM6A mutant tumours in cell line and patient derived xenograft models177. These 
studies highlight that when a mutant gene product is not directly targetable, knowledge 
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of the signaling pathways and interactors of the protein may identify interactions that 
can be targeted instead. 
Whilst the majority of driver events were identified in the ancestral clusters, some 
subclones contained additional potential driver mutations whilst others did not. The lack 
of drivers in some subclonal clusters could mean that the event driving this outgrowth 
is yet to be identified. However, it is also possible that the driver events in the ancestral 
clone were sufficient to drive recurrent tumour outgrowth and the subclonal mutations 
identified in these clusters are simply passenger events. 
The subclone composition of bladder tumours will be influenced by tumour resection164. 
It is likely that this physically removes some subclones with private mutations and may 
leave behind cells containing the ancestral mutations due to a large area of the 
urothelium being altered4. Indeed, the observed presence of an ancestral clone in all 
tumours is suggestive of a “field defect” in the urothelium. This may explain the lack of 
shared subclones identified between tumours from the same patient as these have 
been removed. Only three patients, P0418, P0960 and P2161, contained subclones 
that were shared across tumours. This could be indicative of incomplete resection and 
regrowth, undetected microscopic growths or could be due to the shedding and 
reimplantation of tumour cells. Whole organ mapping studies of cystectomy specimens 
have shown that geographically distant regions of altered mucosa that may appear 
phenotypically normal are clonally related22,168. Sequencing of adjacent normal 
samples in patients with multifocal or recurrent disease identified some of the 
mutations present in the tumours55. Mutations that were shared between multifocal 
tumours, or spatially distinct regions within a tumour, were much more likely to be 
detected than private mutations suggestive of spread of the ancestral mutations 
forming the field disease. By combining whole-organ mapping with next generation 
sequencing the extent of this widespread field disease can be fully realized, a full 
understanding of which could help inform therapeutic design and surgical procedures.  
An interesting occurrence is the observation of convergent evolution in tumours from 
many of the patients. Private mutations hitting the same driver genes within a patient 
were identified in 3 of the patients analysed by exome sequencing and two of the 
targeted sequencing panel. In patient P0533 both exome-sequenced tumours 
contained disruptive mutations in the RB1 gene; a splice-donor mutation in P0533-
S3B-BX and a nonsense mutation in P0533-S04-PX. These mutations were both 
present in clusters that had undergone a clonal sweep and were likely present in 
almost all cells of each tumour (Figure 5.5). A deletion of 13q13.3 - 13q14.3, covering 
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the genomic position of RB1, was identified in all tumours from patient P0533, 
suggesting that almost all pRB activity was eradicated in both tumours. The 
convergence on complete loss of pRB activity could suggest that loss of this pathway 
was important for tumour outgrowth in this patient and may represent a therapeutic 
opportunity353, either through targeting the E2F pathway354-356 or through the conferred 
increased sensitivity to radiation therapy357 and cisplatin-based therapies. Separate 
mutations in PIK3CA were also identified in P0533-S02 and P0533-S04. These are 
known APOBEC targets83 and likely reflect the activity of the APOBEC enzymes rather 
than convergent evolution. 
Other driver genes seen to be privately mutated in tumours from the same patient 
include KMT2C in patient P2161, TSC1 in patient P2218, FAT1 in patient P0468 and 
ATM and KDM6A in patient P0536. Interestingly patient P2218 had loss of 
chromosome 9, on which TSC1 is encoded, and tumour P0418-S01 had loss of a 
region of chromosome 4 including the region encoding FAT1. Like RB1, both of these 
are tumour suppressor genes thus function of the proteins encoded by these genes are 
likely eradicated. Convergent evolution of mutations affecting the same gene in 
different subclones, often separated by space or time, has been reported in many 
cancers including renal cell carcinoma53, chronic lymphocytic leukaemia358 and brain 
metastases64. This may signify that tumour evolution has constraints. Further analysis 
of multiple regions and tumours from individuals is required to shed increased light on 
the convergent nature of cancer.  Perhaps this will identify predictable evolutionary 
paths that could be targeted359. 
Investigations into the mitomycin C-associated variants identified that these were 
present in the subclonal clusters. Analysis of the mutation spectrum showed two very 
different substitution patterns in the clonal vs subclonal variants and statistical analysis 
of these differences confirmed a significant difference in the number of C > A, C > T 
and C > G mutations. The subclonal mutations contained predominantly C > A 
mutations, consistent with those identified in Chapter 4 and correlating with the 
increase in C > A mutations identified in in vitro studies201,202,204. This resulted in a 
much-reduced transition:transversion ratio for the subclonal variants. It was reasoned 
that the unique tandem substitutions identified in the post-MMC tumours could be used 
to represent the MMC-induced event as this was an event specific to these tumours. 
Only 2 tandem substitutions were identified in post-MMC unique clonal clusters. The 
rest were present in subclonal clusters, providing further evidence that the MMC-
associated variants tend to be subclonal in nature. 
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The observation of therapy-induced subclonal mutations is not unique. A high 
proportion of mutations associated with a cisplatin signature in MIBC were found to be 
subclonal176 and treatment with temozolomide has been shown to induce subclonal 
hypermutation in glioblastoma360. In MIBC it was suggested that the short interval 
between treatment and recurrence may not have provided enough time for mutations 
to undergo a clonal sweep, thus the subclonal nature of the chemotherapy related 
events was suggested to be in relation to time176. In our cohort the median time from 
the start of the MMC treatment course until the sequenced post-MMC tumour was 232 
days (range 97-486 days). This may not have provided enough time for clones 
containing MMC-associated mutations to grow to clonal levels. It would be interesting 
to look at tumours from patients that recurred later to see if MMC-induced events 
become clonal. 
Copy number and hotspot gene mutation analysis failed to determine the clonal origins 
of tumours from 8 patients. The addition of variant identification, either by WES or by 
targeted sequencing of the bladder cancer panel, identified a clear monoclonal origin 
for a further 5 patients (P0468, P0933, P0990, P2161 and P2218). No additional 
mutations were identified that were shared by all three tumours for patient P0536 but 
tumours P0536-S01 and P0536-S03 shared an additional 4 mutations. These two 
tumours therefore arose from a monoclonal origin. The origin of tumour P0536-S02 
could not be explicitly determined. However, the presence of the two hotspot mutations 
would suggest a monoclonal origin. Additionally, convergent evolution was identified in 
this patient with tumour P0536-S02 also containing mutations in ATM and KDM6A that 
were distinct from the mutations in these genes identified in the other two tumours. 
This may provide further evidence that tumour P0536-S02 is likely clonally related to 
the other tumours from this patient. 
Tumours from patient P2291 did not share any mutations or CN alterations suggestive 
of an oligoclonal origin. Whilst the majority of bladder cancers show a monoclonal 
origin26,29,159,160 a small fraction of patients have been reported to show evidence of 
oligoclonal tumours161,361,362. These early investigations into the clonality of bladder 
cancer utilized methods such as X-chromosome inactivation160,362, LOH analysis26 and 
TP53 mutational status161,361. Given that cancer is genetically unstable and may have 
subclonal diversity, the use of small numbers of genetic markers may not provide a full 
picture of the relatedness of the tumours. Next-generation sequencing provides 10’s to 
1000’s of potential genomic markers that can be used to assess clonality. NGS studies 
involving paired tumour samples from patients with recurrences61,164, matched pre- and 
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post-chemotherapy samples176 including metastases62 as well as multifocal 
tumours174,180 have all demonstrated clonal relationships between tumours from the 
same patient. It is possible that shared mutations have not been identified in patient 
P2291 due to the limited number of genes targeted in the bladder cancer panel utilized. 
However, as these genes represent the most frequently mutated genes in bladder 
cancer one would assume that if any variants were to be detected then analysis of this 
panel of genes would greatly facilitate this. Tumours were assessed by short-tandem-
repeat (STR) profiling which confirmed that they came from the same patient. Notes 
taken by the clinician at the time of resection suggest that the recurrent tumour was 
resected from around the original resection site making the oligoclonal finding even 
more interesting. These results are suggestive of a potential “field cancerization” where 
multiple cells have become transformed. This could come from exposure to mutagens, 
however no occupational hazards or history of smoking were noted at consent, or 
could be due to a genetic predisposition. However, these results must be viewed with 
caution; the single shared reads identified in two mutations may be suggestive of a 
shared minor subclone. Targeted deep sequencing would be required to confirm or 
refute this. Sequencing of any additional tumours from this patient would be interesting 
but as yet this patient has had no recurrences since tumour P2291-S02. 
5.4 Summary 
Clonal clustering identified the presence of subclones in all tumours. However, the 
number of subclones identified per tumour was quite low (average of 2, range of 1-4). 
Analysis of the different clusters identified that mitomycin C-related mutations tended to 
be subclonal in nature. Targeted sequencing of a panel of genes commonly mutated in 
bladder cancer was used to improve analysis of clonality for 5 patients. This identified 4 
patients with tumours of a monoclonal origin and confirmed a likely oligoclonal origin 
for tumours from patient P2291. 
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Chapter 6  
Final discussion 
Non-muscle-invasive bladder cancer (NMIBC) is a clinically challenging disease. The 
high rate of recurrence and the possibility of progression to muscle invasive disease in 
these patients necessitates continued surveillance for many years after diagnosis6. 
Despite having a good prognosis, patients are treated with DNA damaging 
chemotherapy. Some chemotherapy agents have been shown to create new mutations 
in cancers114,177, potentially driving evolution that could lead to treatment resistance and 
progression. As yet, the mutational effect of mitomycin C (MMC) chemotherapy 
treatment has not been investigated in bladder cancer. This project aimed to use next 
generation sequencing (NGS) to characterise the copy number alterations (CNAs) in a 
cohort of 67 tumours from 23 patients with recurrent disease, and identify any potential 
genomic alterations associated with MMC chemotherapy in NMIBC. 
Initially, a cohort of patients with recurrent non-muscle-invasive disease was analysed 
for changes in copy number using shallow-pass whole-genome sequencing. This 
identified that the copy number (CN) profiles of the tumours from each patient were 
predominantly similar, even after treatment with MMC. For the majority of patients, 
tumours shared a subset of copy number alterations considered to be likely early 
events, after which some tumours evolved additional alterations. Hierarchical clustering 
of the cohort identified that tumours from the same patient tended to cluster together, 
suggesting that tumours are relatively stable at the CN level. This observation of 
conservation of CNAs across bladder tumours from an individual patient has been 
identified in other studies investigating multifocal and recurrent tumours29,167. Studies 
performing hierarchical clustering of multiple non-muscle-invasive tumours from the 
same patient have also reported that tumours tend to cluster together163,167. This 
stability in CNAs is not limited to NMIBC; investigations in muscle-invasive bladder 
cancer (MIBC) have also identified that tumours from the same patient cluster close 
together62. Taken together, these studies suggest that some CNAs are early events in 
bladder cancer and may imply that bladder cancer is relatively stable during evolution 
at the CN level. 
Early in vitro studies identified several structural rearrangements in cells after treatment 
with MMC194,199,281 leading us to hypothesize that MMC treatment in bladder cancer 
patients could lead to the formation of CNAs in post-treatment tumours. Analysis of 
tumours from patients that underwent 6 weeks of MMC treatment demonstrated that 
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MMC did not appear to alter the CN landscape, with no MMC-specific CN events and 
no significant change in the fraction of genome altered (FGA) being identified after 
therapy. For individual patients, some tumours showed an increase in the FGA after 
therapy, some a decrease, whilst others showed no change at all. This lack of change 
in the CNA landscape after treatment has also been reported in MIBC treated with 
cisplatin176, another DNA alkylating agent that can form intrastrand and interstrand 
crosslinks363. This could suggest that the generation of CNAs by these agents is 
uncommon. Alternatively, the lesions induced by MMC could be highly cytotoxic and 
therefore are not represented at a detectable level in the post-treatment samples. 
Investigations using model cell lines, or tumour organoids, combined with single cell 
sequencing directly after treatment could be used in the future to identify if MMC does 
induce CNAs. The maintenance of such alterations in cells could be examined by next-
generation sequencing at different follow-up times after drug treatment. 
It is also possible that MMC induces structural rearrangements that do not involve a 
change in copy number. The presence of such rearrangements could be investigated 
using cytogenetic methods such as FISH and chromosome painting or a different next-
generation sequencing strategy. Mate-pair sequencing has been used to resolve 
structural rearrangements364,365 and could be used to resolve any potential structural 
rearrangements not identified by shallow-pass whole genome sequencing (WGS) or 
whole exome sequencing (WES) in the current study. The technique leverages the 
known distance between the two read ends to identify any pairs that show discordant 
mapping. This information can then be used to disambiguate structural rearrangements 
such as insertions, deletions, inversions and translocations257. Alternatively, long-read 
methods, such as Oxford Nanopore sequencing, could be used to investigate structural 
rearrangements. The length of a read for Nanopore technologies is limited only by the 
size of the input DNA366 and sequencing reads in excess of 2 Mb have been 
reported367. One of the benefits of these long reads is that regions of repeats can be 
covered in a single read, making alignment easier and therefore making it possible to 
resolve regions of the genome that are inaccessible with short-read sequencing368. 
Nanopore technology has even been used to sequence through the Y-chromosome 
centromere369. As the structural rearrangements induced by MMC in vitro occurred 
primarily within the repeat rich, heterochromatic, peri-centromeric regions of 
chromosomes 1, 9 and 16196-198, Nanopore sequencing technology could allow the 
identification of breakpoints in these repetitive regions. 
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Previous studies in model organisms identified deletions ranging in size from 110 bp to 
8 kb in mouse models203 and from 2 bp to 318.8 kb in C.elegans205. These deletions 
are small, focal events that are below the limit of detection of our shallow-pass WGS 
and would therefore have been missed. Higher coverage of around 5x364 would allow 
the identification of these regions but would come with an increased overall cost as 
currently samples are multiplexed in pools of 50 and this generates an average raw 
coverage depth of 0.7x.  
As the majority of MMC-associated mutations were subclonal, it could be hypothesized 
that any copy number alterations caused by treatment may also be subclonal. These 
would be missed by shallow-pass whole genome sequencing as the coverage is not 
deep enough for this type of analysis. Analysis of the exome sequencing data using the 
FACETS package enabled the identification of subclonal CNAs, yet no difference in the 
number of subclonal CNAs was identified between the two treatment groups (data not 
shown). It is possible that CNAs present in the non-coding regions of the genome could 
be missed by WES, especially in long intergenic regions, as exons are not evenly 
placed within the genome370.  
To investigate the effect of MMC at the single nucleotide level, pre-MMC and post-
MMC treatment tumours from 8 patients underwent WES. Patients were selected from 
the copy number cohort if their pre- and post-treatment tumours occurred within a short 
timeframe (less than 2.5 years) and no instillations of BCG therapy had been given 
between the tumours. Tumours were assessed for changes in mutational burden, types 
of base substitution and mutational signatures. This identified an increase in the 
number of C > A transversions and an increase in tandem substitutions, specifically at 
CC or GG bases in the MMC treated tumours. These alterations are concordant with 
mutations caused by MMC in vitro201,202 and in vivo203. 
Deconvolution of the mutational signatures in this study associated these MMC-
induced changes with COSMIC mutational signature 24, the aflatoxin signature. It is 
likely that this reflects the preference of both MMC and aflatoxin for the generation of C 
> A mutations. This highlights a limitation of mutational signatures at present, as many 
signatures may have a similar sequence context preference. The recent analysis by 
the PanCancer Analysis of Whole Genomes (PCAWG)312 will likely improve delineation 
of signatures. However, to generate a true signature of MMC mutagenesis, more 
tumours need to be sequenced. 
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Alongside the increase in C:G > A:T mutations, an increase in tandem substitutions, 
specifically at CpC or GpG dinucleotides, was identified in the MMC treated tumours. 
These results reflect those of previous in vitro studies201,202,204, however in vivo studies 
did not identify any increase in single base mutations and instead identified an increase 
in deletions203,205. To be activated, MMC first requires reduction. Reduction of the drug 
may occur differently within a tumour environment compared to within model 
organisms, and this could explain the lack of correlation between the two. In the in vitro 
models, Srikanth et al.201 used NaBH4, which has the potential for both mono- and bi-
functional activation, whilst Maccubbin et al.202 used only mono-functionally activated 
MMC. Both identified single base changes associated with monofunctional activation. 
Additionally, Srikanth et al. detected tandem substitutions, associated with intra-strand 
crosslinks from bifunctional activation. The deletions identified in the in vivo studies are 
likely induced by interstrand crosslinks which may have been missed in the study by 
Srikanth et al. as they may have interfered with the packaging of the lambda phage. 
This could suggest that in the model organism studies, MMC was always bifunctionally 
activated, and therefore not able to generate SNVs. The presence of both SNVs and 
tandem substitutions in our study suggests that both mono- and bifunctional activation 
occurred within the tumours.  
Overall, there was no difference in the total mutational load between pre- and post-
MMC tumours. However, each post-MMC tumour contained many private mutations, 
with an average of 29% of the total mutations per patient being unique to the post-
MMC tumour. Across all patients, 31% of the post-MMC unique mutations were 
observed in a signature that we associated with MMC therapy (signature 24). This 
suggests that whilst there was no change overall in mutation load, MMC was a 
significant contributor to the mutational burden post-treatment. A similar picture was 
painted in MIBC treated with cisplatin-based chemotherapy, where no increase in 
mutational burden was identified post-chemotherapy despite the generation of new, 
treatment-associated mutations176. 
In the case of the muscle-invasive study, the pre-treatment samples were from 
biopsies, not tumour resections, and patients were treated with a neo-adjuvant 
regime176. In our study, each patient underwent tumour resection prior to 
chemotherapy, from which samples were taken for sequencing. Patients then 
underwent a course of MMC treatment (which started between 1 day and 10 months 
later) followed by resection of the post-MMC tumour (3 to 16 months after treatment 
initiation). Analysis of tumours at the subclone level identified that between pre-MMC 
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and post-MMC tumours, a median of 1.5 subclones were lost (range: 1-3) and 2 gained 
(range: 1-3). Contrasting with observations in the MIBC study176, no minor subclones 
pre-treatment were identified as expanded post-treatment as only highly prevalent 
subclones or the ancestral clone was maintained post-MMC treatment. Due to tumour 
resection, it is impossible to say if MMC treatment eradicated any clones or if these 
were removed by resection alone. This data could suggest that resection removes the 
most recently evolved clones that are likely present in the tumour outgrowth. The 
ancestral mutations and highly prevalent, early subclones could possibly be identified 
in the tissue surrounding the tumour and it is possible these could lead to tumour 
outgrowth. Indeed, in the analysis of the adjacent normal urothelium in recurrent and 
multifocal patients, mutations that were shared by multiple tumours were more likely to 
be detected in the “normal” sample55. Full organ mapping of a cystectomy specimen 
using next-generation sequencing would provide valuable information on the spreading 
of these clones. 
MMC is a DNA damaging agent and overall a trend towards an increase in mutations 
was seen in post-MMC tumours. A significant increase in the number of non-silent 
mutations affecting coding regions of genes was identified. This could possibly be 
related to the sequence specificity of MMC for CpG dinucleotides which are enriched in 
exons and promoter regions relative to the rest of the genome206. It would be 
interesting to investigate the distribution of MMC induced mutations using whole 
genome sequencing to identify if these are indeed enriched in the promoter and exonic 
regions. Additionally, if mutations in the promoter regions are identified, it would be 
interesting to see if they have any effect on gene expression levels. Alternatively, the 
increase in non-silent coding mutations could reflect positive selection for potentially 
functional mutations. Investigations into the synonymous and non-synonymous 
mutation rates could shed some light on this. However, it was not possible to carry out 
such analysis in the current study due to time limitations. 
The increase in the number of non-synonymous mutations observed in MMC-treated 
tumours might lead to some subclones expressing an increased number of 
neoantigens, thus increasing immunogenicity371. As identified in other cancers, such as 
lung372 and melanoma 373, a high mutation burden has been associated with an 
increased response to immunotherapy in MIBC374,375 and this is thought to be related to 
the increase in novel neoantigens. BCG is an immunotherapy and is preferentially used 
for high-risk NMIBC where outcomes are better than for chemotherapy. Stage T1 
grade 3 tumours have been shown to have a higher level of genome instability through 
  
192 
CN analysis125,126 and a higher mutational burden in high-risk NMIBC has been 
associated with reduced progression and better response to intravesical BGC 
therapy173. If an increased number of non-synonymous mutations post-MMC treatment 
is a feature of such treatment it could be hypothesized that these patients will respond 
better to BCG therapy and may suggest that a combination of the two therapies may 
improve response rates. Indeed, several clinical studies have investigated the efficacy 
of combining mitomycin C and BCG for the treatment of NMIC376-380. A study 
investigating the use of sequential BCG and MMC vs BCG alone for the treatment of 
patients with carcinoma in situ (CIS) did not support the use of the combination therapy 
for the treatment of CIS379, a conclusion supported by other studies221,376. However, a 
study investigating the combination in intermediate and high-risk NMIBC patients 
demonstrated an improvement in the disease-free interval and recurrence rate, yet this 
was at the cost of a greater toxicity compared to BCG alone378. 
Many of the studies investigating combination therapy have used different treatment 
schedules and compared to different control groups: some compared to BCG alone, 
others to MMC alone. Deng et al.381 performed a systematic review of 25 such studies. 
Overall, they identified that a combination of both MMC and BCG showed improved 
responses. They postulated that the induced disruption of the urothelium by MMC 
treatment could improve the attachment of BCG to the bladder wall and improve anti-
tumour activity. The results from our study could suggest that an increase in non-
synonymous mutations might also contribute to an improved response. The prediction 
of neoantigen generation would have provided further evidence for this hypothesis. It is 
possible to predict the presence of neoantigens from WES data382, however there was 
not enough time to carry out such an analysis during the timeframe of the current 
project. Follow-up work for publication should include this analysis. 
It would be interesting to analyse mutation data from patients undergoing the BCG-
MMC combination therapy as well as mutation data from patients undergoing BCG 
monotherapy and compare this to the data generated by our study. This could help 
explain the improved response identified in patients undergoing the combination 
therapy and may help identify why BCG is better than MMC in the treatment of high-
risk patients.  
In this cohort the total mutation rate is higher than that reported previously for NMIBC 
by Hurst et al.82 (5.90 vs 2.41 mutations per megabase (Mb) respectively) and this may 
be due to the different stages and grades used in the two cohorts. Other studies have 
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used NGS to investigate higher-risk NMIBC; Meeks et al.173 investigated high-risk 
NMIBC whilst Pietzak et al.157 investigated both low- and high-grade stage Ta tumours 
as well has high-grade stage T1 tumours. Both of these studies report a much higher 
mutation rate with 10-15 mutations per Mb identified by Meeks et al. and a mutation 
rate of 9 mutations per Mb in high-grade tumours reported by Pietzak et al. Both of 
these studies used targeted sequencing panels which inflates the mutation rate and 
makes them less easy to compare to other studies without additional bioinformatic 
steps. Additionally, the use of different variant calling methodologies could result in 
inconsistent numbers of variants being identified. For example, Hurst et al.82 used 
VarScan2 to call their variants and this variant caller was identified to be the most 
stringent variant caller in our analysis. This means that their analysis may have missed 
some lower-frequency mutations. In comparison, our pipeline was developed to identify 
shared variants, including those at low frequencies, whilst maintaining a low false-
positive rate. This highlights the benefits of large sequencing schemes, such as the 
TCGA and ICGC, as these provide a standard approach to analysing samples, making 
results more comparable. 
Clonal evolution analysis identified mostly simple subclonal evolution patterns. All 
tumours had a set of ancestral mutations that remained present in all cells throughout 
tumour development. After accounting for these ancestral clones, pre-MMC and post-
MMC tumours differed in the subclones they contained; subclones were lost from the 
pre-MMC tumours and different subclones gained in the post-MMC tumours. No 
subclones were identified that were present at a low level in one tumour yet expanded 
in another tumour. It is possible that minor subclones were missed in this analysis due 
to the relatively low depth of sequencing for subclone delineation. Alternatively, these 
subclones may have been removed by resection as discussed previously. Deeper 
targeted sequencing of selected mutations could be used to confirm shared and unique 
mutations. Time and resources did not allow for this to occur during the project, but this 
kind of validation would be important for future work. 
The observation of Sylvester et al.213 that a single immediate instillation of 
chemotherapy resulted in an increased risk of death in higher risk patients is 
suggestive that chemotherapy influences tumour evolution in this patient subgroup. 
Our data shows that MMC treatment can certainly induce new mutations and there is 
the possibility that these could contribute to disease progression. In our cohort, no 
patients had progression to muscle-invasive disease. As a follow-up study, it would be 
interesting to analyse tumours from patients who progressed after receiving multiple 
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instillations of MMC to examine whether the progressed tumours contain MMC-induced 
alterations, what the frequency of those alterations are, and if treatment alters 
subclonal dynamics. This represents a feasible study as patients undergoing a course 
of MMC chemotherapy are of intermediate to high-risk of progression, therefore such 
samples should be available for analysis. 
One of the objectives for this study was to investigate the relationships between 
tumours from the same patient. Overall, a monoclonal origin was identified for 21 out of 
23 of the patients in the study using a combination of copy number analysis and 
hotspot mutation analysis. This was supplemented by sequencing of a targeted gene 
panel for tumours where necessary. Due to a lack of available sample, it was not 
possible to carry out further analysis using targeted sequencing of tumours from one 
patient (P2065) for whom monoclonality could not be established. Two tumours from 
this patient both contained loss of chromosome Y but only tumour P2065-S01 also 
contained hot-spot mutations in FGFR3 and PIK3CA. As there are only two loci 
available for comparison in these tumours (i.e. the two mutations) neither a monoclonal 
or oligoclonal origin can be defined for this tumour. Targeted sequencing of whole -
genome amplified DNA could help define the origins of these tumours but there was 
not enough time available to optimise and implement this. 
An oligoclonal origin was suggested for tumours from patient P2291 with 6 unique 
mutations identified in tumour P2291-S01 and 8 unique mutations identified in tumour 
P2291-S02. To our knowledge, this is the first study using NGS-based approaches to 
identify a possible oligoclonal origin for recurrent tumours from a bladder cancer 
patient. It is possible that limiting analysis of these tumours to 140 genes may have 
missed shared mutations elsewhere. However, this gene panel is representative of the 
most frequent mutations in bladder cancer. Whole-genome sequencing of this patient 
would be interesting. It would unambiguously define the relationship between the two 
tumours and, if monoclonality was demonstrated, could identify alterations that occur 
very early on in bladder cancer. Additionally, it would be interesting to look for possible 
pathogenic germline variants within this patient as these could provide evidence for a 
predisposition to bladder cancer. 
Overall, the combination of these results and others from the literature26,29,61,62,164 
suggest that the majority of recurrent and multifocal bladder cancers are clonal in 
origin. The analysis of multiple related tumours from an individual generates a higher 
resolution for the identification of early events within bladder carcinogenesis, as 
alterations need to be present in all  these tumours. In this study, TERT promoter 
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mutations, chromosome 9 loss and FGFR3 mutations were identified to be early 
events, present on the trunk of the tumour evolutionary trees. These results are 
consistent with previous data154,163,383.Through the assessment of more paired data it 
may be possible to identify additional common early events, especially if this is done 
using deep sequencing data. It is essential that this analysis uses multiple tumours 
from the same patient as this is the only way to disambiguate highly prevalent clones 
as evidenced by patient P1870, for whom analysis of an additional tumour by targeted 
sequencing identified that the driver mutation in KDM6A predicted to be ancestral by 
exome sequencing of two tumours was actually a later event. 
There are several limitations to this study. The primary issue is the relatively low 
number of samples analysed. Pre-MMC and post-MMC tumours from 8 patients were 
analysed by WES with a total of 18 tumours being assessed. The data generated did, 
however, clearly demonstrate MMC-associated alterations in 7 out of the 8 patients. 
The similarities between our observations and mutations generated by MMC 
experimentally suggests that these findings are truly reflective of the effects of 
treatment with a course of MMC chemotherapy. Sequencing of an additional cohort of 
tumours from patients that have undergone such a course of therapy would validate 
the results from this project. 
There was no control group used within this study, which is a limitation. It would be 
difficult to define a control group, as the majority of patients with recurrent disease will 
undergo some form of treatment. For the identification of the MMC signature, the lack 
of a control group is mitigated in part by the heterogeneity of the treatment timings of 
the patient cohort. For some patients, the pre-treatment tumour was the initial primary 
tumour whilst for others it was a later recurrent tumour, yet the same signature was 
found in all cases. This is highly suggestive that the signature is indeed a MMC-related 
signature and not related to recurrent tumours. Additionally, using matched pre- and 
post-treatment samples is a form of control within itself. However, sequencing of a 
panel of paired, treatment naïve, recurrent tumours would allow us to determine if 
treatment with MMC increases the mutation rate in the recurrent tumours compared to 
resection alone. 
The sequencing depth of the current study limits the ability to investigate the clonal 
dynamics. Despite achieving an average coverage of 80x, only 71% of targeted bases 
were sequenced to 50x or higher, and many mutations had coverage of only 30x. 
Targeted re-sequencing of variants with an orthogonal method, such as Ampliseq, 
would ensure accuracy of the sequencing results. Important mutations in terms of 
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clonal dynamics could be targeted to ensure that these were not present at low levels 
in the pre-treatment tumours. 
As patients underwent resection prior to treatment, this study was limited in its power to 
detect any mutations present in subclones that may have conferred sensitivity to MMC 
treatment. Additionally, the results from this study suggest that resection may limit the 
detection of subclones that may be resistant to the therapy. A recent clinical trial 
investigating the use of MMC in the neo-adjuvant setting could shed some light on 
possible markers of sensitivity or resistance. The trial, chemoresection and surgical 
management in low-risk non-muscle-invasive bladder cancer (CALIBER - clinical trial 
number: NCT02070120), aimed to identify if MMC could be used to chemoresect 
tumours by treating patients with 4 once weekly instillations of MMC, rather than using 
surgery. Unfortunately, the trial ended early as the complete response rate at 3 months 
was low in the chemoresection group (estimated rate of 37.3% vs 80.8% in the surgery 
group)384. Sequencing of samples from patients that underwent chemoresection in this 
trial would provide a greater insight into the role of MMC in clonal dynamics. 
Comparing tumours from patients that failed chemoresection with those who had a 
response could identify markers of recurrence or sensitivity.  
Whilst we have investigated the alterations present in DNA after MMC treatment, we 
have not examined genome-wide mRNA expression data for these samples. mRNA 
subtyping of bladder cancer has identified distinct subtypes, and these display 
differential survival outcomes and sensitivity to chemo- and immuno-therapies 
(reviewed in 385). It would be interesting to use mRNA profiling to subtype the tumours 
and identify if MMC treatment changes the subtype of the tumour at all.  
This study may have underestimated the extent of intratumour heterogeneity. Biopsies 
were taken from the resected samples and this may mean that we have missed some 
subclones due to spatial separation of the subclones. In MIBC, multi-region sequencing 
of primary and metastatic bladder suggested a complex mixture of clones, however 
these were not spatially distinct63. An additional study that analysed 8 regions from a 
single muscle-invasive bladder tumour also identified intermixing of the identified 
subclones in all regions61. This may suggest that spatial heterogeneity is low within 
bladder tumours but, as yet, this not been systematically investigated in NMIBC. 
In conclusion, our study has shown that MMC has a clear mutational effect on tumour 
DNA that can be identified in post-MMC treated tumours. The clinical implications of 
these findings are as yet unknown. The ability of MMC to generate new mutations 
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provides an opportunity for these mutations to provide a growth advantage to a cell 
with an otherwise low malignant potential, which could promote recurrence and 
progression. On the other hand, the generation of non-synonymous mutations could 
increase the number of neoantigens and consequently the immunogenicity of these 
tumours thus providing a potential opportunity for the use of a combination of MMC and 
BCG treatment. Ultimately, more studies are required to investigate the mutagenic 
landscape of MMC treatment and to discern the effect of MMC treatment on the clonal 
dynamics of NMIBC. The incorporation of genomic data, such as WGS, WES or RNA-
seq data into clinical trials would help identify possible correlations between cancer 
genome characteristics and patient outcome. Additionally, a large-scale systematic 
review of the long-term outcomes of patients receiving a course of mitomycin C is 
warranted to ensure that the treatment is of benefit to patients in the long term. 
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Appendix A  
Clinical timelines for all 23 patients 
 
The disease history for each patient is depicted over the next four figures. Tumour 
events for which fresh frozen biopsy material was available are depicted by large solid 
circles. Tumours that were resected but not sampled and have formalin fixed paraffin 
embedded (FFPE) tumour material available are indicated by dashed circles. Other 
events that may have been removed by diathermy are indicated by small black circles. 
Mitomycin C (MMC) treatment courses are indicated by green boxes. BCG treatment is 
indicated by light blue arrows. Tumours that underwent copy number (CN) profiling are 
indicated by a red square. Tumours that underwent whole exome sequencing (WES) 
are indicated by dark blue arrows. Red triangles represent resection of upper tract 
disease. * P0533 was diagnosed 3 years previous but there is no information available 
for this time point
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Appendix B  
Black-listed regions for CNA analysis 
Chromosome Start End 
chr1 123400000 144323271 
chr2 89346407 95501179 
chr3 90112909 93794219 
chr4 48936766 51851287 
chr5 45617513 50369323 
chr7 56951145 63142518 
chr8 43176239 47320014 
chr9 39034407 68120289 
chr10 37984863 42524659 
chr11 50163315 55410244 
chr12 34352090 38227527 
chr13 17700000 18753153 
chr14 17200000 19696838 
chr15 17000508 23409383 
chr16 32470325 46572884 
chr17 21686799 27369989 
chr18 0 117149 
chr18 14397773 21233605 
chr19 24065361 27794772 
chr20 26300552 31408829 
chr21 0 12000000 
chr22 0 16927042 
chrX 57919249 61000000 
chrY 10400000 11919235 
chrY 56677925 57227415 
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Appendix C  
Files used for phylogenetic tree generation 
C.1 ngCGH output example 
Name Chromosome Start End Value 
chrY_2781914 chrY 2781914 3533334 -2.190506 
chrY_3534345 chrY 3534345 4439886 -2.141596 
chrY_4439889 chrY 4439889 5357964 -2.228308 
chrY_5357964 chrY 5357964 6287018 -2.153669 
chrY_6290705 chrY 6290705 7094954 -2.215597 
chrY_7095527 chrY 7095527 7598757 -1.726559 
C.2 TuMult probe file example 
Name Chr StartPosition EndPosition StartCytoband EndCytoband 
Chr-1-10002 1 10002 844162 1p36.33 1p36.33 
Chr-1-844743 1 844743 944382 1p36.33 1p36.33 
Chr-1-944657 1 944657 1013776 1p36.33 1p36.33 
Chr-1-1013787 1 1013787 1073139 1p36.33 1p36.33 
Chr-1-1073197 1 1073197 1155631 1p36.33 1p36.33 
C.3 TuMult profile file example 
P0198_ 
S1.value 
P0198_ 
S1.statu
s 
P0198_ 
S2.value 
P0198_ 
S2.statu
s 
P0198_
S3.valu
e 
P0198_ 
S3.statu
s 
P0198_
S4.valu
e 
P0198_ 
S4.statu
s 
0 0 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 
-0.73757 -1 -0.8885 -1 -0.82799 -1 -0.92319 -1 
-0.73757 -1 -0.8885 -1 -0.82799 -1 -0.92319 -1 
C.4 TuMult reference data set example 
 Chr-1-10002 Chr-1-844743 
Chr-1-
944657 
Chr-1-
1013787 
Chr-1-
1073197 
P0198B 0 0 0 0 0 
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Appendix D  
Genes in bladder cancer targeted sequencing panel 
Symbol Symbol Symbol Symbol 
ACAN EGFR LARP1B RAD21 
AHNAK2 ELF3 LGALS8 RARG 
AKT1 EP300 LPHN3 RB1 
ARHGAP18 EPG5 LRRC7 RBM10 
ARHGEF10 ERBB2 MAGI3 RBM6 
ARHGEF3 ERBB3 MAML1 RHOA 
ARID1A ERCC2 MAPK8IP3 RHOB 
ARID2 ESPL1 MECOM RREB1 
ARID4A FANCA MYCBP2 RXRA 
ASH1L FAT1 MYO5B RYR2 
ASXL2 FAT2 NAT10 SCN1A 
ATM FAT3 NCOR1 SLC25A48 
ATP6V1B2 FAT4 NCSTN SPTAN1 
ATP7B FBXW7 NF1 STAG1 
B3GNT9 FGFR3 NFE2L2 STAG2 
BRAF FMN1 NFE2L3 STK38 
BRCA2 FOXA1 NOTCH1 SYNE1 
BTG2 FOXQ1 NOTCH2 SYNE2 
C1ORF173 FREM2 NOTCH3 TET3 
CACNA1D HAUS6 NRAS TEX15 
CCND1 HEPACAM OSMR TNC 
CCND3 HERC1 PAIP1 TP53 
CDKN1A HMCN1 PALM3 TRAK1 
CDKN2A HRAS PCDHA9 TSC1 
CDKN2B HRNR PDZD2 TSC2 
CEP290 INADL PGS1 TXNIP 
CHD6 ITK PHF3 UEVLD 
CLTC KDM3A PIK3CA USP47 
CLU KDM6A PIK3R1 UTY 
COL11A1 KIF16B PIK3R4 VCAN 
CPAMD8 KLF5 POLE WHSC1L1 
CREBBP KMT2A POLE2 WNK1 
DLG4 KMT2C POTEF ZFHX3 
DOPEY1 KMT2D PTEN ZFP36L1 
DUX4L4 KRAS RAB11FIP1 ZFYVE26 
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Appendix E   
Comparison of copy number results from array CGH 
and shallow-pass WGS for tumour P0468-S01 
Array CGH (aCGH) data for tumour P0468-S01 was generated previously125. At the time of aCGH 
analysis, a matched blood sample was unavailable therefore an unmatched lymphoblastoid cell 
line was used. For the shallow-pass WGS analysis, matched blood was available and used as 
the paired normal. A) Whole genome copy number plots for tumour P0468-S01 generated using 
aCGH (top) or shallow pass WGS (bottom). Green boxes highlight shared alterations whilst the 
red box indicates an alteration that is not shared by the two methods. B) Copy number plots for 
chromosome 2 generated using aCGH (top) or shallow-pass WGS (bottom). C) Copy number 
plots for chromosome 13 generated using aCGH (top) or shallow-pass WGS (bottom). For B) and 
C); green boxes have been drawn around CNAs in the aCGH data that were also identified using 
shallow-pass WGS. These CNAs are highlighted in blue (gain) or red (loss) in the shallow-pass 
WGS panels. 
 
A 
B C 
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The Figure above depicts CNAs identified using aCGH or shallow-pass WGS for the 
same tumour sample (P0468-S01). The basic principle underlying both aCGH and 
NGS based CN methods is the same: both methodologies compare a test sample with 
a reference sample to identify differences. In aCGH this is by competitive hybridization 
to an array of known sequences whilst for NGS the read depth between the two 
samples is compared. For both methods the data needs to be corrected prior to 
analysis; for aCGH this involves correcting for the total signal intensity difference 
between the two fluorescent channels (as there may have been an imbalance in the 
amount of DNA loaded) as well as other biases such as differences between the signal 
from different blocks on the array386.  For our NGS data there are slightly more 
challenges to overcome. Each probe is calculated as the log2 transformation of the 
ratio between the number of reads in the normal and tumour for each window. This can 
be confounded by overall coverage as one sample may have had more reads in total, 
potentially due to slightly more of that library entering the sequencing pool. This was 
corrected by median centering where the median log2 value was subtracted from the 
entire vector of results, eliminating any total read-depth bias. This also centres the data 
around 0. The GC content of the region can also affect coverage, with GC-poor or GC-
rich regions demonstrating lower coverage than balanced regions of the genome387. 
This is corrected for within the Nexus software using a quadratic model. 
The results produced by both methods are largely concordant with the same CN losses 
being identified on 2q and 4q and chromosome 9 as well as the same gain on 
chromosome 13 (A). However, there is one difference between the results generated 
by the two approaches; a low level CN gain on chromosome 7 was identified in the 
shallow-pass WGS that was not detected in the aCGH data. This could be due to the 
sensitivity of the two methods; the WGS method appears to show better differentiation 
between regions of CNA and CN neutral regions as the log2 ratios for the regions of 
CNA are larger or smaller than those seen by aCGH for gains or losses respectively. 
This may be due to the inherent difficulty in quantifying small changes in fluorescent 
signal in aCGH analysis compared to quantifying changes in read depth in the analysis 
of the WGS data386. Alternatively this difference could be due to the use of different 
sections of the tumour for DNA extraction. As the tumour is stage T1 grade 2 it is 
possible that the tumour could be heterogenous. Indeed, the low level of the gain 
suggests that it is likely to be a subclonal alteration. It could also be possible that the 
gain is an artifact in the WGS method potentially due to an increase in overall coverage 
in the tumour compared to the matched normal. However, the median centering of the 
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data performed should eliminate this kind of error. Additionally, this low level gain is 
also seen in another tumour from this patient, validating its presence.  
Looking at the individual chromosomes highlights the same CN loss on chromosome 2 
(B) but a slightly different profile for the CNAs detected by the two methods on 13q (C). 
The CN gain on 13q is present in the aCGH data, albeit at a lower amplitude, but the 
regions of CN loss surrounding the region are not present. This is likely due to 
differences in the resolution of the two approaches: the array contained approx. 4000 
probes spaced just under 1 Mb apart whilst the shallow-pass WGS contained an 
equivalent of ~12800 probes. In the aCGH data, only 3 probes spanned the entire 
region of CNA on this chromosome, and with the large size of the probes (average 162 
kb) some of the regions of loss and gain were present within the same probe region, 
reducing the sensitivity of the probe to detect either alteration. In the shallow-pass 
WGS data, 18 probes spanned the region, improving the sensitivity of breakpoint 
detection. 
There are some individual probes in the aCGH data that do not align with the rest of 
the data or with results from WGS. As these are individual probes it is likely that these 
events are just noise. This may be a consequence of not using a matched normal for 
comparison in this data. 
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Appendix F  
Whole genome copy number plots 
 
Whole genome copy number plots for tumours from patient P0198.  
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Whole genome copy number plots for tumours from patient P0418. 
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Whole genome copy number plots for tumours from patient P0468. 
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Whole genome copy number plots for tumours from patient P0533. 
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Whole genome copy number plots for tumours from patient P0536. 
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Whole genome copy number plots for tumours from patient P0717. 
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Whole genome copy number plots for tumours from patient P0926 
 
 
 
 
Whole genome copy number plots for tumours from patient P0933. 
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Whole genome copy number plots for tumours from patient P0960. 
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Whole genome copy number plots for tumours from patient P0990. 
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Whole genome copy number plots for tumours from patient P1326 . 
 
 
 
Whole genome copy number plots for tumours from patient P1777. 
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Whole genome copy number plots for tumours from patient 1485. 
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Whole genome copy number plots for tumours from patient P1870. 
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Whole genome copy number plots for tumours from patient P2065 
 
 
 
 
Whole genome copy number plots for tumours from patient P2104. 
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Whole genome copy number plots for tumours from patient P2218. 
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Whole genome copy number plots for tumours from patient P2291  
 
 
 
 
Whole genome copy number plots for tumours from patient P2440. 
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Whole genome copy number plots for tumours from patient P2329. 
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Appendix G  
Phylogenetic trees inferred from copy number and 
mutation status data using TuMult 
 
Phylogenetic tree showing the inferred relationships between 3 tumours from 
patient P0468 based on CNAs and hotspot mutation status. 
 
 
Phylogenetic tree showing the inferred relationships between 3 tumours from 
patient P0536 based on CNAs and hotspot mutation status. 
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Phylogenetic tree showing the inferred relationships between 5 tumours from 
patient P0717 based on CNAs and hotspot mutation status. 
 
 
Phylogenetic tree showing the inferred relationship between 2 tumours from 
patient P0926 based on CNAs and hotspot mutation status. 
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Phylogenetic tree showing the inferred relationship between 2 tumours from 
patient P0933 based on CNAs and hotspot mutation status. 
 
 
Phylogenetic tree showing the inferred relationships between 3 tumours from 
patient P0990 based on CNAs and hotspot mutation status. 
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Phylogenetic tree showing the inferred relationship between 2 tumours from 
patient P1326 based on CNAs and hotspot mutation status. 
 
Phylogenetic tree showing the inferred relationship between 2 tumours from 
patient P1777 based on CNAs and hotspot mutation status. 
 
 
Phylogenetic tree showing the inferred relationship between 2 tumours from 
patient P2065 based on CNAs and hotspot mutation status. 
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Phylogenetic tree showing the inferred relationship between 2 tumours from 
patient P2104 based on CNAs and hotspot mutation status. 
 
Phylogenetic tree showing the inferred relationship between 2 tumours from 
patient P2291 based on CNAs and hotspot mutation status. 
 
 
 
 
Phylogenetic tree showing the inferred relationships between 3 tumours from 
patient P2218 based on CNAs and hotspot mutation status. 
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Phylogenetic tree showing the inferred relationships between 3 tumours from 
patient P2329 based on CNAs and hotspot mutation status. 
 
 
Phylogenetic tree showing the inferred relationship between 2 tumours from 
patient P2440 based on CNAs and hotspot mutation status 
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Appendix H  
Oncoplot showing the distribution of mutations in the 
top 50 mutated genes identified by exome sequencing 
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Appendix I  
Mutational signature context of pre-MMC, post-MMC 
and post-MMC unique variants for  each patient 
 
 
 
Signature context of SNVs from patients P0418, P0533, P1175, P1870, P2161 and 
P2329. 
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Signature context of SNVs from patients P0960 and P2218. 
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Appendix J  
Kernel density plots 
 
Kernel density plots for tumours from patients P0418, P0960, P1870, P2161 and 
P2329. The VAF (x-axis) is plotted against the density of the VAF (y-axis). 
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Appendix K  
List of suppliers 
Agilent Technologies LDA UK Limited, Life Sciences & Chemical Analysis Group, 
Lakeside, Cheadle Royal Business Park, Stockport, Cheshire SK8 3GR 
https://www.agilent.com/cs/agilent/en/contact-us/united-kingdom  
Beckman Coulter, Oakley Court, Kingsmead Business Park, London Road, High 
Wycombe, HP11 1JU https://www.beckmancoulter.com/en/about-beckman-coulter/life-
sciences  
Bio-Rad Laboratories Ltd., The Junction, Station road, Watford, Hertfordshire WD17 
1ET http://www.bio-rad.com/  
BMG LABTECH Ltd., 8 Bell Business Park, Smeaton Close, Aylesbury, Bucks HP19 
8JR https://www.bmglabtech.com/  
Covaris Ltd., Unit 3, Brighton Office Campus, Hunns Mere Way, Woodingdean, 
Brighton, BN2 6AH https://covaris3.corecommerce.com/  
GE Healthcare Life Sciences, Amersham Place, Little Chalfont, Buckinghamshire, HP7 
9NA https://www.gelifesciences.com/en/gb  
Leica Microsystems Ltd., Larch House, Woodlands Business Park, Breckland, Linford 
Wood, Milton Keynes MK14 6FG https://www.leicabiosystems.com/  
New England Biolabs (NEB), 75-77 Knowl Piece, Wilbury Way, Hitchin, Hertfordshire, 
SG4 0TY https://www.neb.uk.com/  
Promega, Delta House, Enterprise Road, Southampton Science Park, Southampton, 
SO16 7NS https://www.promega.co.uk/  
QIAGEN, Skelton House, Lloyd St N, Manchester M15 6SH 
https://www.qiagen.com/gb/  
Severn Biotech Limited, Unit 2, Park Lane, Kidderminster, Worcestershire, DY11 6TJ 
http://www.severnbiotech.com/  
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Sigma-Aldrich, The Old Brickyard, New Road, Gillingham, Dorset SP8 4XT 
https://www.sigmaaldrich.com/united-kingdom.html  
Thermo Fisher Scientific, Fisher Scientific UK Ltd, Bishop Meadow Road, 
Loughborough LE11 5RG https://www.thermofisher.com/uk/en/home.html  
VWR International, Hunter Boulevard, Magna Park, Lutterworth, Leicestershire LE17 
4XN https://uk.vwr.com/store/  
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